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Abstract
Role of B cell and hematopoietic cell intrinsic actions of ERα in lupus
pathogenesis
Dana E. Tabor, Ph.D.
University of Nebraska, 2016
Supervisor: Karen A. Gould, Ph.D.
Lupus is a chronic autoimmune disease characterized by the presence of autoimmune B
and T cells and the production of pathogenic antibodies against nuclear antigens. Lupus
predominately affects women between menarche and menopause. There are both
genetic and environmental risk factors which affect an individuals’ risk of developing
lupus. Estrogens are a risk factor for developing lupus and are thought to contribute
significantly to the initiation and progression of disease. In lupus-prone mice, genetic
knockout of a receptor for estrogen, estrogen receptor alpha (ERα), causes significant
attenuation of lupus. Previous studies have not identified the cell type or types which
mediate the effects of ERα on lupus. Estrogen has many effects on the immune system
which could contribute to the development of autoimmunity in susceptible individuals.
Particularly, estrogen promotes the survival of highly autoreactive B cells. Therefore, we
hypothesized that ERα expression in hematopoietic cells promotes lupus, and more
specifically, that ERα in B cells promotes lupus.
To test this hypothesis, we created two different murine models of lupus on the lupusprone (NZB x NZW)F1 genetic background. To investigate the role of ERα in
hematopoietic cells, we created chimeric mice with hematopoietic and nonhematopoietic cells with different ERα genotypes. Due to issues with the creation of
successful chimeras, we were not able to use these mice to fully address our
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hypothesis. However, these studies revealed that estrogen plays a role in the success of
hematopoietic reconstitution in females.
To address the hypothesis that ERα expression in B cells promotes lupus, we created a
(NZB x NZW)F1 model with B cell specific deletion of ERα. Although only a moderate
proportion of B cells had successful deletion of ERα, this was sufficient to cause a
significant attenuation of lupus. Mice with B cell specific ERα deletion had fewer
activated B cells, produced fewer pathogenic autoantibodies, and had significantly
prolonged survival compared to control mice. Therefore, these studies have shown that
ERα expression in B cells promotes lupus in the (NZB x NZW)F1 model of lupus.
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Chapter 1: Introduction
Estrogens
Estrogens are a group of naturally occurring and synthetic steroid hormones which
regulate the female reproductive system and are responsible for the development of
female secondary sex characteristics. There are three kinds of naturally occurring
estrogens, which all have different biological activity: estrone (E1), estradiol (E2), and
estriol (E3). Estrogens are produced from cholesterol through aromatization of
androgens. In non-pregnant premenopausal women, the ovary is the principle source of
estrogens E1 and E2, but small amounts of estrogen are also produced in adipose
tissue, skin, bone, and brain, and in men estrogens are produced in the testes (reviewed
in Simpson, 1999). E3 is produced by modification of E1 or E2 and is primarily produced
in the placenta during pregnancy. Serum E2 and E1 increase in the late follicular stage
of the menstrual cycle, while the levels of E3 are generally low and do not fluctuate with
the menstrual cycle (Lipsett, 1978). In premenopausal women, the average serum E2
level varies from about 50 pg/ml to 125 pg/ml over the course of the menstrual cycle,
and postmenopausal women have an average of 54 pg/ml serum E2 (Ghosh, 2014).
Men have an average serum E2 level of 43 pg/ml (Travison, 2014). Estrogens have
many physiological effects in both women and in men, which are discussed in more
detail below.
As steroid hormones, estrogens diffuse freely across cell membranes and elicit genomic
and non-genomic effects by binding to estrogen receptors (ERs). E2 is the most potent
of these naturally occurring estrogens because of its superior binding affinity for ERs.
The relative binding affinity of these naturally occurring estrogens to receptors is E2 > E1
> E3 (Korenman, 1968).
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Estrogen Receptors
Estrogens signal through estrogen receptor alpha (ERα), estrogen receptor beta (ERβ),
and membrane-bound G protein-coupled estrogen receptor 1 (GPER). Estrogens bound
to GPER cause rapid calcium mobilization, and signaling through GPER is responsible
for some of the rapid effects of estrogen. Estrogens bound to nuclear hormone receptors
ERα and/or ERβ cause transcriptional effects on target genes. This introduction will
focus on ERα and ERβ.
ERα and ERβ are nuclear hormone receptors found most abundantly in the cell nucleus.
The most abundant ERα in the nucleus is the full length 66 kDa protein. In the nucleus,
ERα and ERβ can act as transcription factors or interact with other transcription factors
to impact gene expression. Both ERα and ERβ can also be found in the cytoplasm and
bound to the plasma membrane. Upon ligand binding, ERs in the cytoplasm change
conformation to reveal a nuclear localization signal and then translocate to the nucleus.
Plasma membrane ERα is relatively rare, and association of this 46 kDa splice variant of
ERα with the plasma membrane is dependent on post-translational palmitoylation (Li,
2003). Palmitoylated ERβ is also found in the plasma membrane (Galluzzo, 2007).
Plasma membrane bound ERα and ERβ are responsible for the rapid effects of estrogen
signaling not caused by GPER. Estrogen signaling through plasma membrane ERα
leads to phosphorylation of AKT and ERK (Pedram, 2014). ERβ is also found in the
mitochondria where it increases the threshold for apoptosis in a ligand-independent
manner (Yang, 2004; Liang, 2015).
The ERα and ERβ genes are composed of analogous functional domains A-F which
have varying degrees of homology (Figure 1.1). Both genes have an N-terminal A/B
domain which contains an activation factor (AF)-1 transcriptional regulation domain
which is not well conserved between ERα and ERβ. Next, there is domain C, which
2

Figure 1.1 Functional domains of ERα and ERβ
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Figure 1.1 Functional domains of ERα and ERβ
ERα and ERβ are composed of analogous functional domains. The A/B domain contains
an activation function (AF) domain, AF-1, which regulates the transcriptional activity of
the ER. Domain C contains the DNA binding domain (DBD). The D domain contains the
hinge domain (HD) as well as a nuclear localization signal which is revealed upon ligand
binding. The E/F domain contains a second AF binding site (AF-2) and the ligand
binding domain (LBD).
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contains the DNA binding domain (DBD) and dimerization domain. This domain is well
conserved between ERα and ERβ and allows both receptors to bind estrogen response
elements (EREs) in the genome. Domain D is also involved in dimerization, as well as
binding of heat shock proteins, and contains the hinge domain (HD), which undergoes a
conformational change to reveal the nuclear localization signal upon ligand binding. The
C-terminal E/F domain contains a ligand binding domain (LBD) which forms a
hydrophobic pocket, and the AF-2 transcriptional regulation domain. There is a moderate
degree of homology in the ligand binding domain, which causes ERα and ERβ to have
different binding affinities for different estrogenic ligands. Variation in the AF domains
and ligand binding domain causes ERα and ERβ to have different transcriptional effects.
In the inactive state, ERα and ERβ are bound to heat shock proteins, which are released
upon ligand binding. After ligand binding, ERα and ERβ form homo- or heterodimers
through interaction of peptides in the dimerization domain. Homodimers of ERα and ERβ
have different physiological activities, while heterodimers act like ERα homodimers (Li,
2004). The ER dimer moves to the nucleus where it acts as a transcription factor, either
by binding DNA and acting as a transcription factor in ERE-dependent signaling, or by
binding other transcription factors and acting as part of a transcription factor complex
without directly binding DNA in ERE-independent signaling. The conformation of the ER
dimer is independently affected by both the ligand and the sequence of the ERE site with
which it interacts (Yi, 2002; Ramsey, 2001). The ligand, and not the ERE sequence,
dictates the recruitment of co-factors such as SRC-1, TIF-1, TIF-2, and AIB-1 to the ER
complex (Yi, 2002).
The ERE consensus sequence is a 13 base pair palindrome, GGTCAnnnTGACC, which
can contain up to two deviations from the consensus sequence and still elicit binding,
although multiple nearby EREs are required for efficient binding of imperfect sequences
5

(Martinez, 1989). ERα has an approximately two-fold greater affinity for the same EREs
as ERβ, which could be a mechanism underlying the different transcriptional activity of
these receptors (Yi, 2002). Approximately 70,000 potential ERE sites have been found in
the human and mouse genomes, and the most highly estrogen-responsive genes
contain multiple EREs in their promoters (Bourdeau, 2004; Martinez, 1989; Sathya,
1997).
Estrogen Receptors and Reproduction
ERα and ERβ are found throughout the reproductive system in the ovaries, uterus, and
mammary glands in females and the testis of males in both humans and mice (Pelletier,
2000; Irsik, 2013). ERα signaling plays an essential role in regulation of hormones and
reproduction. In mice with ERα knockout (ERα-/-) both female and male mice are infertile.
Female ERα-/- mice have abnormal physiology of the ovaries and uterus; the ovaries
develop large hemorrhagic cysts and do not release mature follicles, while the fallopian
tubes and uterus are small and the uterus does not increase in size in response to E2
treatment (Dupont, 2000; Lubahn, 1993). Infertile male ERα-/- mice have defects in
spermatogenesis resulting in significantly reduced sperm number as well as defects in
the motility of the few sperm that are produced (Eddy, 1996). Interestingly, it is somatic
cells, not germ cells, which require ERα signaling for normal sperm production and male
fertility (Mahato, 2001). Global heterozygosity for ERα (ERα+/-) results in normal fertility
in both females and males. Therefore, at least one functional copy of ERα is essential for
normal fertility. In addition to loss of fertility and physiological abnormalities, ERα-/- mice
also have hormonal abnormalities. Female ERα-/- mice have a ten-fold increase in serum
E2 and an increase in serum testosterone of a similar magnitude (Eddy, 1996). Serum
testosterone levels are elevated by two-fold in male ERα-/- mice, but E2 levels are not
affected (Eddy, 1996; Parikka, 2005). The increased serum hormone levels in ERα-/-
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mice are the result of lack of feedback in the hypothalamic-pituitary-gonadal axis.
Therefore, although ERα-/- mice can provide some useful information, it is important to
remember that in this system estrogen and testosterone levels are significantly elevated
in females, and signaling through ERβ, GPER, and androgen receptors may be
impacted by these hormonal changes. To study the effects of ERα in specific estrogensensitive cells and tissues, models with conditional activation or deletion of ERα have
been developed. Using a conditional deletion approach, it has been shown that ERα-/gonadotropin α-subunit- expressing pituitary cells are sufficient to cause infertility in
female mice, but not in males (Gieske, 2008). These females produce normal follicles,
not the hemorrhagic cysts observed in global ERα-/- females, but do not have regular
estrus cycles (Gieske 2008). Fertility in female mice requires ERα expression in multiple
tissues, for instance, in gonadotropin α-subunit-expressing pituitary cells for regulation of
estrus cycles, and in the uterus for estrogen-induced growth of the uterine lining.
Like ERα, ERβ is widely expressed in the female and male reproductive tracts. However,
unlike ERα-/- mice, ERβ null (ERβ-/-) mice are not completely sterile. ERβ-/- males have
normal fertility, and ERβ-/- females have reduced fertility with fewer litters and fewer pups
per litter than mice with normal ERβ expression (Krege, 1998). The uterus of ERβ-/females appears normal and is responsive to estrogen, but the ovaries release
significantly fewer follicles than normal (Krege, 1998). Thus, ERβ is not essential for
reproduction, but does affect fertility in females.
Unsurprisingly, mice with combined ERα and ERβ deficiency are completely sterile
(Couse, 1999). Individually, ERα+/- and ERβ-/- do not cause complete infertility in mice
of either sex, so it is not unexpected that ERα+/- ERβ-/- male mice have normal fertility,
however, it was surprising that ERα+/- ERβ-/- female mice are unable to produce mature
ovarian follicles and are completely sterile (Dupont, 2000). These data suggest that both
7

ERα and ERβ are important for female fertility and that there is some functional
redundancy between these receptors. Additionally, ERα significantly affects male fertility
while ERβ does not play an essential role.
The expression level of ERs, as well as polymorphisms in these genes, impacts human
fertility. Sperm from men with varicocele-related infertility express lower levels of ERα
and ERβ than healthy sperm, which leads to reduced estrogen-induced motility (Guido,
2011). Polymorphisms in ERα and ERβ in both women and men are associated with
differences in fertility potential (Corbo, 2007; Zulli, 2010). Clearly, estrogen signaling
through ERα and ERβ plays an important role in reproduction.
Estrogen Receptors in Non-Reproductive Physiology
ERs are not only important in reproduction, but also in other tissues throughout the body.
Although ERs are expressed by both females and males, females often have higher
levels of ER expression, and the potential magnitude of ER signaling is greater due to an
increased amount of estrogen available as a ligand. ERα and ERβ are expressed in the
kidney, liver, and heart in both female and male mice, although in the kidney males only
produce 25% the ERβ as females, and ERα is produced at a lower level by males in all
of these tissues (70%, 6%, and 1% of female level, respectively) (Irsik, 2013). In the
kidney, ERα regulates urine osmolality and water homeostasis (Cheema, 2015).
In the cardiac system, estrogens are protective against cardiac disease. Women who
receive postmenopausal hormone replacement therapy (HRT, estrogen alone or
estrogen and progestin) within 10 years of menopause have a reduced risk of death
from coronary heart disease, although this same protection was not seen in women who
began treatment more than 10 years after menopause (Boardman, 2015). ERα in the
coronary endothelium is protective against ischemia-related loss of acetylcholine
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responsiveness and reduces the size of the damaged area after myocardial infarct
(Favre, 2010). ERα also plays an important role in E2-mediated protection from the
development of atherosclerosis, in part by reducing cholesterol levels (Hodgin, 2001). In
the brain, both ERα and ERβ are widely expressed, and both contribute to the
prevention of hypertension by acting on different regions of the brain (reviewed in Hay,
2014).
Many of the cells involved in the growth and maintenance of bones express ERα. Loss
of ERα results in bone defects. ERα-/- mice have shorter vertebrae and limb bones than
ERα+/+ mice, increased trabecular bone volume, and increased tibial thickness (Parikka,
2005). At the cellular level, osteoblasts from ERα-/- mice produce less type I collagen,
and female ERα-/- mice have fewer osteoclasts compared to ERα+/+ mice (Parikka,
2005). ERα not only plays an important role in bone growth, but also bone remodeling.
Many of the cell types involved in maintaining bone structure express ERα, and
estrogens play an important role in maintaining bone mineral density and preventing the
development of osteoporosis. HRT in post-menopausal women prevents osteoporosisassociated bone loss and fracture (Cauley, 2003). In addition to regulating bone growth
and remodeling, ER signaling also plays an important role in the bone marrow by
regulating hematopoiesis.
Estrogen and the Immune System
The immune systems of women and men differ intrinsically, which has long been
attributed the higher levels of estrogen in women. These intrinsic differences are thought
to be related to pregnancy and the need to both immunologically tolerate a fetus and
protect the body from external pathogens. Women produce more robust cellular and
humoral immune responses than men do, and consequently are at a higher risk of
developing autoimmune diseases. Estrogen does not cause an immune response, but
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instead enhances humoral immune responses (Carlsten, 1989). Hematopoietic stem
cells (HSCs) are the source of immune cells, and estrogen has far-reaching effects on
the whole immune system by acting on these undifferentiated cells. Both HSCs and the
more differentiated multipotent progenitors (MPPs) express ERα, while ERβ expression
is only detected in HSCs (Sanchez-Aguilera, 2014). There is no difference in the number
or frequency of HSCs or MPPs in the bone marrow of females and males (Nakada,
2014). In ERα+/+ females, both HSCs and MPPs divide more frequently than in ERα+/+
males or ER-/- mice of either sex, which all divide at the same lower rate (Nakada, 2014).
When estrogen levels are increased in females by pregnancy or E2 administration, the
frequency of HSC division increases further, and the number of HSCs in the bone
marrow significantly increases (Nakada, 2014, Illing, 2012). Males also experience
increased HSC division when treated with E2, propyl pyrazole triol (PPT, an ERα
agonist), or tamoxifen (an ERα agonist in hematopoietic cells) (Nakada, 2014; SanchezAguilera, 2014; Thurmond, 2000). Ergo, females naturally have an increased rate of
HSC division compared to males, which is dependent on ERα signaling and is due to a
naturally higher serum level of E2.
Although HSCs in female mice naturally divide more rapidly than in males, supraphysiological levels of division may have detrimental effects on the HSC population.
Treatment with high dose tamoxifen significantly decreases the long term HSC, short
term HSC, and MPP populations, while increasing the cycling of normally quiescent long
term HSCs (Sanchez-Aguilera, 2014). After three rounds of serial transplantation, E2
treated HSCs have a reduced ability to reconstitute the HSC population in the bone
marrow compared to untreated cells (Illing, 2012). Estrogens lead to an increased rate of
HSC division, and at high enough levels to exhaustion of the HSC population.
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Although there is strong evidence that ERα expression in HSCs plays an important role
in regulating HSC division, it is not the only way through which estrogens affect the HSC
population. Estrogen signaling via other receptors, as well as ERα signaling in stromal
cells, can also affect HSC division. In one study, ERα knockout mice treated with a high
dose of E2 had significant reduction in bone marrow HSCs, although this was not as
dramatic as was seen in ERα+/+ mice (-0.3 vs -0.8 fold) (Thurmond, 2000). This
suggests that ERα only partially regulates this effect, and that signaling through ERβ or
GPER may be involved. The same study also found that expression of ERα in both the
hematopoietic and non-hematopoietic cells contributed to the decrease in the number of
HSCs caused by high dose E2 (Thurmond, 2000). In short, estrogens promote the
division of HSCs, which is partially mediated by ERα. Supra-physiological amounts of
estrogen can cause exhaustion of the HSC population which, in turn, can lead to
alterations in the immune system.
In addition to their effects on HSCs, estrogens also impact the differentiation of
lymphocytes (see figure 1.2 for an overview of B cell development). Estrogen causes an
overall decrease in the total B cell population in the bone marrow; more specifically, it
causes a decrease in the number of developing B cells, and an increase in the
proportion of mature bone marrow B cells (Medina, 2001; Thurmond, 2000; Erlandsson,
2002). Additionally, estrogen causes a decrease in the number of B cells in the spleen
(Erlandsson, 2002). These effects on B cell populations are likely caused by ER
regulation of multiple genes. Estrogen signaling increases the expression of Bcl-2, an
anti-apoptotic molecule, in developing and mature B cells; increased Bcl-2 causes an
increase in mature B cells in the bone marrow (Grimaldi, 2002; Strasser, 1991).
However, overexpression of Bcl-2 does not affect the proportion of developing B cells in
the bone marrow or mature B cells in the spleen (Strasser, 1991). Expression of sFRP5,
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Figure 1.2 B cell development
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Figure 1.2 B cell development
B cells originate in the bone marrow from hematopoietic stem cells (HSCs) which
differentiate into multipotent progenitors (MPPs), and then common lymphoid
progenitors (CLPs) (not shown). CLPs differentiate into pro-B cells which undergo
immunoglobulin (Ig) heavy chain VDJ recombination. At the pre-B cell stage cells
express the recombined heavy chain with surrogate light chain forming the pre-BCR.
Heavy chain autoreactivity is mediated by additional rearrangement, and cells with
autoreactive heavy chain specificity which are not successfully remediated die via
apoptosis. Pre-B cells undergo Ig light chain VJ recombination. Immature B cells
express both heavy and light chains as IgM, and autoreactive cells are remediated or
are rendered anergic. Immature B cells leave the bone marrow and travel to secondary
lymphoid organs, such as the spleen. In secondary lymphoid organs Transitional T1 B
cells must undergo another checkpoint for autoimmunity before becoming Transitional
T2 cells, and then mature B cells. Mature B cells express IgD and can become marginal
zone or follicular B cells. Upon stimulation with cognate antigen and T cell help, memory
B cells and plasmablasts are produced. Plasmablasts give rise to long-lived and shortlived plasma cells.
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a modulator of Wnt signaling, is also increased by estrogen, and causes a decrease in
developing B cell populations in bone marrow and total B cell population in the spleen
(Yokota, 2015). These data suggest that estrogen causes a reduction in developing B
cells and fewer splenic B cells by regulating the expression of multiple genes. Both ERα
and ERβ are involved in the estrogen-mediated decrease in total bone marrow B cells
and the increased proportion of mature B cells in the bone marrow (Erlandsson, 2003).
The B cells of pre- and post-menopausal women and men all express ERα and ERβ at
approximately the same level, but it is the amount of estrogen (and not testosterone) in
the serum that negatively correlates with the total number of bone marrow B cells (Phiel,
2005; Erben, 2001). Additionally, estrogen promotes polyclonal B cell activation, which
results in an increased number of antibody-producing cells, and increased serum
immunoglobulins (Igs) (Carlsten, 1992; Nikolaevich, 1991). There are many ways in
which estrogen promotes the development of autoreactive B cells, which will be
discussed later.
In addition to its effects on B cell development, ERα plays an important role in the
development of the thymus and thymic T cell populations. Both CD4+ and CD8+ T cells
express ERα and ERβ at levels which are consistent among premenopausal women,
postmenopausal women, and men (Phiel, 2005). Estrogen, acting through ERα,
negatively regulates an early lymphocyte precursor population which gives rise to T
cells, and causes decreased thymus cellularity (Medina, 2001; Islander, 2003). In the
thymus, estrogen also causes a decrease in the immature double positive (CD4+CD8+) T
cell population and an increase in more mature single positive (CD4+ or CD8+) T cells
(Staples, 1999). This shift in T cell populations is also observed during pregnancy when
estrogen levels are naturally increased (Rijhsinghani, 1996). In a competitive
repopulation assay, E2-treated lymphocyte precursors produced fewer T cells than
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untreated precursors, but the T cells differentiated into single and double positive T cells
at normal ratios (Medina, 2001). Similarly, the pregnancy-induced disruption in thymic T
cell populations normalizes postpartum and thymic cellularity returns to normal after
weaning (Rijhsinghai, 1996).
The effects of estrogen on T cell development are mediated through both ERα and ERβ.
ERα-/- mice have significantly smaller thymi with lower cellularity compared to ERα+/+
mice (Staples, 1999). For normal size and cellularity of the thymus, expression of ERα is
needed in both the stromal and hematopoietic cells (Staples, 1999). E2 treatment in
ERα+/+ ERβ+/+, ERα-/-, and ERβ-/- mice causes a decrease in thymic cellularity, which
indicates that neither ERα nor ERβ alone is the sole mediator of the effects of E2 on
thymus cellularity (Staples, 1999; Erlandsson, 2001). Thymus structure and T cell
development are regulated by estrogen in a complex way not entirely dependent on
either ERα or ERβ, and the effects on thymic cellularity and T cell populations are
reversible when estrogen levels return to normal.
Estrogen also affects the immune response by regulating the balance of mature T cell
populations. A balance among IFNγ-, IL-2-, and TNFα-producing Th1 cells that promote
a cell-mediated immune response and IL-4-, IL-6-, and IL-10-producing Th2 cells that
promote a humoral immune response is necessary to prevent inappropriate immune
responses. Estrogens affect the Th1/Th2 balance in a bimodal manner, with low levels
leading to an increased Th1 response and high levels leading to a Th2 response.
Studies have shown that this effect is dependent on the expression of ERα in
hematopoietic cells, specifically in T cells (Maret, 2003; Lelu, 2011).
Th17 cells are CD4+ T cells that secrete pro-inflammatory IL-17 cytokines, and thus play
an important role in inflammatory and autoimmune diseases. Depending upon the
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stimulation conditions, estrogen can promote or suppress the production of IL-17 (Khan,
2010; Lelu, 2011). Similarly, estrogen has different effects on Th17 cells in different
disease models. Estrogen increases the number of IL-17-secreting cells and the amount
of IL-17 produced in lupus-prone (NZB x NZW)F1 mice, consistent with estrogen’s
pathogenic role in lupus (Khan, 2010). In contrast, in a murine model of arthritis,
estrogen signaling through ERα plays a protective role by restricting the localization of
Th17 cells so that they do not reside in inflamed joints (Andersson, 2015).
T regulatory cells (Tregs) promote self-tolerance in the periphery by inhibiting the
function of effector T cells. Increased levels of estrogen, by both E2 administration and
pregnancy, cause an increase in the population of Tregs via ERα signaling (Polanczyk,
2004). Not only does E2 cause an increase in the number of Tregs, but it also increases
their capacity to suppress effector T cells (Prieto, 2006).
Estrogen signaling, through ERα, can affect mature T cell populations in a number of
important ways, including regulating the balance of Th1/Th2 cells, regulating Th17 cell
activity, and increasing the regulatory capabilities of Tregs. Unlike with B cells, for which
estrogens are known to promote the development of autoreactive cells, the effect of
estrogens on the development of autoreactive T cells has not been studied.
In addition to its effects on lymphocytes, estrogen may also impact the differentiation
and function of myeloid cells. ERα is expressed in myeloid lineage cells (SanchezAguilera, 2014). However, reports vary on the effect of estrogens on the differentiation of
myeloid cells. One group found that the differentiation potential of common myeloid
progenitors is not affected by E2 treatment, while another reported that HSCs are less
capable of differentiating into granulocytes after treatment with E2 (Medina, 2001; Illing,
2012). ERα signaling can either inhibit or promote the differentiation of dendritic cells,
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depending on the cytokine environment, but it always enhances the dendritic cells’ proinflammatory capacities (reviewed in Kovats, 2012; Seillet, 2013). Megakaryocyte and
platelet counts are low when the E2 level is low and high when E2 levels are high (Fox,
2006). There is not a consensus about the effects of estrogens on monocyte function.
One recent study showed that human primary monocytes have attenuated production of
pro-inflammatory cytokines upon treatment with E2, while another found that women
have higher levels of activated monocytes compared to men (Pelekanou, 2016; Jiang,
2014). Estrogen, through macrophage-intrinsic expression of ERα, promotes
macrophage activation and pro-inflammatory cytokine production (Calippe, 2010).
Clearly, estrogen signaling affects myeloid cells in complex ways, sometimes promoting
and sometimes suppressing the immune response. More research into the effects of
estrogen on different myeloid lineage cells is needed to form a more complete
understanding of these effects.
As discussed here, in addition to their role in reproduction, ERs have a wide range of
effects on normal physiological processes throughout the body, including a strong
impact on the development and function of the immune system. Women are more likely
to develop most autoimmune diseases than men. This phenomenon is thought to be due
to intrinsic, estrogen-mediated, differences in the immune system. In order to develop
improved therapies for estrogen-mediated diseases, we must increase our
understanding of the role that estrogen signaling plays in different cells involved in the
pathogenesis of these diseases.
Systemic Lupus Erythematosus
Many diseases have a strong sex bias. Nearly all autoimmune diseases have a female
gender bias, including Hashimoto’s thyroiditis, Sjogren’s syndrome, rheumatoid arthritis,
and multiple sclerosis. One autoimmune disease with particularly strong sex bias is
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Systemic Lupus Erythematosus (SLE or lupus); between 90-95% of SLE patients are
women. The prevalence of SLE is approximately 107-150 per 100,000 adults, and 180250 per 100,000 women (Chakravarty, 2007). SLE is the most common and the most
severe form of lupus. SLE is a heterogeneous disease that can impact any organ system
and cause a variety of symptoms. Patients that have 4 or more of the 11 symptoms
defined by the American College of Rheumatology (ACR) are diagnosed with SLE.
These symptoms include malar rash, discoid rash, photosensitivity, oral ulcers, arthritis,
serositis, kidney disorder, neurological disorder, blood disorder, immunologic disorder,
and abnormal antinuclear antibody (Arthritis and Rheumatism, 1999). Lupus is a
dynamic disease and lupus patients experience alternating periods of flare and
remission.
Although there is great diversity in the symptoms that lupus patients can develop, there
are many immunological alterations, including the presence of autoreactive B and T
cells, which are commonly observed in lupus patients. The defining characteristic of
lupus is the production of antibodies against nuclear antigens‒ particularly the
production of pathogenic double stranded DNA (dsDNA) antibodies. When these dsDNA
autoantibodies bind antigen they form immune complexes which are deposited in tissues
and cause an inflammatory immune response and tissue damage. Other common
immune abnormalities seen in lupus patients include aberrant B and T cell activation,
defective clearance of apoptotic debris, and production of cytokines that promote
humoral and inflammatory immune responses.
Currently, the etiology of lupus is unknown, but it is thought to be caused by a
combination of genetic and environmental factors. Studies examining the incidence of
lupus in monozygotic and dizygotic twins have shown that monozygotic twins are more
likely to both have lupus than dizygotic twins, but that there is not complete concordance
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(Deapen, 1992). In addition to having a twin with lupus, having first degree relatives with
lupus significantly increases an individual’s risk of lupus. Those with one first degree
relative with lupus have a relative risk of 17.04, which increases to 35.09 for someone
with two first degree relatives with lupus (Kuo, 2015). Additionally, many genes
associated with increased risk of lupus have been identified in lupus patients (Chung,
2014; Radanova, 2015). These studies have clearly established that there is a genetic
component to lupus, but lupus is not a purely genetic disease.
It is believed that genetics predispose an individual to develop lupus and environmental
factors trigger disease onset through phenomena like epitope spreading or molecular
mimicry. Although there are likely many different initiating circumstances which can
prompt the development of lupus in susceptible individuals, there is evidence that
infections are a likely trigger of autoimmunity. Infection provides an opportunity for the
immune system to experience epitope spreading, superantigen exposure, and molecular
mimicry in an activated state. There have been reports of patients that experience an
infection shortly before developing symptoms of lupus (Yamazaki, 2015; Perez-Mercado,
2010; Rajadhyaksha, 2012). By a completely different mechanism, a theory known as
the hygiene hypothesis postulates that infection by microbes is protective against
autoimmunity, and that lack of infection causes the immune system to develop
abnormally and react against the self. So far, there is some support for this hypothesis in
the form of a few case studies, and the assertion that people of African ethnicity living in
the western world develop lupus at higher rates than Africans living in Africa, where they
presumably experience more infections (Praprotnik, 2008; Bae, 1998). However, this
assertion may be incorrect as similar rates of antinuclear autoantibody production have
been found in African Americans and Africans of the same ancestral heritage (Gilkeson,
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2011). Instead, the idea lupus is less common in Africa may be due to differences in the
diagnostic abilities and availability of health care in western and African countries
Although the etiology of lupus is unknown, a defining characteristic of this disease is the
production of anti-nuclear antibodies (ANA), including antibodies against dsDNA. Autoantibodies are produced by activated autoreactive B cells that either escape negative
selection at developmental checkpoints or are produced by somatic hypermutation
(SHM) in the periphery. ANA can be detected in 95% of lupus patients of AfricanAmerican, Afro-Caribbean, and Caucasian heritage (Somers, 2014; Flower, 2012).
Antibodies specific to dsDNA are only detected in only about 37% of lupus patients
(Hanly, 2016, Wichainun, 2013). Detection of both ANA and anti-dsDNA antibodies is
highly specific for lupus (88-96%, and 97-100% respectively), although ANA are
occasionally found in healthy controls (8%) and both antibodies are occasionally found in
patients with multiple other health problems (12% and 3%, respectively) (Wichainun,
2013). Although not detectable in all lupus patients, anti-dsDNA antibodies are very
specific to lupus.
In addition to autoreactive B cells and autoantibody producing plasma cells, lupus
patients have other immune abnormalities that contribute to disease. They have
significantly higher levels of B cell-activating factor (BAFF), which is secreted by
monocytes and activated T cells and promotes the maturation of B cells to plasma cells
(Elbirt, 2014). Patients with lupus have more plasmocytes and plasmablasts than healthy
controls (Korganow, 2010). Most B cells from lupus patients express less CD19 than
controls, which may prevent the negative selection of autoreactive B cells (Korganow,
2010). Some lupus patients have a pre-plasma B cell population with high CD19
expression, which is associated with adverse long-term clinical outcomes (Culton, 2007;
Nicholas, 2008). It is thought that these CD19hi B cells are easily activated and are
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autoreactive. Regulatory B cells (Bregs) are IL-10-producing B cells which negatively
regulate the inflammatory immune response. Bregs from lupus patients cannot
effectively inhibit T cell proliferation (Gao, 2014). In a murine lupus model that lacks
mature B cells, lupus is completely attenuated (Shlomchik, 1994). In the same murine
lupus model, when mature B cells are present but cannot secrete antibodies, some, but
not all, lupus-related outcomes are improved (Chan, 1999). These studies point to both
antibody-dependent and antibody-independent roles for B cells in lupus.
Like B cells, lupus patients also have autoreactive T cells that recognize nuclear
antigens. T cells from lupus patients are resistant to activation-induced apoptosis, which
leads to the survival of autoreactive T cells (Kim, 2010). The T cells of lupus patients
also have more rapid signaling than healthy individuals due to lower TCRζ levels
(Liossis, 1998). When activated, autoreactive B and T cells cause an inflammatory
immune response which leads to tissue damage. Normally, nuclear proteins are
sequestered and are not available to autoreactive B and T cells. However, multiple
defects in the clearance of apoptotic cell debris have been found in some lupus patients,
which lead to a large amount of uncleared nuclear material that is available for antigen
processing and presentation by autoreactive immune cells (Pang, 2014; Li, 2015; Jung
2015). Thus, targeting some of these immune cells for destruction or preventing their
activation could be an attractive therapeutic target for treating lupus.
Lupus can affect people of all ages, but is primarily a disease of young women.
Approximately 85% of adults with lupus are under age 50, and 28% are under 29
(Feldman, 2013). Although the exact statistics vary by study, non-Caucasian women are
at a higher risk of developing lupus than Caucasians. Asian women are twice as likely to
develop lupus as Caucasian women, and Hispanic and Native American women are also
at increased risk (Johnson, 1995; Samanta, 1991; Feldman, 2013). However, most
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dramatically, African American women are 2.5-3.5 times more likely to develop lupus
than Caucasian women (Lim, 2014; Chakravarty, 2007; Anderson, 2008). Unfortunately,
most cohort studies of lupus patients are made up predominately of Caucasian patients,
leaving African Americans and other minorities underrepresented.
The diagnostic criteria for lupus include a broad range of symptoms, and each patient
may experience a different set of symptoms. As such, there are many causes of
morbidity in lupus patients which can range from mild to life-threatening. In addition to
impacting the risk of developing lupus, the patient’s ethnicity influences the symptoms
that they will experience (Samanta, 1991; Feldman, 2013; Gomez-Puerta, 2015). Many
differences can be observed in the incidence of ACR criteria in lupus patients of different
ethnicities (Table 1.1). One important difference is that patients of both African American
and African Caribbean ethnicity have a significantly higher incidence of renal disorder
than Caucasian patients (Somers, 2014; Flower, 2012). It is estimated that lupus
nephritis occurs in 55-69% of Hispanic and African American patients and 23-29% of
Caucasian patients; nephritis is a major concern, because patients with nephritis have a
lower rate of survival than those that do not develop nephritis (Alarcon, 2002; Cervera,
2003; Bastian, 2002). Renal disease is especially threatening for recently diagnosed
patients. Patients that have measurable kidney damage soon after diagnosis are more
likely to develop end stage renal failure and have a significantly increased mortality rate
(Rahman, 2001; Nossent, 2007).
Lupus nephritis is caused by the deposition of immune complexes in the glomerular
basement membrane. This begins a process of renal chemokine expression, immune
cell infiltration, pro-inflammatory cytokine secretion, tissue damage, and loss of
glomerular filtration capacity. Histologically, lupus nephritis can have a wide range of
manifestations including: hypercellularity, immune complex deposits, glomerular
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Table 1.1 Clinical manifestations of lupus in different ethnic populations
Clinical Manifestation

% African
American

% African
Caribbean

% Caucasian

Malar rash

42.7 †

36.4 *

58.9

Discoid rash

32.2 †

33.1 *

13.5

Photosensitivity

41.4 †

5.8 ‡*

58.9

Oral ulcers

37.9 †

20.9 ‡*

48.2

Arthritis

71.8

84.0 ‡*

69.5

Serositis

45.9

50.3 *

42.3

Renal disorder

40.5 †

47.0 *

18.8

Neurologic disorder

21.7 †

17.2

14.0

Hematologic disorder

66.8

74.1 ‡*

64.5

Immunologic disorder

71.0 †

63.2 ‡

61.3

Antinuclear antibody

96.1 †

95.0 *

91.5

†=significant difference between African American and Caucasian
‡= significant difference between African American and African Caribbean
*= significant difference between African Caribbean and Caucasian
Data presented is compiled from Flower, 2012 and Somers, 2014
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sclerosis, crescent formation, and membranous neuropathy. Renal biopsy is used to
diagnose nephritis and the International Society of Nephrology/Renal Pathology Society
guidelines are used to classify the degree of lupus nephritis depending on the cell types
that are affected, and the extent of nephritis in the kidney (Weening, 2004). The immune
complexes which are deposited in tissues contain both antibody and antigen. Antibodies
reactive to dsDNA, chromatin, and proteins, including a variety of nuclear proteins are
found in immune complexes (Mannik, 2003). In healthy individuals, blood-borne immune
complexes are rapidly cleared in the liver, a process which is mediated by both
complement and Fc receptors; both of these clearance mechanisms are less effective in
lupus patients (Edberg, 1987; Davies, 1992; Davies, 2002). Additionally, immune
complexes can also be formed in situ in the kidney via antibody crossreactivity.
Monoclonal anti-dsDNA antibodies and antibodies isolated from the kidneys and urine of
lupus patients bind components of the glomerular basement membrane including
proteoglycan, heparin sulfate, and hyaluronic acid (Sasaki, 1991; Ben-Yehuda, 1995).
Although immune complex formation occurs in all individuals, faulty clearance, an
increased amount of cross-reactive anti-nuclear antibodies, and increased availability of
nuclear antigen make lupus patients susceptible to immune complex-mediated nephritis.
Although renal disease is a significant risk factor for lupus-related mortality, it is not the
only cause of lupus-related death.
A recent meta-analysis confirmed that lupus patients are at significantly increased risk of
dying compared to the general population, specifically due to increased risk of death
from nephritis and infection (Lee, 2016). Encouragingly, the risk for lupus patients of
dying from these causes has been steadily decreasing since the 1970s, as has the
overall risk of death (Bernatsky, 2006). In the past, it was reported that lupus patients
have a high risk of mortality in a bimodal manner, with a large proportion of patients
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dying within a year of diagnosis (Urowitz, 1976). However, in recent decades diagnosis
and therapies have improved, and lupus patients are not at increased risk of dying soon
after diagnosis; in fact, the risk of death is steady over time (Nossent, 2007). Infections
and cardiovascular events, including myocardial infarction and heart failure, are the main
causes of death among lupus patients, and SLE activity is a common contributing factor
(Nossent, 2007). In addition to early kidney damage, a major risk factor for mortality is
youth‒ 40 years old or younger, with those under 24 years old having an even greater
risk of mortality (Bernatsky, 2006). Having multiple comorbidities also significantly
increases the risk of death for lupus patients. The 1-year mortality rate increases
significantly with each comorbidity, from 9% for those with no comorbidities to 30% for
those with 2, and 57% for those with over 5 comorbidities (Anderson, 2008). Additionally,
ethnicity appears to influence the risk of mortality in lupus patients. African Americans
die at a significantly younger age than Caucasians, perhaps in part because they tend to
have more comorbidities, including diabetes mellitus, pericarditis, and thrombocytopenia,
in addition to nephritis/renal failure (Anderson, 2008). Although the rate of mortality for
lupus patients has declined over the past several decades, there is still a need for
improved therapeutic options for lupus patients.
As lupus is a chronic disease that affects many women during the reproductive years,
the effects of pregnancy on disease activity, and the effects of lupus on pregnancy
outcomes, are important considerations. Pregnant lupus patients are at increased risk of
maternal and fetal complications, including lupus flare, spontaneous abortion, and
preterm birth. The mean gestational age at birth for mothers with lupus is 32 weeks
(Feld, 2015). The premature birth rate is 39%, and 23% of pregnancies do not result in
live birth (Smyth, 2010). Several factors correlate with adverse fetal and maternal
outcomes, especially disease flare within 6 months of conception or during pregnancy,
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and prior history of nephritis (Kwok, 2011; Chen, 2015). The risk of fetal loss is
significantly decreased in individuals whose lupus is stable over the course of
pregnancy. Of women without significant lupus activity, 80% of pregnancies resulted in
live births, and 76% ended at full term; among women with significant lupus activity 6
months before pregnancy, only 31% of pregnancies resulted in live birth, and only 23%
were delivered at full term (Chen, 2015). Other studies have reported less dramatic fetal
mortality, with 89% of asymptomatic women and 65% of women with active lupus
achieving live births (Yang, 2014). Regardless of the exact numbers, lupus flare is a
significant risk factor for unsuccessful pregnancy outcome. Patients with a prior history
of nephritis have a significantly increased risk of flare and associated adverse fetal
effects like stillbirth, total fetal loss, fetuses which are small for gestational age, and
preterm delivery (Kwok, 2011). To a degree, the risks involved in pregnancy for lupus
patients can be managed with careful planning of pregnancies.
Since lupus primarily affects women, especially women between menarche and
menopause when estrogen levels are naturally high, it has long been assumed that
estrogen plays an important role in the pathogenesis of lupus. This is supported by the
fact that exposure to endogenous or exogenous estrogens is a risk factor for developing
lupus. Early age of menarche, oral contraceptive use, and post-menopausal HRT
increase the risk of developing lupus (Costenbader, 2007). Although men make up only
a small proportion of lupus patients, there is evidence that estrogen may contribute to
the development of lupus in men. Men with Klinefelter’s syndrome (XXY) have levels of
serum E2 about twice as high as healthy men, and are at greater risk for developing
lupus compared to healthy men (Wang, 1975; Socfield, 2008; Seminog, 2014).
Although estrogen is a risk factor for developing lupus, studies on the effects of estrogen
on disease activity in patients with lupus have not been so clear cut. Studies examining
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oral contraceptive use and lupus flare have shown mixed results (Jungers, 1982;
Sanchez-Guerrero, 2005; Petri, 2005). Similarly, there is no consensus on whether postmenopausal hormone replacement therapy increases the risk of lupus flare (Fernandez,
2006; Buyon, 2005). Over the course of pregnancy, estrogen and prolactin levels
increase dramatically, but the incidence of lupus flare correlates more closely with the
level of prolactin than with estrogen (Tsesis, 2013; Jara, 2007). Overall, the evidence for
estrogen as a risk factor for lupus flare is inconclusive.
There are several ways that estrogens can promote the development of autoimmunity.
Besides its impact on B cell development, estrogen can predispose B cells to
autoimmunity by impacting the negative selection of autoreactive cells and B cell
receptor (BCR) specificity. There are several checkpoints in B cell development where
autoreactive B cells are normally removed by induction of apoptosis or anergy; however,
estrogen signaling through ERα increases the frequency of high-affinity autoreactive B
cells by allowing them to escape negative selection at immature and T2 stages of
development, thus allowing the accumulation of autoreactive B cells (Grimaldi, 2006;
Hill, 2011). Estrogen promotes the development of autoreactive B cells by increasing the
expression of Bcl-2, CD22, Shp-1, and Vcam-1, which blunts the BCR signal, and
protects against BCR-mediated apoptosis (Grimaldi, 2002). Increased expression of Bcl2 alone leads to the production of autoantibodies, and to systemic autoimmunity
(Strasser, 1991).
In addition to allowing the survival of autoreactive B cells during development, estrogen
also promotes autoimmunity by impacting the specificity of the BCR. Genomic estrogen
signaling through EREs leads to expression of activation-induced deaminase which
promotes somatic hypermutation and class switch recombination (Mai, 2010; Pauklin,
2009). Somatic hypermutation can lead to de novo autoreactivity in B cells that originally
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expressed a non-autoreactive BCR (Guo, 2010). Additionally, somatic hypermutation of
the BCR promotes T cell activation and the formation of memory T cells (Jiang, 2012).
Estrogen also causes an increase in the splenic marginal zone B cell population, a
population which is more likely to be autoreactive against some antigens (Hendricks,
2011; Enghard, 2011). Therefore, estrogen affects B cells in multiple ways which
promote autoimmunity and immune activation.
As previously discussed, estrogens can signal through two nuclear hormone receptors:
ERα and ERβ. Studies of lupus-prone mice have concluded that ERα promotes lupus in
these models, while ERβ does not promote disease (Li, 2007; Svenson, 2008; Bynote,
2008). ERα signaling increases the number of Ig-secreting B cells and total serum IgG
(Erlandsson, 2003; Li, 2007). In the (NZB x NZW)F1 lupus model, ERα signaling
promotes the production of anti-dsDNA IgG autoreactive antibodies, particularly the
IgG2a and IgG2b isotypes (Bynote, 2008; Li, 2007).
Exposure to estrogen is a risk factor for developing lupus, yet lupus is still relatively rare
among those exposed to estrogen. Aside from other genetic differences which may
cause increased susceptibility to lupus, ER-intrinsic factors could impact ER signaling in
those prone to lupus, including receptor expression and genetic polymorphisms. The
promoter region of ERα is significantly demethylated in peripheral blood lymphocytes
from lupus patients, which correlates with increased amounts of ERα mRNA and protein
in these cells (Liu, 2014; Inui, 2007). It is not known if demethylation of ERα occurs
before or after the onset of clinical disease. Other studies have reported that lupus
patients and healthy controls express the same amount of ERα in B cells, T cells, and
monocytes (Suenaga, 1998; Rider, 2006). Despite the proposed differences in ERα
expression, there are no differences in the binding efficiency and binding characteristics
of ERα in lupus patients and healthy controls (Suenaga, 1996).
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Polymorphisms in ERα are associated with an increased risk of lupus in some
populations. The best studied, rs2234693 (commonly referred to as PvuII) and
rs9340799 (commonly referred to as XbaI), are located in an intronic region between
exon 1 and exon 2 of ERα. In Caucasian American patients, PvuII and XbaI
polymorphisms are significantly associated with lupus, and individuals homozygous for
either PvuII or XbaI have an even greater risk of lupus than those with only one copy
(Wang, 2010). However in adult Chinese, Korean, and Swedish lupus patients, there is
no association of the PvuII and Xbal polymorphisms with risk of lupus (Lu, 2009; Lee,
2004; Johansson, 2005). Although the Swedish study did not find an association
between these polymorphisms and increased risk of lupus, this study did find that the
PvuII polymorphism was associated with malar rash and that the XbaI polymorphism
was associated with photosensitivity (Johansson, 2005). Different combinations of PvuII
and XbaI alleles are associated with increased production of Th2 cytokines IL-4 and IL10 in lupus patients (Lu, 2009). Heterozygosity for an exon 8 polymorphism of ERα,
rs2228480, is also associated with an approximately 3 fold increase in lupus risk (Kassi,
2005). Although these do not by any means represent all of the possible genetic
contributions, any of these polymorphisms could predispose individuals to develop lupus
by altering their sensitivity to estrogen.
Lupus Treatments
Because lupus is such a heterogeneous disease, there are a range of treatments used,
which can be customized to each patient depending on their level of disease activity and
symptoms. Most of the current treatments for lupus cause broad immunosuppression
which makes patients susceptible to infection. In addition to immunosuppression, many
of the drugs used to treat lupus have serious side effects, and these treatments should
be given for the shortest amount of time and at the lowest effective dose to avoid side

29

effects. This can be a problem for a chronic disease like lupus where patients are never
cured and may require treatment for the rest of their lives. Current therapies for lupus
include: non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, glucocorticoids,
immunosuppressive drugs, and the recently approved antibody belumimab.
NSAIDs, such as ibuprofen and aspirin, are used to treat some mild to moderate
symptoms of lupus, including joint pain, mild inflammation, and fever. While these
medications have relatively mild side effects, they may not be appropriate for patients
with kidney disease because with long-term use they can cause reduced glomerular
filtration and increased blood pressure.
Antimalarials hydroxychloroquine and chloroquine are some other commonly used lupus
treatments. Use of these medications has increased over the past decade, and about
half of lupus patients take antimalarials at some time after diagnosis (Norgaard, 2015).
Antimalarials protect against the development of lupus nephritis and end-stage renal
disease, and improve the survival of lupus nephritis patients (Galindo-Izquierdo, 2016;
Zheng, 2012). Lupus patients taking hydroxychloroquine have a lower risk of serious
infection than patients taking immunosuppressive drugs, glucocorticoids, and even those
not taking medication (Feldman, 2015). Antimalarials can be used for long term
treatment and may be used in combination with other lupus medications. Often, the
addition of an antimalarial medication allows patients to use a lower dose of other, more
toxic, medications. Antimalarial drugs work via several mechanisms, including interfering
with the antigen-presentation function of T cells, antagonism of nucleic acid-sensing
TLRs, and by inhibiting the production of pro-inflammatory cytokines (Wallace, 2012;
Silva, 2013). Although generally safe, damage to the retina can be a side effect of these
drugs.
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When NSAIDs and antimalarials cannot effectively control lupus symptoms,
glucocorticoids such as prednisone are often prescribed. Glucocorticoids act by binding
the glucocorticoid receptor and mimicking the anti-inflammatory effects of cortisol.
Glucocorticoids significantly improve the survival of lupus patients (Zheng, 2012).
However, there are many side effects of these drugs which can significantly affect the
patient’s quality of life. Lupus patients that take glucocorticoids have a significantly
increased risk of serious infection, which can be life-threatening (Feldman, 2015). Other
symptoms include changes in appearance such as weight gain, round face shape,
redistribution of fat to the abdomen with thin arms and legs, and fluid retention. Patients
taking glucocorticoids can also experience osteoporosis and bone necrosis which can
necessitate joint replacement, cataracts, glaucoma, and psychological problems. To
decrease the risk of these side effects, glucocorticoids should be taken at the lowest
effective dose.
For severe forms of lupus, there are many immunosuppressive drugs that can be used
including: azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, leflunomide,
and cyclophosphamide. These drugs were originally developed as chemotherapeutic
agents or to prevent rejection after an organ transplant and are used for severe lupus
that affects organs or organ systems. These drugs interfere with cell replication,
suppressing the immune response through various mechanisms, some of which
specifically affect immune cells and some of which affect all replicating cells. Many of
these medications are “steroid sparing”, which means that while taking these drugs,
patients are able to take a reduced dose of glucocorticoids. Because these drugs inhibit
cell proliferation and the natural immune response, lupus patients taking
immunosuppressive drugs are at increased risk of serious infection (Feldman, 2015). An
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increased risk of developing cancer later in life is also a side effect of many of these
drugs.
In March 2011, the U. S. Food and Drug Administration (FDA) approved belimumab, the
first new lupus therapy to be approved in over 50 years. Belimumab was approved for
lupus patients without active kidney or central nervous system disease. Belimumab is a
human monoclonal antibody against B-cell activating factor (BAFF). BAFF is a B cell
growth factor essential for B cell survival. Without BAFF, B cells undergo apoptosis and
very few mature B cells develop (Marino, 2014). Overexpression of BAFF leads to both
an expanded B cell population and the production of an increased proportion of highaffinity autoreactive B cells (Ota, 2010). BAFF is overexpressed in peripheral blood of
lupus patients, and is positively correlated with increased disease activity (Ju, 2006;
Duan, 2016). Lupus patients treated with belimumab (in addition to standard of care)
have fewer peripheral B cells, including transitional and naïve B cells, pre-switched
memory B cells, and plasmablasts/ plasma cells (Jacobi, 2010). They also have
significantly less total IgG and less anti-dsDNA antibodies (Stohl, 2012).
Belimumab shows that biologics have great potential to improve on current lupus
treatments; however, belimumab itself is far from a magic bullet. After one year of
treatment, only 7.5-11.2% more patients treated with belimumab had disease
improvement compared to placebo-treated patients (Furie, 2011). Additionally, the risk of
sever flare was only reduced from 29.6% in placebo treated patients to 19-20.4% in
belimumab treated patients (Stohl, 2012). The cost of belimumab is approximately
$35,000 per year, which is quite high for the small percentage of patients who respond
positively to this treatment (Lamore, 2012). Furthermore, patients treated with
belimumab are also at increased risk of infection.
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Another monoclonal antibody, rituximab, is occasionally used to treat lupus, although it is
not FDA approved for this purpose. Rituximab is an antibody against CD20, which is
present on B cells from the pre-B cell stage in the bone marrow through the memory B
cell stage. It is approved for the treatment of B cell leukemia and lymphoma as well as
rheumatoid arthritis. Although stage III clinical trials of lupus patients treated with
rituximab did not show an improvement over treatment with placebo, it may still be
beneficial to some lupus patients, particularly African Americans (Merrill, 2010).
With the exception of NSAIDs taken for minor to moderate inflammation and pain,
therapies for lupus are broadly immunosuppressive and can have severe side effects,
especially when taken for a long time, as is necessary for a chronic disease like lupus.
Overall, the adherence to lupus medications is quite poor. Nonadherence (taking
medication appropriately <80% of the time) to lupus medications (prednisone,
hydroxychloroquine, other immunosuppressive drugs) has been estimated to be around
50% by multiple studies (Koneru, 2008; Abdul-Sattar, 2015; Ting, 2012). Some of the
risk factors for nonadherence include a low education level, not understanding the
directions given by the physician, taking more than one medication per day, and taking
medications more than once per day (Koneru et al, 2008; Abdul-Sattar 2015). This
means that not only can lupus treatment have severe side effects; treatment is also often
complicated and burdensome for patients. Physicians that treat lupus patients must try
to balance treating the symptoms of lupus, which can themselves be deadly, with the
side effects and mental burden caused by treatments. There is an obvious need to
improve the treatments for lupus, both in terms of decreasing serious side effects and
simplifying the treatment schedule, which should lead to increased patient compliance to
medication use.
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Research investigating the pathogenesis of lupus has revealed some new potential
approaches for the treatment of lupus. Genetic deletion of the ERα gene in lupus-prone
mice significantly attenuates disease, as does removing the endogenous source of
estrogen in young mice by ovariectomy (Bynote, 2008; Sobel, 2005). Among lupus
patients, postmenopausal women have fewer flares and a less disease activity
compared to premenopausal women (Urowitz, 2006). These data suggest that
antiestrogen therapies may be beneficial for lupus patients. Because lupus is
predominately a disease of young women, systemic antiestrogens would be
inappropriate as they interfere with fertility, and with bone and cardiovascular health.
Several different estrogen-modulating drugs are currently used to treat other diseases,
but none have been used to treat lupus.
Currently, estrogen-modulating therapies are used to treat and prevent conditions in
women including ER-positive breast cancers and osteoporosis. These therapies work by
several different mechanisms, from selectively antagonizing ERs to inhibiting the
production of estrogen. Selective ER modifiers (SERMs) act as ER agonists in some
tissues and as ER antagonists in others. Tamoxifen is a SERM which acts as an ER
antagonist in the breast and an ER antagonist elsewhere in the body, and is used for the
treatment of ER-positive breast cancers and the prevention of breast cancer in women
with a high risk of breast cancer. The SERM raloxifene acts as an ER agonist in bone
and an antagonist in the breast and uterus, and is approved for treatment of
osteoporosis and to reduce the risk of developing invasive breast cancer in
postmenopausal women. Bazedoxifene is a SERM used in conjunction with conjugated
estrogens, and is known as a Tissue Selective Estrogen Complex (TSEC). Bazedoxifene
is used to prevent osteoporosis and treat moderate-to-severe hot flashes in menopausal
and post-menopausal women. Fulvestrant is a pure ER antagonist. It binds ERs, blocks
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the binding of endogenous estrogens, and targets ERs for degradation. Aromatase
inhibitors are used to block the aromatization of testosterone to estrogen, but these
drugs are only effective in postmenopausal women because premenopausal women
produce too much aromatase to be effectively inhibited. To inhibit estrogen production in
premenopausal women, gonadotropin-releasing hormone agonists can be used;
however, these drugs are not appropriate for long-term therapy. Estrogen production can
also be permanently stopped by oophorectomy, which causes loss of fertility and
premature menopause.
Some of these estrogen-modulating therapies can have unintended effects on tissues
throughout the body, and have side effects which may be acceptable for cancer patients
who only require treatment for a limited period of time, but are unacceptable for lupus
patients who require long-term treatment. The SERMs and TSEC discussed here have
been approved by the FDA, and several other SERMs are currently being evaluated.
The use of a SERM or targeted delivery of the antiestrogen fulvestrant could be used to
antagonize ERs in the cells where ER signaling promotes lupus.
The specific cell type or types that mediate the effects of estrogens on lupus have not
been previously identified. We believe that cells of the immune lineage, particularly B
cells, promote lupus through ERα signaling. B cells are essential to the development of
lupus. Lupus-prone mice without mature B cells do not develop disease (Shlomchik,
1994). Estrogens have many effects of B cells which promote the development of
autoimmunity, which are discussed in more detail above. Estrogen signaling through
ERα allows autoreactive B cells to escape negative selection at tolerance checkpoints by
upregulating anti-apoptotic molecules, promotes affinity maturation of autoreactive B
cells, and promotes B cell activation (Grimaldi, 2002; Grimaldi, 2006; Hill, 2011; Guo,
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2010; Yoachim, 2015). Depletion of ERα from B cells would mitigate these effects, while
avoiding the broad immunosuppression caused by other lupus therapies.
Murine Models of Lupus
There are many murine models used to study lupus. In some models, the onset of lupus
can be induced by a single injection with pristane or allogenic donor cells (to induce
graft-versus-host disease). One advantage to using an inducible lupus model is that the
onset of lupus is uniform among all mice in the study. Drug-induced lupus also occurs in
humans after prolonged exposure to certain medications. However, unlike inducible
murine lupus, human patients fully recover after discontinuing the medication causing
the reaction.
In addition to inducible murine models of lupus, there are other murine lupus models in
which disease develops spontaneously as the result of genetic predisposition. Lupus as
a result of genetic predisposition is more relevant to human SLE, which has a strong
genetic component. Some genetic models of lupus have been used to identify genes
that confer lupus susceptibility.
Since lupus is a heterogeneous disease with many different manifestations and
symptoms, and no simple genetic cause, there is no perfect murine lupus model. Each
model recapitulates some aspects of disease, but none capture the full picture of lupus.
Some common genetic models of lupus are the MRL/lpr, BXSB, (NZB x NZW)F1, and
NZM2410 mice. These mice all produce antibodies against nuclear antigens which form
immune complexes, and glomerulonephritis is the main cause of death in all of these
lupus-prone mice. MRL/lpr mice have a spontaneous lymphoproliferation mutation in the
Fas gene, which is a receptor essential for Fas/Fas ligand-induced cell death. Mice of
both sexes develop systemic autoimmunity, aberrant T cell division, and immune
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complex-mediated glomerulonephrosis at a similar rate. In the BXSB strain, male mice
develop lupus at a much younger age than females because of the Yaa mutation carried
on the Y chromosome. (NZB x NZW)F1 mice are produced by crossing a New Zealand
Black (NZB) female with a New Zealand White (NZW) male. The parental NZW strain is
healthy and does not develop any lupus-like symptoms. However, NZB mice are prone
to leukemia, similar to chronic lymphocytic leukemia, by one year of age (Phillips, 1992).
The F1 offspring of this cross inherit risk alleles from each parent, which together confer
susceptibility to develop a lupus-like disease. (NZB x NZW)F1 mice of both sexes
develop autoantibodies and fatal glomerulonephritis, but females develop these
symptoms and die several months before males. The NZM2410 strain was derived from
offspring from a female (NZB x NZW)F1 bred with her NZW father (Rudofsky, 1999).
Female and male NZM2410 mice develop early-onset severe nephritis. These mice
have been extensively used to identify lupus susceptibility loci from the NZB and NZW
genomes.
Our lab uses (NZB x NZW)F1 mice for lupus studies. This model recapitulates some of
the important aspects of lupus, including the production of antibodies against nuclear
antigens, including chromatin and dsDNA, and the development of fatal
glomerulonephritis. However, importantly, the (NZB x NZW)F1 model is the only one
with a female sex bias. Studies from our lab showed a 100% penetrance of severe
glomerulonephritis in both female and male (NZB x NZW)F1 mice by 18 months of age;
however, female mice had a median survival time of 238 days while the median survival
time of males was 321 days (Bynote, 2008).
Although our lab uses (NZB x NZW)F1s, several different murine lupus models have
been used to study the effects of estrogen on lupus. In (NZB x NZW)F1, NZM2410, and
MRL/lpr mice, the detrimental effects of estrogen on lupus are mediated by ERα and not
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ERβ (Bynote, 2008; Li, 2007; Svenson, 2008; Cunningham, 2014). In lupus-prone mice
of both sexes, ERα signaling promotes the production of pathogenic autoantibodies and
the production of pro-inflammatory IFN-γ (Bynote 2008; Li, 2007). The activation of B
and T cells in (NZB x NZW)F1 mice is also promoted by ERα (Gould Lab, unpublished
data). Lupus-prone mice with ERα knockout have significant attenuation of albuminuria,
decreased lupus-associated kidney damage, and dramatically improved survival (Bynote
2008; Svenson et al, 2008).
Because we know how the lupus phenotype is affected by ERα signaling in lupus-prone
(NZB x NZW)F1 mice, we can use this model to identify the cell type or types that cause
the negative effects of estrogen on lupus. With this knowledge, we can advance the field
and begin to develop targeted antiestrogen therapies for lupus.
Summary
Lupus is a chronic autoimmune disease that predominately affects young women.
Exposure to estrogen, both endogenous and exogenous, is a risk factor for developing
lupus, and estrogens promote the development of autoimmunity in several ways.
Multiple murine lupus models have shown that estrogen promotes lupus via ERα
signaling. Taken together, the data presented here support the hypothesis that estrogen
signaling through ERα in cells of the immune system, particularly in B cells, promotes
lupus. To address this hypothesis, we have performed experiments investigating the role
of ERα in both all hematopoietic cells, and B cells in particular, in a lupus-prone mouse
model.
The role of ERα in hematopoietic cells was examined using lupus-prone (NZB x NZW)F1
chimeric mice with hematopoietic cells of one ERα genotype and non-hematopoietic
cells of a different ERα genotype. These studies revealed an important role for ERα in
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the successful engraftment of hematopoietic cells in female mice, but unfortunately were
not able to demonstrate that ERα in hematopoietic cells promotes lupus. To address the
role of ERα in B cells on lupus, we produced (NZB x NZW)F1 mice with cre-mediated
deletion of ERα specifically in B cells. Although we found that the cre knockin allele had
its own significant effects and caused relatively low efficiency of ERα deletion, we
showed that ERα signaling in B cells contributes significantly to the development of
lupus. Therefore, our studies have shown that disruption of ERα signaling in B cells is a
novel therapeutic target for lupus.
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Chapter 2: Dissertation Overview
Hypothesis and Objectives
The objective for these specific aims is to determine the effects of ERα on hematopoietic
cells in general, and B cells in particular, on lupus in (NZB x NZW)F1 lupus-prone mice.
In specific aim 1 we hypothesized that ERα signaling in hematopoietic cells promotes the
development of autoimmunity in (NZB x NZW)F1 mice, and that the lack of ERα in
hematopoietic cells would attenuate disease. In specific aim 2, we hypothesized that
ERα signaling in B cells promotes the production of autoantibodies and accelerates
mortality in (NZB x NZW)F1 mice.
Rationale
Lupus is a chronic autoimmune disease that predominately affects young women.
Exposure to estrogen, both endogenous and exogenous, is a risk factor for developing
lupus, and estrogens promote the development of autoimmunity by impacting the
development and activation of immune cells. Multiple murine lupus models have shown
that estrogen promotes lupus via ERα signaling. In these studies, ERα signaling was
affected throughout the body, and the specific cell type or types which promote lupus via
ERα were not elucidated. Therefore, our lab sought to determine the cell type or types
which mediate the effects of ERα on lupus.
In lupus patients, several types of immune cells function abnormally in ways which
contribute to lupus. Impaired negative selection leads to the persistence of autoreactive
B cells and the development of autoreactive plasma cells. Macrophages from lupus
patients have an impaired ability to phagocytose apoptotic debris, leading to an
increased presence of nuclear antigens. Follicular dendritic cells present autoantigens
from apoptotic cell debris to B cells, resulting in the activation of autoreactive B cells.
Some of these abnormalities have been shown to be dependent on ERα. ERα is
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expressed by hematopoietic cells at different stages and in different lineages including:
HSCs, MPPs, common myeloid progenitors, common lymphoid progenitors, B cells, T
cells, and myeloid cells (Sanchez-Aguilera, 2014).
B cells are essential to the development of lupus. Lupus-prone mice without B cells have
a completely attenuated lupus phenotype (Shlomchik, 1994). Estrogens have many
effects on B cells which promote the development of autoimmunity. Estrogen signaling
through ERα allows autoreactive B cells to escape negative selection at tolerance
checkpoints by upregulating anti-apoptotic molecules, and promotes affinity maturation
of autoreactive B cells (Grimaldi, 2002; Grimaldi, 2006; Hill, 2011; Guo, 2010). ERα also
promotes the activation of B cells in female mice carrying lupus susceptibility loci
(Yoachim, 2015).
Additionally, CD4+ T cells are stimulated by E2 through ERα, resulting in a Th-1 immune
response and IFN-γ production (Maret, 2003). In lupus-prone mice, ERα promotes T cell
activation, and ERα knockout causes a significant decrease in the serum level of IFN-γ
(Yoachim, 2015; Bynote, 2008). In contrast to its effect on CD4+ T cells, ERα signaling in
antigen-presenting splenic macrophages leads to decreased stimulation of CD4+ T cells
and a reduced Th-1 response (Lambert, 2005). These data suggest that ERα signaling
regulates the immune response by causing different effects in different types of immune
cells.
Taken together, these data strongly suggest that ERα signaling in hematopoietic cells
plays a role in the development of autoimmunity. Therefore, we were interested to
investigate the effects of loss of ERα in hematopoietic cells on lupus. Because B cells
play such a central role in lupus, and because of the strong evidence that ERα in B cells
promotes the development of autoimmunity, we were also interested in the role that ERα
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in B cells plays in lupus. The results of these studies will give new insight into the
pathogenesis of lupus, and could reveal novel therapeutic targets for the treatment of
lupus.
Specific Aims
Aim1: To determine how ERα signaling in hematopoietic cells impacts lupus in (NZB x
NZW)F1 mice.
The role of ERα in hematopoietic cells was examined using lupus-prone (NZB x NZW)F1
chimeric mice transplanted with hematopoietic cells of a different ERα genotype. The
engraftment of transplanted cells in these chimeric mice was determined by QPCR
analysis of peripheral blood DNA. Additionally, the survival of host plasma cells was
analyzed by QPCR of isolated plasma cells, and the antigen specificity of these cells
was analyzed by ELISPOT. The development of lupus including autoantibody
production, glomerulonephritis, and survival was analyzed in these mice. The results of
these studies are presented in chapter 3.
Aim 2: To determine how ERα signaling in B cells affects lupus in (NZB x NZW)F1 mice.
To address the role of ERα in B cells on lupus, we produced (NZB x NZW)F1 mice with
cre-mediated deletion of ERα specifically in B cells using the CD19-Cre knockin allele.
The efficiency of cre-mediated deletion of ERα was examined using QPCR. Survival was
monitored for up to one year. The production of antibodies and autoantibodies was
analyzed by ELISA. Histology was used to assess the development of
glomerulonephritis, and flow cytometry was used to assess the impact of ERα deletion
on B cell development. The results of these studies are presented in chapter 4.
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Chapter 3: Loss of estrogen receptor alpha in hematopoietic cells
temporarily attenuates lupus and impacts hematopoietic
reconstitution
Abstract
Estrogen signaling through ERα promotes lupus in lupus-prone (NZB x NZW)F1 mice.
Knockout of ERα in (NZB x NZW)F1 mice significantly attenuates autoantibody
production, glomerulonephritis, and mortality. We hypothesized that ERα signaling in
hematopoietic cells was responsible for these effects. To investigate this, we created
chimeric (NZB x NZW)F1 mice with different combinations of ERα+/+ and ERα-/hematopoietic and non-hematopoietic cells. ERα-/- hematopoietic and ERα-/- nonhematopoietic cells negatively impacted engraftment in female, but not male, mice.
Female ERα+/+ mice given ERα-/- hematopoietic cells had a lower rate of engraftment
than those given ERα+/+ cells, and female ERα-/- mice that received ERα+/+ hematopoietic
cells had a low level of engraftment, which decreased over time. In mice that were
successfully transplanted, the genotype of the transplanted bone marrow had no impact
on the latency to development of albuminuria or the development of glomerulonephritis.
Furthermore, there was no difference in the survival of ERα+/+ mice that were
successfully transplanted with either ERα-/- or ERα+/+ hematopoietic cells. However, we
did find that ERα+/+ females that received ERα-/- hematopoietic cells produced fewer
autoantibodies at a young age. However, this difference did not persist over time. We
postulate that the delayed production of pathogenic autoantibodies in ERα+/+ mice that
were transplanted with ERα-/- hematopoietic cells was the result of residual host-derived
(ERα+/+) plasma cells. Up to ten months after transplantation, host-derived plasma cells
were detected in some female and male mice. Furthermore, through analysis of
irradiated, but untransplanted mice, we showed that although immune cells were
significantly depleted, a significant amount of ERα+/+ dsDNA-reactive plasma cells
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survived irradiation. Altogether, these data suggest that residual autoreactive ERα+/+
hematopoietic cells may be sufficient to drive lupus in (NZB x NZW)F1 mice.
Additionally, these studies demonstrated that ERα signaling modulates the
hematopoietic reconstitution potential in female mice.
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Background
ERα signaling promotes the pathogenesis of lupus in (NZB x NZW)F1 mice. It causes
increased production of autoantibodies, increased glomerulonephritis, and shorter
survival (Bynote, 2008; Li, 2007). These effects were observed in models where mice
had ERα knockout or ERα stimulation throughout the body. Because these models
looked at the effects of ERα in the entire body, they cannot be used to identify which cell
type or types mediate the pathogenic effects of ERα. For this, other models must be
developed where the effects of ERα can be examined in specific cell types.
Hematopoietic stem cells give rise to the cells of the immune system including B cells, T
cells, macrophages, and dendritic cells. Lupus patients have many hematologic
abnormalities, including a reduced number of peripheral leukocytes. Some of the
abnormalities observed in the immune cells of lupus patients may contribute to the
development and survival of autoreactive B and T cells and the development of
autoimmunity.
Some of the immune alterations found in lupus patients are related to defective
clearance of apoptotic cell debris, which can be a source of nuclear autoantigens if not
properly degraded. Lupus patients have a higher proportion of apoptotic white blood
cells, and are not able to clear apoptotic debris as rapidly as healthy people (Fan, 2014;
Gaipl, 2007). Both monocyte-derived and tingible body macrophages from lupus patients
are impaired in their ability to phagocytize apoptotic cells, which leads to the
accumulation of apoptotic debris in germinal centers (Tas, 2006; Baumann, 2002). This
free apoptotic debris can be taken up by follicular dendritic cells and presented to B
cells, and lead to activation of autoreactive B cells (Gaipl, 2007).
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Defective clearance of apoptotic bodies, and presentation of nuclear antigens by
follicular dendritic cells can lead to the activation of autoreactive B cells, but lymphocytes
from lupus patients have other characteristics which can also contribute to aberrant
activation of the immune system. Anti-inflammatory Bregs from lupus patients have a
decreased ability to inhibit T cell proliferation, independent of any lupus-related T cell
defects (Gao, 2014). Additionally, T cells from lupus patients have more rapid and
robust responses to T cell receptor stimulation (Vassilopoulos, 1995; Liossis, 1998).
Both CD4+ and CD8+ T cells substantially contribute to the production of anti-dsDNA IgG
by B cells in lupus patients (Linker-Israeli, 1990). Alterations in B and T cell function can
lead to synergistic B and T cell activation which, combined with a less effective Breg
population, can lead to increased immune activation. This may contribute to the increase
in B cells and plasma cells, and the higher percentage of activated B cells found in lupus
patients (Fan, 2014; Korganow, 2010).
Although these particular effects have not been explicitly linked to estrogen, estrogen
affects the immune system in many ways that promote the development of
autoimmunity. Estrogen (through ERα) promotes the development of autoreactive B cells
by allowing high-affinity autoreactive B cells to escape negative selection at tolerance
checkpoints (Grimaldi, 2006; Hill, 2011, Grimaldi, 2002). Estrogen also promotes B cell
autoreactivity by promoting somatic hypermutation in the periphery, which can cause
mutations that lead to an autoreactive BCR (Mai, 2010; Pauklin, 2009; Guo, 2010).
Additionally, somatic hypermutation causes T cell activation and the formation of
memory T cells (Jiang, 2012).
In addition to its effects on B cell autoreactivity, estrogen may promote lupus by
stimulating Th2 immune responses. E2 promotes the activation of both CD4+ and CD8+
T cells (Wang, 2008). Exposure to estrogen causes CD4+ T cells to produce fewer Th1
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and more Th2 cytokines, thus promoting a humoral immune response (Polanczyk, 2005;
Haghmorad, 2014). This is protective in the EAE model of multiple sclerosis (Lelu,
2011), where E2 protects against the development of disease, but may be pathogenic in
lupus which is mediated by the Th2 immune response. Additionally, E2 prevents Fasdependent apoptosis in activated Th2, but not Th1, cells by increasing Bcl-2 expression
(Huber, 1999). A similar phenomenon is seen in lupus patients where estrogen inhibits
the activation-induced apoptosis of T cells by down-regulating the expression of FasL
(Kim, 2010).
Not all T cells promote Th2 immune responses in response to estrogen signaling. iNKT
cells produce IFN-γ, a Th1 cytokine, in response to estrogen signaling through ERα
(Gourdy, 2005). Exposure to estrogens increases the number of T regs and enhances
their capacity to suppress CD4+ effector T cells (Polanczyk, 2005). The antiinflammatory effects of Tregs have been suggested to be dependent on Treg intrinsic
expression of ERα (McKarns, 2015). Thus, not all of the effects of ERα on hematopoietic
cells promote immune stimulation and the development of autoimmunity.
Additionally, estrogens promote autoimmunity by acting on myeloid lineage cells.
Chronic ERα stimulation by E2 causes increased production of inflammatory cytokines
and nitric oxide by macrophages (Calippe, 2008; Calippe, 2010). E2 promotes the
differentiation of dendritic cells with potent antigen-presentation capabilities, which
strongly promote the proliferation of CD4+ T cells (Paharkova-Vatchkova, 2004). ERα
stimulation also causes dendritic cells to produce inflammatory IFN-α and TNF-α (Seillet,
2012). Together, these studies show that ERα promotes autoimmunity though multiple
mechanisms by acting on both lymphoid and myeloid cells. Therefore, we hypothesized
that cells of the hematopoietic lineage are likely responsible for ERα’s role in promoting
lupus.
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To study the impact of ERα in hematopoietic cells on lupus, we created (NZB x NZW)F1
chimeras by transplanting ERα-/- and ERα+/+ hematopoietic cells into mice with that were
ERα+/+ elsewhere in the body. Because ERα in stromal cells plays an important role in
the development of the cells that the stroma supports (as demonstrated in the thymus
and testis), we also transplanted ERα+/+ hematopoietic cells into ERα-/- and ERα+/recipients.
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Methods
Production of experimental mice
All animals were housed under conditions of controlled humidity, temperature, and
lighting in facilities accredited by the American Association for Accreditation of
Laboratory Animal Care, operating in accordance with standards set by the Guide for the
Care and Use of Laboratory Animals. Mice had ad libitum access to 7904 Teklad
Irradiated S-2335 Mouse Breeder Diet (Harlan Teklad, Madison, WI, USA). All
procedures involving live animals were approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee.
Age and sex matched (NZB x NZW)F1 mice between 8-12 weeks old were used as both
cell donors and recipients for these studies. Recipient mice were irradiated with two
doses of 5 Gy, 4 hours apart with a RS-2000 irradiator in the Biological Irradiator Core
(RAD Source Technologies Inc., Alpharetta, GA, USA).
Bone marrow and spleen cells were isolated from donor mice in a laminar flow hood
under sterile conditions. Cells were suspended in RPMI cell culture medium (Gibco,
Waltham, MA, USA) at 1x107 live cells/ 100 μl. Approximately 2x107 bone marrow cells
and 1x107 splenocytes were injected i.v. via the tail vein immediately after the second
dose of irradiation. Mice were given antibiotic-supplemented water (1 g/L neomycin and
125 mg/L polymyxin B) 4 days before transplant until 2 weeks post-transplant, to prevent
infections while the transplanted immune system was established (Sigma-Aldrich, St.
Louis, MO, USA; Calbiochem, San Diego, CA, USA).
The following combinations of transplants were performed. ERα+/+ or ERα-/- cells into
ERαfl/+ recipients, and ERα+/+ cells into ERα+/- or ERα-/- recipients, outlined in Table 1.
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The floxed (fl) allele of ERα is functionally a wild type allele, and (NZB x NZW)F1.ERα+/mice develop lupus which is indistinguishable from (NZB x NZW)F1.ERα+/+ mice.
Analysis of engraftment efficiency
Blood was collected 8 weeks after transplant, and red blood cells lysed with ACK lysis
buffer (Gibco). DNA was then isolated with a DNeasy kit using the protocol for cultured
cells (Qiagen, Hilden, Germany). Blood DNA was analyzed for engraftment using Sybr
green (Applied Biosystems, Foster City, CA, USA) quantitative PCR (QPCR) and a 7500
Real Time PCR System (Applied Biosystems). For ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+
transplants, ERαfl F: 5’-CTATACGAAGTTATGGATCCCTAGC-3’ and ERαfl R: 5’CACATGCAGCAGAAGGTATTTG-3’ primers were used to detect the ERαfl allele (149
bp product) and ERαEx5 F: 5’-GGAAGGCCGAAATGAAATGGG-3’ and ERαEx5 R: 5’CCAACAAGGCACTGACCATC-3’ primers were used to detect exon 5 of ERα (140 bp
product). Exon 5 of ERα is identical in the ERαfl, ERα-, and ERα+ alleles. Grafts with
≥95% efficient engraftment (<5% ERαfl DNA detected) were considered successful for
these sets of transplants. For ERα+/+→ERα-/- and ERα+/+→ERα+/- transplanted mice,
NeoC F: 5’-GGCATTCTGCACGCTTCAAA-3’ and NeoC R: 5’TTGTTCAATGGCCGATCCCA-3’ (104 bp product) primers were used to detect the ERαallele, and compared to ERα exon 5. The NeoC primers over-reported the amount of
ERα- DNA present in samples by ~5%, so the cutoff for successful engraftment was
placed at 90%.
Analysis of chemokines and receptors
Bone marrow was collected from 3 month old (NZB x NZW)F1 ERα-/- and ERα+/+ mice.
RNA was isolated from cells using the Absolutely RNA Miniprep Kit (Aligent
Technologies, Santa Clara, CA, USA). Up to 2.5 μg RNA was converted to cDNA using
SuperScript VILO Master Mix (Invitrogen, Carlsbad, CA, USA) and was diluted 1:80
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before use. RT PCR was performed using Power SYBR Green PCR Master Mix (Applied
Biosystems). The following primers were used: Cxcr4 F: 5’AAACCTCTGAGGCGTTTGGT-3’ and Cxcr4 R: 5’-GCAGGGTTCCTTGTTGGAGT-3’
(148 bp product), Cxcr7 F: 5’-ACAGGCTATGACACGCACTG-3’ and Cxcr7 R: 5’ACGAGACTGACCACCCAGAC-3’ (92 bp product), Cxcl12 F: 5’CAGAGCCAACGTCAAGCA-3’ and Cxcl12 R: 5’-AGGTACTCTTGGATCCAC-3’ (128 bp
product). Each of these primers was normalized to GAPDH. The GAPDH primers were,
F: 5’-TGCACCACCAACTGCTTAG-3’ and R: 5’-GGATGCAGGGATGATGTTC-3’ (177
bp product).
Survival studies
Mice were monitored biweekly for albuminuria with Albustix (Bayer Corporation, Elkhorn,
IN, USA). Upon a positive (2+ or greater) reading, mice were tested weekly. Mice were
considered positive for albuminuria upon two consecutive readings of 2+ (100 mg/dl) or
greater. Mice were also visually examined weekly for physical symptoms of distress.
Mice were sacrificed upon two consecutive albuminuria readings of 4+ (>2000 mg/dl) or
upon signs of significant distress.
Serological analysis
Enzyme Linked Immunosorbent Assay (ELISA) was used to measure serum antibody
levels. Anti-chromatin IgG ELISA plates were made with Immulon 2 HB plates (Thermo
Fisher Scientific, Waltham, MA, USA) coated with excess histone proteins and dsDNA.
Diluted serum samples were incubated on the plate. The plate was washed, and then
incubated with anti-mouse IgG HRP conjugate (EMD Millipore, Billerica, MA, USA). After
washing, TMB substrate (Alpha Diagnostic International, San Antonio, TX, USA) was
added for 20 minutes or until a significant color change developed, after which Stop
Solution (Alpha Diagnostic International) was added to the wells, and the plate was read
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on a 96 well microplate reader at 450 nm. For wash steps, 0.05% Tween-20 in PBS was
used. Anti-dsDNA IgG ELISAs were done with Immulon 2 HB plates (Thermo Fisher
Scientific) coated with only dsDNA, and the same procedure was followed as for the
anti-chromatin ELISAs.
Flow cytometry
To assess cells by flow cytometry, bone marrow and spleen cells were isolated from
mice at the end of the survival study. Bone marrow cells were gently pipetted up and
down and spleen cells were passed through a 70 μm cell strainer (Thermo Fisher
Scientific) to create single cell suspensions. Red blood cells were lysed with ACK lysis
buffer (Gibco) and stained with combinations of CD138 PE, CD19 APC, CD27 V450,
CD4 PE, CD25 APC-Cy7, CD62L APC, CD69 FITC, CD80 FITC, and CD86 PE (all BD
Biosciences, San Jose, CA, USA). Propidium iodide was used as a live/dead stain (BD
Biosciences). Cells were fixed with 0.6% formalin. Flow cytometry was performed with a
BD LSRII Flow Cytometer and analyzed with FACSDiva software (BD Biosciences, v.
8.0).
Periodic acid-Schiff staining and analysis
Kidneys were collected from mice upon death or sacrifice at the end of the survival study
and fixed in 10% formalin for 24 hours. Fixed kidneys were paraffin embedded,
sectioned, stained with the Periodic Acid-Schiff Kit (Sigma-Aldrich), and analyzed by
light microscopy. One hundred glomeruli per kidney were evaluated as previously
described (Bynote, 2008). Briefly, kidneys with 20-50% affected glomeruli have
moderate glomerulonephritis, and those with < 50% affected glomeruli have severe
glomerulonephritis.
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Plasma cell isolation and genotyping
Plasma cells were isolated from mice at the time of death or at one year of age. Briefly,
single cell suspensions were made from the bone marrow and spleen, and red blood
cells were lysed. The CD138+ plasma cell kit and AutoMacs (Miltenyi Biotech, BergischGladbach, Germany) were used to isolate CD138+ plasma cells. DNA was collected from
these cells using the DNeasy kit (Qiagen) and QPCR was performed as described
above for engraftment efficiency using ERαfl and ERαEx5 primers.
ELISPOT
To examine the potential of autoreactive plasma cells to survive irradiation, 10 week old
mice were irradiated with two doses of 5 Gy four hours apart, but were not injected with
cells from a donor mouse. After irradiation, mice were monitored three times daily for
signs of distress. 7-8 days after irradiation, mice were sacrificed and bone marrow and
spleen cells were collected, single cell suspensions made, and stained for fluorescence
activated cell sorting (FACS) with CD138-PE, MHCII-V500, and propidium iodide as a
live dead gate (BD Biosciences). FACS was used to purify populations of live long-lived
(CD138+ MHCIIlo) and short-lived (CD138+ MHCIIhi) plasma cells. Cells were sorted with
a FACSAria II (BD Biosciences). Isolated cells in RPMI +10% fetal bovine serum were
applied to an Immulon 2 HB plate coated with dsDNA and were incubated at 37ºC with
6% CO2 in a humid environment for 24 hours. Biotinylated anti-mouse IgG (Vector
Laboratories, Burlingame, CA, USA) was applied, followed by streptavidin-alkaline
phosphatase (Southern Biotech, Birmingham, AL, USA). Next, 1 mg/ml 5-bromo-4chloro-3-indolyl phosphate (Sigma-Aldrich) in AMP buffer was applied until colored spots
developed. The plate was rinsed with running water and spots counted under a
dissecting microscope.
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Statistics
Statistical analysis was done using SPSS software (IBM, v. 23). P values of less than or
equal to 0.05 are considered significant. Kaplan Meyer survival curves and log rank tests
were used to evaluate survival. A 2-sided Fisher’s exact test was used to analyze the
engraftment efficiency of ERαfl transplants. Student’s t tests were used to evaluate the
efficiency of some transplant, ELISA, flow cytometry, histology, and QPCR data.
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Results
Production of Experimental Animals
To analyze the effect of ERα in hematopoietic cells on lupus in (NZB x NZW)F1 mice, we
produced two sets of chimeric mice. The first set was designed to compare the effects of
ERα-/- and ERα+/+ hematopoietic cells in ERα+/+ (NZB x NZW)F1s. The second set used
ERα+/+ hematopoietic cells in both ERα-/- and ERα+/- recipients to evaluate the
contributions of ERα in non-hematopoietic cells to lupus. The first set of chimeras was
produced by transplantation of ERα+/+ or ERα-/- bone marrow into lethally irradiated
ERαfl/+ recipients (ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+). The loxP sites in the ERαfl allele
are located in introns surrounding ERα exon 3, and functions as ERα+ allele when it has
not undergone recombination (as is the case in this cre recombinase-free system)
(Dupont, 2000). Transplantation of hematopoietic cells to ERαfl/+ recipients allowed us to
detect cells derived from the host mouse in QPCR assays.
The second set of chimeric mice was produced by transplanting ERα+/+ bone marrow
into lethally irradiated ERα+/- or ERα-/- mice (ERα+/+→ERα+/- and ERα+/+→ERα-/-). For this
set of chimeras, cells from the host can be detected by QPCR for the null allele of ERα.
ERα+/- mice were used as recipients because the null allele of ERα could be detected by
QPCR to determine engraftment efficiency. Heterozygosity for the null allele of ERα has
no impact on the lupus phenotype in (NZB x NZW)F1 mice (Bynote, 2008). The chimeric
mice used for these studies are named so that the first genotype indicates the donated
hematopoietic cells and the second indicates the genotype of the recipient mouse and
the non-hematopoietic cells (Table 3.1).
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Table 3.1 The ERα genotype of hematopoietic and non-hematopoietic cells in
chimeric mice
Transplant

Hematopoietic cells

Non-hematopoietic cells

ERα-/-→ERαfl/+

ERα-/-

ERαfl/+

ERα+/+→ERαfl/+

ERα+/+

ERαfl/+

ERα+/+→ERα-/-

ERα+/+

ERα-/-

ERα+/+→ERα+/-

ERα+/+

ERα+/-
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Optimization of the Transplantation Protocol
Before these experiments began, preliminary experiments were carried out to optimize
the transplantation protocol. Different strains of mice can tolerate different amounts of
irradiation, and when we began these experiments there was no information available
about the amount of irradiation (NZB x NZW)F1 mice could tolerate. A protocol from
another lab at our institution specified that mice should be irradiated with 10 Gy (1000
rad) prior to transplant to produce chimeric mice (Garg, 2009). When 10 Gy of x-ray
irradiation was administered to (NZB x NZW)F1 mice in a single dose, followed
immediately by cell transplant, mice lost an average of 15% of their body weight and
showed visible signs of distress before they died, an average of 12 days after the
procedure. Other available protocols specified that irradiation should be given in a split
dose, with a four hour gap between doses. When (NZB x NZW)F1 mice were irradiated
with a split dose of irradiation (5 Gy, then four hours later 5 Gy) and then immediately
transplanted with hematopoietic cells, the mice did not develop visible signs of distress,
and only lost an average of 3% of their initial body weight after 2 weeks. The survival of
(NZB x NZW)F1s treated with single and split dose irradiation is shown in Figure 3.1a.
To determine if the irradiation and transplantation procedure had a significant impact on
the long-term survival of (NZB x NZW)F1 mice, the survival of a small group of female
mice transplanted with ERα+/- bone marrow was monitored. These mice had a median
survival of 211 days, which is not different from the 239 day median survival time of
unirradiated ERα+/- females (Figure 3.1b). Thus, this split dose irradiation protocol did not
negatively impact the median survival time in (NZB x NZW)F1 mice.
ERα is necessary for Efficient Bone Marrow Engraftment in Females but not Males
The engraftment efficiency of bone marrow transplants was measured with DNA isolated
from peripheral blood 8 weeks after transplant. The efficiency of ERα-/-→ERαfl/+ and
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Figure 3.1 Split dose irradiation does not significantly affect survival of (NZB x
NZW)F1 mice
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Figure 3.1 Split dose irradiation does not significantly affect survival of (NZB x
NZW)F1 mice
(NZB x NZW)F1 mice were irradiated with 10 Gy of x-ray irradiation in single and split
doses and transplanted with hematopoietic cells. (a) Mice that received a single dose of
irradiation died soon after transplant while mice that received a split dose survived much
longer (p=0.003). The median survival (b) is not different between female mice treated
with a split dose of irradiation and female mice that were not irradiated.
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ERα+/+→ERαfl/+ transplants was determined by measuring the relative abundance of
recipient-derived DNA (as measured by the ERαfl allele) by QPCR. Efficiency of
ERα+/+→ERα-/- and ERα+/+→ERα+/- transplants was determined by measuring the amount
of recipient-derived DNA (as measured by the ERα- allele) by QPCR. ERα-/-→ERαfl/+ and
ERα+/+→ERαfl/+ transplants with ≥ 95% engraftment were considered successful, and
unsuccessfully transplanted mice were excluded from further studies. The primers used
to measure ERα- DNA slightly over-represent the amount of ERα- DNA in each sample,
so in engraftment is slightly overestimated in ERα+/+→ERα-/- and ERα+/+→ERα+/transplants, so mice with ≥ 90% estimated engraftment were considered successful.
For female mice, there was a statistically significant difference in the transplant efficiency
between mice with different ERα genotypes in hematopoietic cells. In females, the
success rate of the ERα-/-→ERαfl/+ grafts was significantly less than that of the
ERα+/+→ERαfl/+ grafts (Figure 3.2a). Among ERα-/-→ERαfl/+ females, only 35% had
successful grafts, with a median of 90% engraftment, while in ERα+/+→ERαfl/+ females,
68% had successful grafts with a median of 100% engraftment.
There was also a statistically significant difference in the transplant efficiency, measured
8 weeks after transplant, between female mice with different ERα genotypes of nonhematopoietic cells. The estimated rate of engraftment in ERα+/+→ERα-/- females was
significantly lower than in ERα+/+→ERα+/- females (Figure 3.2b). Among ERα+/+→ERα+/females the median estimated engraftment was 88.5%, while in ERα+/+→ERα-/- females
the median estimated engraftment of was 39%. This indicates that loss of ERα in both
hematopoietic and non-hematopoietic cells significantly impacts the success of
hematopoietic reconstitution in females.
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Figure 3.2 Loss of ERα causes impaired hematopoietic reconstitution in female
mice
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Figure 3.2 Loss of ERα causes impaired hematopoietic reconstitution in female
mice
Engraftment efficiency was detected by QPCR of DNA from peripheral blood. (a) The
group of female ERα-/-→ERαfl/+ chimeras had significantly fewer successful transplants
compared to ERα+/+→ERαfl/+ females (p=0.047). (b) Female ERα+/+→ERα-/- chimeric
mice also had significantly lower rates of engraftment compared to ERα+/+→ERα+/females (p=0.016). Among male mice (c-d) the ERα genotype of hematopoietic and nonhematopoietic cells did not affect transplant success.
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The engraftment efficiency in male mice did not depend on ERα genotype. There was no
difference in the proportion of successful transplants between ERα-/-→ERαfl/+ and
ERα+/+→ERαfl/+ males (Figure 3.2c). 73% of ERα-/-→ERαfl/+ males had successful grafts
with a median engraftment of 100%, and 80% of ERα+/+→ERαfl/+ males had successful
grafts with a median of 100% engraftment. Likewise, ERα+/+→ERα-/- and ERα+/+→ERα+/male mice did not differ in transplantation efficiency (Figure 3.2d). The median estimated
engraftment efficiency was 90% for ERα+/+→ERα-/- males, and 93% for ERα+/+→ERα+/males. Therefore, loss of ERα in either hematopoietic or non-hematopoietic cells does
not impact the success of hematopoietic reconstitution in males.
In addition to successful initial engraftment (measured 8 weeks after transplant, at about
4 months of age), successful bone marrow transplants must be able to maintain
engraftment over time. To assess engraftment efficiency over time, we isolated DNA
from blood collected at monthly intervals, and used QPCR to measure the ERαfl or ERαDNA originating from the host in selected samples. At least 3 mice of each sex and
genotype were evaluated at 6 months of age, and some were additionally evaluated at 8
and 10 months of age.
In both female and male ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ mice, the engraftment
efficiency was stable between 4-8 months of age for females and 4-10 months for males
(Figures 3.3a-d). The degree of engraftment did not significantly decrease in either set of
female mice between 4-6 months, or male ERα-/-→ERαfl/+ mice between 4-10 months.
The degree of engraftment did significantly decrease between 4 and 10 months in
ERα+/+→ERαfl/+ males, however this was a small decrease, corresponding to less than
2% per month (average 100% at 4 months vs 93% at 10 months).
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Figure 3.3 part 1 Engraftment efficiency decreases over time in female
ERα+/+→ERα-/- chimeras
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Figure 3.3 part 2 Engraftment efficiency decreases over time in female
ERα+/+→ERα-/- chimeras
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Figure 3.3 Engraftment efficiency decreases over time in female ERα+/+→ERα-/chimeras
Engraftment efficiency was measured at later time points. The engraftment efficiency did
not change significantly between 4 and 8 months in (a) female ERα+/+→ERαfl/+ chimeras,
(b) female ERα-/-→ERαfl/+ chimeras, or between 4 and 10 months in (d) male
ERα+/+→ERαfl/+ chimeras. In (c) ERα-/-→ERαfl/+ males engraftment decreased slightly but
significantly between 4 and 10 months, at a rate of less than 2% per month (p=0.01).
The engraftment of (f) female ERα+/+→ERα-/-chimeras decreased significantly between 4
and 6 months (p=0.03), but no decrease in engraftment occurred between 4 and 6
months in (e) female ERα+/+→ERα+/- mice, (g) male ERα+/+→ERα+/- mice, or (h)
ERα+/+→ERα-/-male mice.
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The engraftment efficiency of ERα+/+→ERα+/- and ERα+/+→ERα-/- chimeras was remeasured at 6 months of age. In female ERα+/+→ERα-/- chimeras, there was a significant
decrease in engraftment efficiency between 4 and 6 months of age (Figure 3.3f). On
average, the amount of donor-derived DNA detected in these mice decreased by 14%
over this period, although this amount varied by individual. Female ERα+/+→ERα+/- and
male ERα+/+→ERα-/- and ERα+/+→ERα+/- chimeras had stable engraftment, and there was
no significant variation in engraftment between 4 month and 6 months (Figure 3.3e,g,h).
Therefore, in female mice, loss of ERα in recipient mice transplanted with ERα+/+
hematopoietic cells results in a progressive decrease in the proportion of ERα+/+
hematopoietic cells. This effect is not observed in female ERα-/-→ERαfl/+ mice which also
had lower engraftment efficiency 8 weeks after transplant compared to controls. In male
mice, the ERα genotype of hematopoietic and non-hematopoietic cells does not cause a
large progressive decrease in engraftment efficiency.
CXCR4, CXCR7, and CXCL12 Expression is Not Affected by ERα
The success of hematopoietic reconstitution was affected by the ERα genotype of
hematopoietic cells and non-hematopoietic cells in female, but not male mice. The
chemokine CXCL12 mediates localization of HSCs to the stem cell niche by interacting
with the chemokine receptors CXCR4 and CXCR7 on hematopoietic cells. The
expression of these is regulated by estrogen (Boudot, 2011; Li, 2013). A change in the
expression of one or more of these molecules could be responsible for impaired
hematopoietic reconstitution in female mice.
Therefore, we examined the expression of CXCL12, CXCR4, and CXCR7 in global
ERα+/+ and ERα-/- mice. RNA was isolated from the bone marrow of ERα+/+ and ERα-/mice, and analyzed by QRT-PCR for CXCR4, CXCR7, and CXCL12, and compared to
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GAPDH. We found no significant differences in the expression of CXCR4, CXCR7, or
CXCL12 in bone marrow cells from ERα+/+ and ERα-/- mice (Figure 3.4).
ERα in Hematopoietic Cells Does Not Affect Albuminuria or Survival
Although they do not all develop disease at exactly the same time, (NZB x NZW)F1 mice
develop lupus at a predictable rate. Females develop and succumb to disease several
months before males. ERα+/+ females develop albuminuria with a median latency of 201
days, while ERα+/+ males develop albuminuria at a median latency of 335 days (Bynote,
2008). The median lifespan for ERα+/+ females is 238 days and for ERα+/+ males is 321
days (Bynote, 2008). ERα-/- (NZB x NZW)F1 mice have significantly delayed albuminuria
and prolonged survival. For female (NZB x NZW)F1 mice, loss of ERα increases the
median survival time by >308 days, and median survival is extended by 113 days in
males (Bynote, 2008). Therefore, loss of ERα has a greater impact on lupus in female
mice.
In this study, albumin in the urine, or albuminuria, was measured as a non-invasive way
to assess renal function. Albumin is a protein which is excluded from the urine by healthy
kidneys, but is present in the urine of individuals with nephritis, and an increased
concentration of albumin correlates with increased kidney damage. These chimeric mice
were also monitored for survival until they reached a maximum of one year of age.
In ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ female mice with successful engraftment, there
was no difference in the incidence and latency to albuminuria (Figure 3.5a). 83% of
ERα-/-→ERαfl/+ and 92% of ERα+/+→ERαfl/+ females developed detectable albuminuria
before death, at a median age of 234 and 244 days, respectively. Similarly, there was no
difference in the survival of ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ females (Figure 3.5b).
The median survival of ERα-/-→ERαfl/+ females was 258 days, which is not different from
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Figure 3.4 Expression of chemokine receptors is not affected by ERα deficiency
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Figure 3.4 Expression of chemokine receptors is not affected by ERα deficiency
Levels of CXCR4, CXCR7, and CXCL12 mRNA were quantitatively measured in bone
marrow cells from ERα+/+ and ERα-/- mice. There were no significant differences in
mRNA levels in (a) female or (b) male mice.
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Figure 3.5 The ERα genotype of hematopoietic cells does not impact the survival
of (NZB x NZW)F1 chimeras
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Figure 3.5 The ERα genotype of hematopoietic cells does not impact the survival
of (NZB x NZW)F1 chimeras
(a) Albuminuria was measured in female ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ mice, and
no difference was found in the median latency to albuminuria. Survival was monitored for
up to one year in (b) female and (c) male ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ mice, and
there was no difference in the median survival in mice of either sex.
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the 271 day median survival of ERα+/+→ERαfl/+ females. This suggests that, in female
mice, the ERα genotype of hematopoietic cells does not affect the development of lupus.
Albuminuria and survival were initially monitored in ERα+/+→ERα+/- and ERα+/+→ERα-/chimeric mice. However, after it became clear that the engraftment in ERα+/+→ERα-/females was uniformly unsuccessful, the albuminuria and survival studies were
discontinued. All remaining mice in this arm of the study were sacrificed at six months of
age.
No female mice from the ERα+/+→ERα-/- group achieved successful engraftment, so
these mice have a hematopoietic compartment which consists of a mixed population of
ERα+/+ and ERα-/- cells. When mice from this group were compared to ERα+/+→ERα+/mice, there was no difference in survival (Figure 3.6a). ERα+/+→ERα-/- females had a
median survival of 247 days, and ERα+/+→ERα+/- females had a median survival of 278
days. Because the hematopoietic compartment of ERα+/+→ERα-/- females is a mixed
population, we cannot draw conclusions about the impact of ERα in non-hematopoietic
cells on lupus with these mice.
Albuminuria was not accurately assessed in males, because I was not able to
consistently express urine in male mice, so albuminuria data will not be presented for
males, but the survival of males was monitored for up to one year. There was no
difference in the survival of ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ male mice (Figure 3.5c).
ERα-/-→ERαfl/+ males had a median survival time of 338 days, and ERα+/+→ERαfl/+ males
had a median survival time of 358 days. This suggests that the ERα genotype of
hematopoietic cells does not affect survival in male mice.
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Figure 3.6 The ERα genotype of non-hematopoietic cells does not impact the
survival of chimeric (NZB x NZW)F1s
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Figure 3.6 The ERα genotype of non-hematopoietic cells does not impact the
survival of chimeric (NZB x NZW)F1s
Survival was monitored for up to one year. In (a) female mice, including mice with
inefficient engraftment, survival was not different in ERα+/+→ERα+/- and ERα+/+→ERα-/mice. (b) There was no difference in the survival of ERα+/+→ERα+/- and ERα+/+→ERα-/male mice.
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There was no difference in the survival of ERα+/+→ERα-/- and ERα+/+→ERα+/- male mice
(Figure 3.6b). Neither group of male mice reached 50% mortality over the course of this
study, so the median survival could not be calculated for these groups.
Together, these survival studies suggest that ERα-/- hematopoietic cells are unable to
attenuate lupus in female and male mice. Additionally, in male mice, no difference in
survival was observed in mice with ERα-/- and ERα+/+ non-hematopoietic cells, which
suggests that ERα in non-hematopoietic cells does not affect the development of lupus.
Hematopoietic Estrogen Receptor Alpha Influences Autoantibody Production
(NZB x NZW)F1 lupus-prone mice produce antibodies against many nuclear antigens.
To determine the effect of hematopoietic ERα expression on autoantibody production,
ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ mice with successful engraftment were evaluated for
autoantibody production using serum samples collected at monthly intervals. Nonpathogenic anti-chromatin IgG autoantibodies, which are among the first autoantibodies
detected in lupus, were measured in female ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ mice at
5, 6, and 7 months of age. At 5 months of age, both groups produced very little antichromatin IgG and there was no difference in antibody production between these
groups. However, at 6 months of age ERα+/+→ERαfl/+ females produced significantly
more anti-chromatin IgG than ERα-/-→ERαfl/+ females (Figure 3.7a). At 7 months of age,
there was no difference in the amount of anti-chromatin IgG produced by the two groups.
In both groups of chimeric mice, there is a trend of increasing antibody production as
mice age, which is consistent with previous observations in (NZB x NZW)F1 mice. These
data suggest that female mice with ERα-/- hematopoietic cells have attenuated lupus at 6
months, but by 7 months this attenuation is overcome and immune activation is similar to
females with ERα+/+ hematopoietic cells.
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Figure 3.7 Fewer autoantibodies are produced by female ERα-/- → ERαfl/+ chimeras
at 6 months of age
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Figure 3.7 Fewer autoantibodies are produced by female ERα-/- → ERαfl/+ chimeras
at 6 months of age
(a) Serum α-chromatin IgG was measured by ELISA in female ERα+/+→ERαfl/+ and ERα-/→ERαfl/+ mice at 5, 6, and 7 months of age. ERα-/-→ERαfl/+ mice produced significantly
less α-chromatin IgG at 6 months of age (p=0.006). (b) Anti-dsDNA IgG antibodies were
measured in the same mice at 6, 7, and 8 months of age in the same mice. At 6 months
ERα-/-→ERαfl/+ mice produced less anti-dsDNA IgG. (c) Anti-dsDNA IgG was measured
in male mice at 8 months of age, and there was no difference in antibody production
between ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ males.
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Pathogenic anti-dsDNA IgG autoantibodies were measured at 6, 7, and 8 months of age
in ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ females. Anti-dsDNA IgG production followed the
same trend that was observed with anti-chromatin IgG production in these mice. At 6
months of age, ERα+/+→ERαfl/+ females produced significantly more anti-dsDNA IgG than
ERα-/-→ERαfl/+ females (Figure 3.7b). However, by 7 and 8 months of age there was no
difference in the anti-dsDNA IgG production between these groups. As with antichromatin IgG, anti-dsDNA IgG usually increases over time in (NZB x NZW)F1 mice.
This was observed in these experimental mice until 8 months of age, by which time
many of the sickest mice had died, and the average level of anti-dsDNA IgG plateaued.
Therefore, female mice with ERα-/- hematopoietic cells produced less anti-dsDNA IgG at
6 months of age, but as these mice aged, autoimmunity was activated, and lupus was no
longer attenuated.
The latency to death in chimeric mice is similar between females at 6 months of age,
and males at 8 months of age; therefore, anti-dsDNA IgG production was measured in
ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ males at 8 months of age. Male mice produce the
same amount of this antibody at 8 months of age (Figure 3.7c).
B and T cell Populations Are Unaffected by Hematopoietic ERα
ERα affects the development of many types of immune cells. Plasma cells and activated
B and T cells are cells associated with more aggressive lupus, while other immune cells,
like Tregs, negatively regulate the immune response. We examined several lymphocyte
populations in the bone marrow and spleens of chimeric mice to see if ERα expression
in hematopoietic cells affected these populations. The cells for this experiment were
collected when mice were removed from the survival study due to signs of illness. A
large proportion of male mice survived until the end of the study without developing
signs of illness. This, combined with the relatively small number (n = 15/ group) of mice
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produced for these studies, resulted in a very small number of ill male mice. Therefore,
we were not able to capture data from enough ill males to compare ERα+/+→ERαfl/+ and
ERα-/-→ERαfl/+ mice. Almost all female mice showed signs of illness over the course of
the study, so we were able to capture data from enough ERα+/+→ERαfl/+ and
ERα-/-→ERαfl/+ female mice to compare these two groups.
No differences were found in the percentage of plasma cells, memory B cells, or Tregs
in either the bone marrow or spleens of ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ female mice
(Table 3.2). This indicates that at the end-stage of disease, the sizes of these B and T
cell populations are not different in mice with and without ERα expression in
hematopoietic cells.
One consequence of knockout of ERα in (NZB x NZW)F1 mice is a dramatic reduction in
the activation of B and T cells (Gould lab, unpublished data). Activation of B and T cells
was also examined in female ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ mice. There was no
difference in the percentage of activated B cells or activated T cells in the spleen (Table
3.3). This indicates that, at least at the end stage of disease, ERα-/- and ERα+/+
hematopoietic cells are similarly activated in (NZB x NZW)F1 chimeras.
ERα Does Not Impact the Development of Moderate to Severe Glomerulonephritis
In order to determine if the development of glomerulonephritis was affected by ERα in
hematopoietic and non-hematopoietic cells, kidneys were collected at the end of the
survival study. Kidneys sections were stained with Periodic acid-Schiff, and analyzed for
signs of nephritis. All kidneys that were examined from ERα+/+→ERαfl/+ and
ERα-/-→ERαfl/+ mice had moderate to severe glomerulonephritis (Figure 3.8a). There was
no difference in percentage of affected glomeruli between ERα+/+→ERαfl/+ and
ERα-/-→ERαfl/+ females; the mean percent of affected glomeruli was 78% and 80%,
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Table 3.2 Lymphocyte populations in chimeric mice
Bone marrow

Spleen

ERα-/-→ERαfl/+

ERα+/+→ERαfl/+

ERα-/-→ERαfl/+

ERα+/+→ERαfl/+

% Plasma cells

5.4 ± 1.3

8.0 ± 3.8

2.5 ± 0.3

2.4 ± 0.05

% Total memory
B cells

3.2 ± 1.2

4.7 ± 1.3

5.4 ± 1.2

1.3 ± 0.3

% T regulatory
cells

6.0 ± 2.0

8.2 ± 5.8

4.1 ± 2.0

6.4 ± 1.6

Plasma cells- % of live CD138+ cells
Total memory B cells- % of CD27+ of live CD19+ cells
T regulatory cells- % of CD25+ CD62Llo of live CD4+ cells
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Table 3.3 B and T cell activation in the spleen
ERα-/-→ERαfl/+

ERα+/+→ERαfl/+

% Activated B cells

12.4 ± 2.1

13.0 ± 3.3

% Activated T cells

17.5 ± 4.8

18.9 ± 3.9

Activated B cells- % of CD80/86+ of live CD19+ cells
Activated T cells- % of CD69+ of live CD4+ B cells

82

Figure 3.8 part 1 Chimeric (NZB x NZW)F1 mice develop severe glomerulonephritis
at the same frequency
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Figure 3.8 part 2 Chimeric (NZB x NZW)F1 mice develop severe glomerulonephritis
at the same frequency
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Figure 3.8 Chimeric (NZB x NZW)F1 mice develop severe glomerulonephritis at the
same frequency
Kidneys collected at the end of the survival study were stained with PAS and evaluated
for glomerulonephritis. (a) Almost all kidneys from the ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+
chimeras had severe glomerulonephritis and those that did not had moderate
glomerulonephritis. (b) Although few mice in the ERα+/+→ERα+/- and ERα+/+→ERα-/groups were kept until the end of the survival study, the kidneys from these mice all had
moderate or severe glomerulonephritis. Representative sections from (c) female
ERα+/+→ERαfl/+, (d) female ERα-/-→ERαfl/+, (e) male ERα+/+→ERαfl/+, and (f) male ERα-/→ERαfl/+ chimeras are shown.
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respectively. Similarly, there was no difference in the percentage of affected glomeruli in
males. Male ERα+/+→ERαfl/+ mice had an average of 77% affected glomeruli, while
ERα-/-→ERαfl/+ males had an average of 74% affected glomeruli. Representative images
of PAS-stained kidneys from each of these groups are shown (Figure 3.8c-f).
Because the survival studies for ERα+/+→ERα+/- and ERα+/+→ERα-/- mice were
terminated prematurely, there were few samples available from mice that had completed
the survival study in which to analyze glomerulonephritis. However, 2-4 samples per
group were analyzed, and all showed signs of moderate to severe glomerulonephritis
(Figure 3.8b). All types of chimeric mice from these studies developed
glomerulonephritis characteristic of lupus in (NZB x NZW)F1 mice. Therefore, these
mice are dying from lupus-related causes, not as a side effect of the irradiation and
transplantation procedure.
Autoreactive Plasma Cells Survive Irradiation
ELISA data indicated that the development of autoimmunity is delayed in ERα-/-→ERαfl/+
females compared to ERα+/+→ERαfl/+ females, which supported our hypothesis that ERα
in immune cells promotes lupus. However, the subsequent increase in autoantibody
production suggested that somehow ERα-/- immune cells became activated and were
driving the progression of lupus. If ERfl/+ host-derived plasma cells were driving
autoantibody production in 7 and 8 month old ERα-/-→ERαfl/+ female mice, this could
also be the reason that we did not observe a difference in survival between mice with
ERα-/- and ERα+/+ hematopoietic cells.
In an effort to address the hypothesis that the failure to see attenuation of lupus in
ERα-/-→ERαfl/+ mice was due to antibody production by residual, host-derived ERαfl/+
plasma cells, we looked for the presence of ERαfl/+ plasma cells in mice at the end of the
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survival study. CD138+ plasma cells were isolated with a magnetic column, DNA was
isolated, and QPCR used to detect the amount of DNA derived from host plasma cells.
DNA from the ERαfl/+ host could be detected in 60% of plasma cell samples from bone
marrow and 62.5% from spleen (Figure 3.9a). Overall, ERαfl/+ DNA was detected in 6 of
9 mice used for this experiment from both ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ mice. All of
the mice in which ERαfl/+ plasma cell DNA was not detected were one year old, so it is
possible that ERαfl/+ plasma cells could have been detected in these mice at a younger
age. This indicates that long-lived plasma cells may survive irradiation, and persist for 710 months after irradiation.
Although detection of ERαfl/+ plasma cells in chimeric mice indicated that some host
plasma cells either survived irradiation or arose from cells that did, this experiment did
not address the specificity of these cells. To determine if host dsDNA-reactive plasma
cells survived irradiation, young (NZB x NZW)F1 mice were irradiated and not injected
with replacement bone marrow. After one week, plasma cells were isolated and antidsDNA IgG ELISpot was performed. Figure 3.9b shows an example of ELISpot wells
containing blue-green spots which represent dsDNA-reactive plasma cells.
Irradiation of young mice caused a greater than ten-fold decrease in the number of live
cells recovered from the bone marrow and spleen. Accordingly, after one week the
spleen weight was reduced by 65-75% in irradiated mice compared to unirradiated
littermate controls. Live long-lived plasma cells (PI- CD138+ MHCIIlo) and short-lived
plasma cells (PI- CD138+ MHCIIhi) were isolated from the bone marrow and spleen and
applied to a plate coated with dsDNA.
dsDNA-reactive long-lived and short-lived plasma cells were detected in the spleen and
bone marrow of young, irradiated mice. The percent of dsDNA-reactive cells ranged
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from 0.27-0.41% (Table 3.4). This is a relatively high percentage of plasma cells to be
reactive to a single antigen. These results show that pathogenic dsDNA-reactive plasma
cells can survive irradiation in 10 week old (NZB x NZW)F1 mice. These residual
pathogenic cells may be sufficient to cause lupus in these mice.
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Figure 3.9 Autoreactive plasma cells from the host survive irradiation
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Figure 3.9 Autoreactive plasma cells from the host survive irradiation
Plasma cells were isolated from ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ mice at the end of
the survival study, and the origin of the cells was evaluated by QPCR. (a) Plasma cells
from host mice were detected in the bone marrow and spleen of mice which had
received both ERα+/+ and ER-/- transplants. (b) An example of an ELISPOT plate
showing dsDNA-reactive plasma cells.
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Table 3.4 dsDNA-reactive plasma cells survive irradiation in young (NZB x NZW)F1
mice

Long-lived plasma cells

Short-lived plasma cells

Spleen

0.27 ± 0.07%

0.41 ± 0.29%

Bone marrow

0.37 ± 0.09%

0.41 ± 0.07%

Long-lived plasma cells (PI- CD138+ MHCIIlo)
Short-lived plasma cells (PI- CD138+ MHCIIhi)
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Discussion
ERα signaling promotes the pathogenesis of lupus in (NZB x NZW)F1 mice (Bynote,
2008; Li, 2007). To investigate the cell type/types that mediate this effect, we created
chimeric (NZB x NZW)F1 mice with ERα-/- hematopoietic cells or ERα-/- nonhematopoietic cells. Although our studies were not able to delineate the impact of ERα-/hematopoietic and non-hematopoietic cells on lupus, our studies demonstrated the
importance of ERα signaling on hematopoietic reconstitution.
Age- and sex-matched (NZB x NZW)F1 ERα+/+ and ERα-/- bone marrow was
transplanted into (NZB x NZW)F1 ERαfl/+ mice to examine the impact of the ERα
genotype of hematopoietic cells on lupus. Among female mice, ERα-/-→ERαfl/+ chimeras
have significantly less successful grafts than ERα+/+→ERαfl/+ chimeras, but grafts from
both these sets of mice were stable over time. There was no difference in the
engraftment efficiency between ERα+/+→ERαfl/+ and ERα-/-→ERαfl/+ male mice. Therefore,
ERα-/- hematopoietic cells from female and male mice have different potential for
engraftment. This difference is caused by intrinsic differences between cells from
females and males. HSCs from females require ERα to maintain the normal rate of cell
division (Nakada, 2014). ERα-/- cells from females could also have an impaired ability to
hone to the stem cell niche.
In a set of complementary experiments, ERα+/+ bone marrow was transplanted to ERα+/or ERα-/- mice in order to determine the impact of ERα in non-hematopoietic cells on
lupus in (NZB x NZW)F1 mice. At 8 weeks after transplant, ERα+/+→ERα-/- female mice
have dramatically lower engraftment efficiency compared to ERα+/+→ERα+/- females, and
the efficiency of engraftment in ERα+/+→ERα-/- females decreases over time. We believe
that this is caused by an exhaustion of ERα+/+ hematopoietic cells in ERα-/- female mice
where serum E2 levels are 10x higher than in ERα+/+ females. Treatment with estrogen
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causes an increased rate of HSC and MPP division in a cell intrinsic manner (Nakada,
2010; Illing, 2012). This estrogen-induced increase in division is mediated by ERα
(Nakada, 2010). Additionally, extended treatment with high dose E2 causes exhaustion
of ERα+/+ hematopoietic cells, while ERα-/- cells are resistant to this effect (Thurmond,
2000). Together, this supports our theory that the progressive decrease in engraftment
efficiency in ERα+/+→ERα-/- female chimeric mice is due to exhaustion of ERα+/+
hematopoietic cells caused by the high level of serum E2 in female ERα-/- mice.
Exhaustion of ERα+/+ hematopoietic cells causes ERα-/- cells that survived irradiation to
comprise an increasing proportion of the hematopoietic population in these mice.
We hypothesized that another factor that may contribute to engraftment failure in
ERα+/+→ERα-/- female mice may be a difference in the bone marrow microenvironment.
A difference in the bone marrow microenvironment between female ERα+/+ and ERα-/mice could prevent HSCs from locating and engrafting in the stem cell niche. Our
analysis of chemokine receptors CXCR4 and CXCR7, and the chemokine ligand
CXCL12, which are involved in HSC homing to the stem cell niche, did not reveal a
difference in the expression of these molecules between ERα-/- and ERα+/+ female mice.
Estrogen also has bone marrow stromal cell intrinsic effects, which affect the
development of hematopoietic cells (Smithson, 1995). Therefore, ERα-/- bone marrow
stromal cells could negatively impact the survival of ERα+/+ hematopoietic cells.
No difference in engraftment success was observed in (NZB x NZW)F1 male mice from
either set of transplants. This result was not surprising, because ERα does not have the
same effects on hematopoietic cells in males that it has in females. HSCs divide at the
same rate in ERα+/+ and ERα-/- male mice (Nakada, 2014). Additionally, male ERα-/- mice
have the same level of serum E2 as ERα+/+ males, so ERα+/+ hematopoietic cells would
not undergo rapid E2-induced division, as in females.
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In female and male mice that were considered successful transplants, we found that the
ERα genotype of hematopoietic cells does not impact median survival. The median
survival times of ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ females are not different from each
other, but are 20-33 days longer than global ERα+/+ females (Bynote, 2008). Similarly,
the median survival of male ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ chimeras are not
different, but are 17-37 days longer than global ERα+/+ males. The delay in lupus-related
death observed in chimeras compared to non-transplanted (NZB x NZW)F1s likely
occurs because, although the donor bone marrow cells are age-matched with the
recipients, reconstitution of the hematopoietic compartment takes several weeks, and
the pathogenic processes that promote lupus are delayed while reconstitution takes
place.
Female ERα-/-→ERαfl/+ chimeras had lower levels of anti-chromatin and anti-dsDNA
antibodies at 6 months of age (2.5-3 months before death) compared to ERα+/+→ERαfl/+
females. However, the amount of anti-chromatin and anti-dsDNA antibodies was not
significantly different between these groups at 7 months of age. This suggests that
although ERα-/- hematopoietic cells attenuate lupus at a young age, this effect is
overcome in older mice, leading to increased autoantibody production.
The unsuccessful engraftment of ERα+/+→ERα-/- female mice prevented us from
assessing the impact of ERα in non-hematopoietic cells on lupus in female mice. These
mice had hematopoietic compartments composed of a mix of ERα+/+ and ERα-/- cells.
There was no difference in the survival of male ERα+/+→ERα-/- and ERα+/+→ERα+/- mice,
which suggested that the ERα genotype of non-hematopoietic cells does not impact the
development of lupus.
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A confounding factor that should be considered when interpreting these results is the
incomplete ablation of the host immune system. Although irradiation effectively kills
rapidly dividing cells, long-lived plasma cells are resistant to irradiation-induced cell
death and can survive for more than 6 months after irradiation (Miller, 1967). A recent
study has shown that many long-lived plasma cells are produced in young (NZB x
NZW)F1 mice (> 105 by 6 weeks of age in the spleen) many hundreds of which are
dsDNA-reactive (Taddeo, 2015).
For ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ chimeras, mice with up to 5% of host DNA in the
peripheral blood were considered to have successful engraftment. Our ELISpot analysis
showed that 0.27-0.41% of plasma cells were dsDNA reactive in 10 week old (NZB x
NZW)F1 mice that express ERα. This seems to be quite a large percentage of plasma
cells to be reactive against a single antigen. There have been few reports of the
percentage of plasma cells reactive to a single antigen, likely because the frequency of
these cells is very low. A study of 5-7 month old (NZB x NZW)F1s found that ~0.03% of
bone marrow plasma cells were dsDNA reactive, while ~0.07% of spleen plasma cells
were dsDNA reactive (Winter, 2015). Therefore, our analysis found that young, irradiated
(NZB x NZW)F1 mice had a larger proportion of dsDNA-reactive plasma cells compared
to older, unirradiated (NZB x NZW)F1 mice. Thus, we propose that the host-derived
ERα-competent dsDNA-reactive cells significantly accelerated the development of lupus
in (NZB x NZW)F1 chimeric mice.
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Chapter 4: Deletion of ERα in B cells attenuates lupus in (NZB x
NZW)F1 mice
Abstract
Lupus is a systemic autoimmune disease that disproportionally affects women and is
characterized by the production of autoreactive antibodies against nuclear antigens.
Estrogen has long been believed to play an important role in the pathogenesis of lupus.
Knockout of ERα considerably ameliorates lupus in lupus-prone mice. Because of the
significant pathogenic role of B cells in lupus, we hypothesized that ERα expression in B
cells promotes lupus. To test this hypothesis, we generated a murine lupus model where
ERα is deleted from B cells using a cre-loxP system on the (NZB x NZW)F1 genetic
background. On this genetic background, the B cell specific CD19-Cre driver induced
only moderately efficient deletion of ERα. Despite this, mice with B cell specific ERα
deletion, albeit incomplete, survived significantly longer than controls, and produced
significantly lower levels of pathogenic anti-dsDNA autoantibodies. B cell specific
deletion of ERα did not disturb B cell populations in the bone marrow or spleen, but it
caused a significant reduction in the proportion of B cells that were activated.
Additionally, we found that the CD19-Cre knockin allele had a significant impact on lupus
and B cell populations. This emphasizes the need for cre-only controls in experiments
using cre-loxP systems.
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Background
Lupus is a disease in which multiple types of hematopoietic cells function abnormally in
ways that lead to the development of systemic autoimmunity. Although multiple types of
hematopoietic cells contribute to lupus, B cells play a central role. Lupus patients, as
well as lupus-prone mice, have autoreactive B cells that produce autoantibodies.
Antibodies against dsDNA are pathogenic in lupus. In a lupus-prone mouse strain that
lacks mature B cells, the lupus phenotype is completely ameliorated (Shlomchik, 1994).
A mild form of lupus occurs when the same strain of lupus-prone mice produce B cells
that do not secrete antibody (Chan, 1999).
Depletion of B cells is an attractive therapeutic target for the treatment of lupus, but
disappointingly, B cell depletion with the CD20 antibody rituximab did not significantly
improve symptoms in lupus patients. In 2011, belimumab became the first new FDA
approved lupus treatment in 56 years. Belimumab is an antibody that restricts the
number of B cells produced by depleting the B cell growth factor BAFF, which is required
for the survival of developing B cells. Despite the low proportion of patients who showed
significant symptom improvement from belimumab treatment, its approval by the FDA
demonstrates both the great need for new lupus therapies and the potential for B cell
targeting by future lupus therapies.
Lupus is a disease that predominately affects young women, and it has long been
thought that estrogens play a key role in the development of lupus. Exposure to both
endogenous and exogenous estrogens is a risk factor for developing lupus
(Costenbader, 2007). In lupus-prone mice, estrogen signaling through ERα significantly
promotes autoantibody production and mortality (Li, 2007; Bynote, 2008). In these
studies, the cell type or types responsible for these effects could not be identified.
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Estrogens have many effects on the immune system, and particularly impact B cells in
multiple ways which contribute to the development of autoimmunity.
Immature B cells in the bone marrow which have strongly autoreactive BCRs normally
undergo clonal deletion. In the periphery, autoreactive mature B cells are rendered
anergic at the transitional stage in secondary lymphoid organs. High levels of E2 allow
high-affinity autoreactive B cells to escape negative selection at the immature and T2
stages (Grimaldi, 2006). Additionally, in a high-estrogen environment, estrogen signaling
in B cells, predominately through ERα, causes upregulation of CD22 and SHP-1 which
leads to decreased BCR signaling, thereby increasing the concentration of antigen
required for tolerization of autoreactive B cells, and protecting autoreactive B cells from
receptor-mediated apoptosis (Grimald, 2002; Hill, 2011). High levels of E2 also cause
increased expression of anti-apoptotic Bcl-2 and the B cell survival factor BAFF
(Grimaldi, 2002; Hill, 2011). By decreasing the strength of BCR signaling and increasing
the expression of pro-survival molecules, estrogens enhance the survival of high-affinity
autoreactive B cells.
In addition to autoreactive B cells that arise as the result of VDJ recombination,
autoreactive B cells can be generated by somatic hypermutation in the periphery.
Estrogen promotes somatic hypermutation by stimulating the expression of activationinduced deaminase (Mai, 2010; Pauklin, 2009). Therefore, estrogen can potentially
promote the development of autoreactive B cells via multiple pathways.
Enhanced survival of autoreactive B cells in mice treated with high levels of E2 causes
an increase in the marginal zone B cell population in the spleen (Grimaldi, 2001;
Grimaldi, 2006). In lupus-prone mice, the spleen marginal zone B cell population is
enriched for dsDNA-reactive B cells compared to follicular B cells (Enghard, 2011).
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Additionally, ERα promotes the activation of splenic B cells in female mice that carry a
(NZB x NZW)F1-derived lupus susceptibility loci (Yoachim, 2015).
Together, these data led us to hypothesize that ERα signaling in B cells promotes lupus.
To test this hypothesis, we have generated lupus-prone (NZB x NZW)F1 mice with ERα
deletion in the B cell compartment. (NZB x NZW)F1 lupus-prone mice have several
important similarities to lupus patients. (NZB x NZW)F1 mice produce pathogenic antidsDNA antibodies and develop fatal glomerulonephritis. They also have a gender bias,
with female mice developing and succumbing to disease several months before males.
To develop (NZB x NZW)F1 mice with B cell specific ERα deletion, we created NZB
females that carry the CD19-Cre knockin allele and are globally heterozygous for ERα.
These females were bred to NZW males homozygous for the floxed allele of ERα. B
cells begin to express CD19 at the pro-B cell stage in the bone marrow. CD19
expression causes deletion of the floxed ERα allele in B cells, while ERα is left intact in
non-B cells. Global ERα+/- does not impact the survival or development of
glomerulonephritis in (NZB x NZW)F1 mice (Bynote, 2008).
Previously, it has been shown that the deletion efficiency of the CD19-Cre knockin allele
is 75-80% in bone marrow B cells and 90-95% in spleen B cells on the 129 genetic
background (Rickert, 1997). Although the CD19-Cre knockin allele has been extensively
used in other mouse strains, to our knowledge, this is the first report of its use in a lupusprone mouse model. Our studies show that deletion of ERα in a moderate proportion of
B cells caused significant amelioration of lupus in (NZB x NZW)F1 mice.
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Methods
Production of experimental animals
To produce NZB mice carrying the CD19-Cre knockin allele, B6.129P2(C)-Cd19
tm1(cre)Cgn/

J mice were purchased (The Jackson Laboratory, Bar Harbor, ME, USA) and

crossed with NZB mice. Genotyping for the CD19-Cre knockin allele was done with
(IMR1084Tg F:5’-GCGGTCTGGCAGTAAAAACTATC-3’ and IMR1085Tg R: 5’GTGAAACAGCATTGCTGTCACTT-3’) primers, with (COO3IC F: 5’CTAGGCCACAGAATTGAAAGATCT-3’ and COO4IC R 5’GTAGGTGGAAATTCTAGCATCATCC-3’) primers as an internal positive control.
Offspring carrying the CD19-Cre knockin allele (CD19-Cre) were backcrossed to NZB
mice for 4-5 more generations using simple sequence length polymorphism (SSLP)
marker assisted selection. NZB.CD19Cre/+ mice were then crossed to NZB.ERα+/- mice
previously generated in our lab, producing NZB mice heterozygous for both CD19-Cre
and ERα (Bynote, 2008). Genotyping for the exon 2 deletion of ERα was performed as
described (www.jax.org/protocols). The ERaEx2 F primer: 5’TACGGCCAGTCGGGCATC-3’ (0.5 uM/rxn) and either the ERaEx2wtR 5’GTAGAAGGCGGGAGGGCCGGTGTC-3’ (0.06 uM/rxn) or ERaEx2null R 5’GCTACTTCCATTTGTCACGTCC-3’ (2 uM/rxn) primers were used to produce 234 bp
and ~300 bp products, respectively. NZW.ERαfl/fl mice homozygous for an ERα allele in
which exon 3 is flanked by loxP sites, were previously produced by backcrossing the
floxed ERα allele from B6.ERαf/fll mice to the NZW background using marker assisted
selection, and intercrossing NZW.ERαfl/+ mice as previously described (Nelson, 2016).
Genotyping for the ERαfl allele was done with the primers N6delcKF: 5’GACTCGCTACTGTGCCGTGTGC-3’ and N6del3R 5’CTTCCCTGGCATTACCACTTCTCCT-3’. The ERα+ allele produces a 275 bp product,
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while the ERαfl allele produces a 475 bp product. To produce experimental mice,
NZB.CD19Cre/+; ERα+/- female mice were crossed with NZW.ERαfl/fl males.
In addition to marker assisted selection performed in our lab, the genetic backgrounds of
NZB.CD19Cre/+ and NZW.ERαfl/fl mice were analyzed at the DartMouse Mouse Speed
Congenic Core Facility at Dartmouth Medical School. Using a 1449 SNP Illumina
beadchip, the genetic origins of 733 SNPs spread throughout the genome were
determined.
All animals were housed under conditions of controlled humidity, temperature, and
lighting in facilities accredited by the American Association for Accreditation of
Laboratory Animal Care, operating in accordance with standards set by the Guide for the
Care and Use of Laboratory Animals. Mice had ad libitum access to 7904 Teklad
Irradiated S-2335 Mouse Breeder Diet (Harlan Teklad, Madison, WI, USA). All
procedures involving live animals were approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee.
Quantification of ERα deletion
To evaluate the efficiency of Cre-mediated ERα deletion in B cells, CD19+ cells were
isolated from the bone marrow and spleen of 2-6 month old (NZB x NZW)F1 CD19Cre/+;
ERαfl/-, CD19Cre/+; ERαfl/+ , CD19+/+; ERαfl/+, and CD19+/+; ERαfl/- mice. Briefly, bone
marrow and spleen cells were isolated, passed through a 70 µm cell strainer to create a
single cell suspension, and red blood cells lysed with ACK lysis buffer (Gibco, Waltham,
MA, USA). Cells were labeled using CD19 Microbeads, and CD19+ cells were isolated
using an AUTOMacsPro as per manufacturer protocol (Miltenyi Biotech, BergischGladbach, Germany). After isolation, DNA was isolated from CD19+ cells using a
DNeasy Kit as per manufacturer protocol for cultured cells (Qiagen, Hilden, Germany).
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Quantitative PCR was performed on isolated CD19+ cell DNA as previously described
(Nelson, 2016). Briefly, a primer set was developed flanking the LoxP sites around ERα
Exon 3 (ERαDel F: 5’-TGGAATGAGACTTGTCTATCTTCG-3’, ERαDel R: 5’AACCAAGGAGAACAGAGAGACT-3’). From these primers, wild type and floxed ERα
alleles flank regions of 699 and 773 bp, respectively, while ERα which has undergone
recombination produces a product of 161 bp. In this QPCR assay, the wild type and
floxed ERα alleles do not form products and only ERα that has undergone deletion is
measured by this assay. A primer set in the unaffected ERα Exon 5 serves as a control
in a separate reaction (ERαEx5 F: 5’-GGAAGGCCGAAATGAAATGGG-3’ and ERαEx5
R: 5’-CCAACAAGGCACTGACCATC-3’).
Survival studies
Survival of animals was monitored over one year. Animals were euthanized by CO2
asphyxiation when they exhibited persistent albuminuria of 4+ (>2000 mg/dl) or physical
signs of distress. Albuminuria was initially measured monthly, and with increasing
frequency after a positive measurement using Albustix (Bayer Corporation, Elkhorn, IN,
USA).
Histological analysis
Kidneys were collected from mice upon death or sacrifice at the end of the study.
Tissues were fixed in 10% formalin for 96 hours, paraffin embedded, and sectioned.
Kidney sections were stained with Periodic Acid Schiff (Sigma-Aldrich, St. Louis, MO,
USA) and 100 glomeruli per kidney were evaluated as previously described (Yuan,
2013). Kidney sections were stained with anti-mouse IgG to detect immune complexes
and color developed with the DAB kit (Vector Laboratories, Burlingame, CA, USA). To
quantify the amount of immune complex (IC) staining in glomeruli, the color density of
≤20 immune complex stained and unstained glomeruli was measured and averaged. A
102

ratio of the two densities was calculated, and a higher number indicates more IC
staining.
Serological analysis
Serum was collected from mice at monthly intervals beginning at 2 months of age.
Enzyme Linked Immunosorbent Assay (ELISA) was used to measure serum antibody
levels. Anti-dsDNA IgG ELISAs were done using Immulon 2 HB plates (Thermo Fisher
Scientific, Waltham, MA, USA) coated with excess calf thymus dsDNA (Rockland
Immunochemicals Inc., Limerick, PA, USA). Diluted serum samples were incubated on
the plate, followed by anti-mouse IgG HRP conjugate, TMB substrate, and Stop Solution
(Alpha Diagnostic International, San Antonio, TX, USA) was added and plates read at
450 nm. Plates were washed with 0.05% Tween-20 in PBS.
Total IgM, IgG1, IgG2a, IgG2b, and IgG3 ELISAs were done using Immulon 2 HB plates
(Thermo) coated with 5 ng/ml capture antibody (Southern Biotech, Birmingham, AL,
USA) and incubated overnight at 4ºC. Briefly, wells were incubated in blocking solution,
incubated with samples and standards, then incubated with isotype specific alkaline
phosphatate-labeled antibody, after which 1 mg/ml PNPP solution was applied for 20
minutes (Southern Biotech). Plates were read on a microplate reader at 415 nm. The
concentrations of IgG1, IgG2a, IgG2b, and IgG3 were added together to find total IgG.
Anti-dsDNA Ig2a and IgG2b ELISAs were performed by applying standards and samples
to dsDNA-coated Immulon 2 HB plates (Thermo Fisher Scientific). Isotype specific
alkaline phosphatate-labeled antibodies, and PNPP solution (Southern Biotech) were
added and plates read as for total isotype ELISAs.

103

Flow cytometry
To assess B cell development by flow cytometry, single cell suspensions were prepared
and incubated with primary antibody for 30 minutes on ice. After staining for surface
proteins, cells were incubated with Propidium Iodide (BD Biosciences, San Jose, CA,
USA) for 10 minutes as a live/dead stain. After staining, cells were fixed with 0.6%
formalin. The antibodies used were CD4-PE, CD5-PE, CD19-FITC, CD69-FITC, CD86PE, B220-APC, CD93-BB515, CD279-APC, CXCR5-PECy7 (all BD Biosciences), IgMFITC (Southern Biotech), IgD-APC-Cy7 (Biolegend, San Diego, CA, USA), CD21eFlour450, and CD23-PE-Cy7 (eBioscience Inc., San Diego, CA, USA). Apoptosis was
analyzed with Teleford reagent. Flow cytometry was performed with a BD LSRII Flow
Cytometer and analyzed with FACSDiva software (BD Biosciences, v.8.0).
Statistics
Statistical analysis was done using SPSS software (IBM, v. 22). P values of less than or
equal to 0.05 are considered significant. Kaplan Meyer survival curves with log rank
tests were used to evaluate survival, and student’s t tests or ANOVA were used to
analyze QPCR, ELISA, histology, and flow cytometry data.
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Results
Production of Experimental Animals
(NZB x NZW)F1 mice are a commonly used model of lupus. Characteristics of this
model include the presence of autoreactive B and T cells, the production of autoreactive
antibodies, and the development of fatal glomerulonephritis. To explore the role of ERα
in B cells in lupus, we used the cre-loxP system to create a mouse model with ERα
deletion in B cells on a lupus-prone genetic background.
NZB.CD19Cre/+ mice were produced by backcrossing the CD19-Cre knockin allele onto
the NZB background using simple sequence length polymorphism (SSLP) marker
assisted selection. The 111 SSLP markers used for this process and their genetic
locations are listed in Table 4.1. By the N5 generation, an average of only 7% of SSLP
markers indicated remaining heterozygosity, while 93% were homozygous for NZB. In
addition to our SSLP analysis, 733 SNPs were analyzed using DNA from an N5 NZB
which was estimated by our SSLP analysis to be 94% NZB. SNP analysis showed this
N5 NZB was 96% homozygous for NZB (Figure 4.1). All major areas of heterozygosity
had been identified by our SSLP genotyping, and no remaining areas of residual
heterozygosity were found in known SLE susceptibility loci. At this point, CD19-Cre was
determined to be extensively backcrossed onto the NZB background.
NZB.CD19Cre/+ mice were crossed with NZB.ERα+/- mice to produce NZB.CD19Cre/+;
ERα+/- mice. NZB.CD19Cre/+; ERα+/- females were crossed with NZW.ERαfl/fl males to
produce (NZB x NZW)F1 CD19Cre/+; ERαfl/- mice, which should have no functional ERα
alleles in CD19+ B cells after cre-mediated recombination. Previous studies have shown
that global ERα+/- has no impact on lupus (Bynote, 2008). Therefore, any differences
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Table 4.1 SSLP markers used for the production of NZB.CD19-Cre mice
Marker (location in cM, Mb)
D1Mit316 (2.46, 10.3)
D1Mit169 (9.9, 24.1)
D1Mit123 (17.67, 39.2)
D1Mit132 (39.51, 77.1)
D1Mit440 (44.98, 90.7)
D1Mit495 (55.79, 129.5)
D1Mit159 (69.03, 161.6)
D1Mit111 (76.73, 170.9)
D1Mit426 (84.32, 182.3)
D1Mit209 (96.35, 193.3)
D2Mit1 (2.33, 3.8)
D2Mit83 (19.38, 28.8)
D2Mit156 (31.66, 56.9)
D2Mit327 (40.88, 69.3)
D2Mit94 (47.93, 80)
D2Mit395 (59.97, 119.4)
D2Mit411 (80.04, 159.4)
D2Mit145 (86.75, 166.2)
D3Mit203 (10.82, 26.8)
D3Mit51 (ND, 77.0)
D3Mit26 (34.97, 79.5)
D3Mit311 (40.14, 92.8)
D3Mit320 (66.75, 143.2)
D3Mit19 (ND, 164.4)
D4Mit193 (13.99, 32.3)
D4Mit17 (33.96, 63)
D4Mit9 (43.34, 94.7)
D4Mit308 (57.66, 123.8)
D4Mit42 (82.64, 150.9)
D5Mit348 (11.97, 24.4)
D5Mit352 (18.4, 36)
D5Mit201 (39.55, 75.6)
D5Mit314 (53.25, 110.1)
D5Mit97 (76.1, 137.5)
D5Mit143 (89.8, 151.8)
D6Mit138 (1.81, 4.5)
D6Mit116 (11.5, 21.1)
D6Mit123 (27.76, 56.9)

D6Mit209 (32.56, 75.5)
D6Mit328 (52.62, 112.7)
D6Mit14 (77.64, 145.6)
D7Mit21 (1.91, 3.3)
D7Mit267 (17.09, 30.3)
D7Mit82 (32.76, 58.8)
D7Mit248 (ND, 63.8)
D7Mit323 (54.45, 108)
D7Mit98 (60.49, 122.1)
D7Mit358 (67.27, 129.9)
D7Mit101 (69.01, 132.8)
D7Mit332 (77.87, 141.2)
D8Mit155 (2.14, 5)
D8Mit289 (16.47, 29.9)
D8Mit69 (29.7, 59.2)
D8Mit178 (34.43, 73.6)
D8Mit211 (52, 105.2)
D8Mit49 (72.38, 126.6)
D9Mit90 (17.8, 32.3)
D9Mit129 (24.45, 43.7)
D9Mit123 (40.88, 73.4)
D9Mit355 (51.41, 98.7)
D9Mit55 (65.28, 114.7)
D10Mit213 (9.75, 20.1)
D10Mit20 (34.83, 66.5)
D10Mit230 (45.28, 89.7)
D10Mit233 (61.58, 113.8)
D10Mit297 (72.31, 124.5)
D11Mit71 (4.7, 6.8)
D11Mit189 (27.39, 45.3)
D11Mit5 (40.59, 67)
D11Mit285 (54.64, 89.8)
D11Mit333 (71.83, 108.6)
D12Mit182 (5.52, 10.9)
D12Mit60 (15.54, 35.5)
D12Mit91 (30.06, 72.8)
D12Mit158 (38.14, 83.7)
D12Mit7 (ND, 103)

D12Nds2 (62.22, 115.1)
D13Mit16 (7.26, 20.4)
D13Mit275 (14.5, 37.4)
D13Mit13 (30.06, 56.6)
D13Mit126 (45.05, 85.5)
D13Mit74 (56.92, 106.7)
D13Mit151 (64.72, 116.3)
D14Mit126 (11.94, 22.7)
D14Mit60 (24.6, 47.7)
D14Mit5 (31.49, 60.3)
D14Mit68 (37.61, 72.9)
D14Mit106 (50.9, 100.6)
D14Mit177 (60.21, 116.8)
D15Mit252 (8.54, 22.6)
D15Mit143 (19.62, 52)
D15Mit67 (32.17, 70)
D15Mit107 (39.79, 84.2)
D15Mit161 (52.78, 96.8)
D16Mit131 (3.41, 7.3)
D16Mit60 (23.27, 32.7)
D16Mit139 (37.28, 65.7)
D16Mit52 (53.73, 92.7)
D17Mit164 (2.11, 3.9)
D17Mit51 (19.74, 43.6)
D17Mit10 (ND, 51.0)
D17Mit93 (45.2, 74.2)
D17Mit122 (52.25, 83.5)
D18Mit222 (8.08, 14.7)
D18Mit177 (21.39, 41.1)
D18Mit186 (45.63, 72.2)
D18Mit144 (57.79, 85.7)
D19Mit96 (15.54, 21.9)
D19Mit88 (32.23, 37.3)
D19Mit90 (35.97, 42.3)
D19Mit103 (48.46, 53.8)
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Figure 4.1 The CD19-Cre knockin allele was backcrossed onto the NZB genetic
background

107

Figure 4.1 The CD19-Cre knockin allele was backcrossed onto the NZB genetic
background
SNP analysis was performed on an NZB.CD19-Cre N5 female mouse to determine the
purity of the genetic background. 96% of informative SNPs were NZB homozygous,
while 4% of SNPs showed residual B6/NZB heterozygosity, including the region
surrounding the CD19-Cre knockin allele on distal chromosome 7.
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observed in lupus in (NZB x NZW)F1 CD19Cre/+; ERαfl/- mice are due to the deletion of
ERα in B cells.
On the (NZB x NZW)F1 Genetic Background, the CD19-Cre Knockin Allele Causes Only
Moderately Efficient Deletion of ERα and Increases B cell Apoptosis
The CD19-Cre knockin allele was previously shown to have a deletion efficiency of 7580% in bone marrow pre-B cells and 90-95% in splenic B cells on the 129 genetic
background (Rickert, 1997). To assess the efficiency of CD19-Cre mediated deletion of
ERα on the (NZB x NZW)F1 genetic background, CD19+ cells from bone marrow and
spleen were isolated from 2-6 month old mice, and DNA from these cells was analyzed
for deletion efficiency. The efficiency of deletion was not different at different ages, nor
were there any sex-related differences in deletion efficiency. No deletion was detected in
any CD19+/+; ERαfl/+ or CD19+/+; ERαfl/- samples (not shown). CD19Cre/+; ERαfl/+ mice
have an average of 27% deletion efficiency in CD19+ bone marrow cells, which is not
significantly different from CD19Cre/+; ERαfl/- mice which have an average deletion
efficiency of 18% (Figure 4.2a). CD19+ spleen cells from CD19Cre/+; ERαfl/+ mice have an
average deletion efficiency of 53%, while CD19Cre/+; ERαfl/- mice have an average
deletion efficiency of 54%. Our results affirm previous findings which showed that that
the efficiency of CD19-Cre mediated gene deletion is higher in splenic B cells than bone
marrow B cells; however, deletion efficiency on the (NZB x NZW)F1 genetic background
is significantly lower than has been previously reported.
We posit that the lupus-prone genetic background of (NZB x NZW)F1 mice is the reason
only a moderate level of ERα deletion is observed. Cre recombinase can cleave at loxPlike sites throughout the mammalian genome, causing dsDNA breaks (Loonstra, 2001).
Many lupus patients cannot effectively repair dsDNA breaks (Bassi, 2008; Davies,
2012). Unrepaired dsDNA breaks lead to cell death. This means that cells that express
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Figure 4.2 The CD19-Cre knockin allele causes apoptosis and decreased CD19
expression in (NZB x NZW)F1 mice
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Figure 4.2 The CD19-Cre knockin allele causes apoptosis and decreased CD19
expression in (NZB x NZW)F1 mice
The efficiency of ERα deletion was measured in (NZB x NZW)F1 mice. (a) ERα deletion
in CD19+ bone marrow and spleen cells was moderately successful. (b) The rate of
apoptosis in CD19+ splenocytes was increased in female mice with the CD19-Cre
knockin allele (p=0.003). Fluorescent intensity of CD19 staining on B cells was
measured in mice with and without the CD19-Cre knockin allele. (c) CD19 expression
was reduced in mice with the CD19-Cre knockin allele (representative sample shown).
(d) Mean fluorescent intensity of CD19 staining was consistently and significantly
reduced in both bone marrow and spleen B cells (p=6.0x10-9, p=3.3x10-13).
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low levels of cre recombinase may have a survival advantage, and this could contribute
to the decreased efficiency of cre-mediated deletion observed in (NZB x NZW)F1 mice.
Our lab has previously observed inefficient Lck-Cre mediated deletion of ERα in T cells
in (NZB x NZW)F1 mice, as well as an increase in T cell apoptosis (Nelson, 2016). We
examined apoptosis in young (NZB x NZW)F1 mice and found that females that have
the CD19-Cre knockin allele had significantly more apoptotic CD19+ splenocytes than
CD19+/+ mice (Figure 4.2b). No difference was observed in apoptosis in CD19+ bone
marrow cells.
In our (NZB x NZW)F1 model, deletion of ERα in B cells was only moderately efficient,
and the B cell population in CD19Cre/+; ERαfl/- mice was composed of a mixture of ERα+/and ERα-/- cells. The mixed nature of the B cell compartment in this model impacted the
magnitude of the effects of B cell ERα on lupus that could be observed.
The CD19-Cre Knockin Allele Causes Reduced CD19 Expression
The CD19-Cre knockin allele by itself has the potential to impact the lupus phenotype in
(NZB x NZW)F1 mice. Mice that carry the CD19-Cre knockin allele have significantly
less CD19 expression on B cells compared to CD19+/+ littermates (Figure 4.2c). In the
bone marrow, CD19-Cre mice have an average of 65% as much CD19 as CD19+/+ mice,
and in the spleen they have an average of 53% as much CD19 (Figure 4.2d). This
decrease in CD19 expression could impact the strength of B cell receptor signaling and
alter the negative selection of autoreactive B cells. The CD19-Cre knockin allele could
also affect the lupus phenotype through the toxic off-target effects of cre expression.
Debris from apoptotic B cells is a source of autoantigen, and leads to acceleration of
disease (Trebeden-Negre, 2003). Because of its potential to impact lupus, the effects of
the CD19-Cre knockin allele alone were examined in (NZB x NZW)F1 mice.
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The CD19-Cre Knockin Allele Causes Accelerated Mortality on the (NZB x NZW)F1
Genetic Background
Comparison of CD19Cre/+; ERαfl/+ and CD19+/+; ERαfl/+ (NZB x NZW)F1 mice revealed
that the CD19-Cre knockin allele itself caused accelerated mortality in female and male
mice. Female CD19+/+; ERαfl/+ mice had a median survival time of 211 days, while
CD19Cre/+; ERαfl/+ females had a median survival time of 171 days (Figure 4.3a). The
median lifespan of (NZB x NZW)F1 CD19+/+; ERαfl/+ females is similar to the median
survival of (NZB x NZW)F1.ERα+/+ females which was 238 days (Bynote, 2008).
Similarly, male CD19+/+; ERαfl/+ mice had a median survival time of 301 days and
CD19Cre/+; ERαfl/+males had a median survival time of 257 days (Figure 4.3b). The
median survival time of (NZB x NZW)F1 CD19+/+; ERαfl/+ males of 301 days is similar to
the median survival of (NZB x NZW)F1.ERα+/+ males which was 321 days (Bynote,
2008). Although we are unable to distinguish whether it is an effect of cre recombinase
or CD19 heterozygosity, it is clear that the CD19-Cre knockin allele causes significantly
accelerated mortality in (NZB x NZW)F1 mice. Therefore, the appropriate control group
for mice with B cell specific deletion of ERα is mice with the CD19-Cre knockin allele.
B cell Specific Deletion of ERα Extends Survival
Our lab has previously shown that total body ERα knockout significantly attenuates the
development of lupus and extends survival in (NZB x NZW)F1 female and male mice
(Bynote, 2008). To determine the effects of B cell specific ERα deletion on survival, mice
were monitored for up to one year. Female CD19Cre/+; ERαfl/+ control mice had a median
survival of 171 days, which is significantly shorter than CD19Cre/+; ERαfl/- mice that had a
median survival time of 239 days (Figure 4.3c). 25% of CD19Cre/+; ERαfl/- females and 2%
of CD19Cre/+; ERαfl/+ female controls survived until the end of the study.
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Figure 4.3 Both the CD19-Cre knockin allele and B cell ERα significantly impact
survival
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Figure 4.3 Both the CD19-Cre knockin allele and B cell ERα significantly impact
survival
Survival was monitored for up to one year. (a) Female and (b) male CD19Cre/+; ERαfl/+
mice have significantly shorter median survival compared to CD19+/+; ERαfl/+ mice
(p=0.0003 females and p=0.0002 males). Compared to CD19Cre/+; ERαfl/+ control mice,
CD19Cre/+; ERαfl/- (c) female and (d) male mice have significantly longer median survival
(p=0.001 females and p=0.050 males).
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Although significant, the 68 day increase in median survival observed in female mice
with ERα deletion in B cells is less dramatic than the survival difference observed in
female mice with ERα-/-, where more than half of the population survived for 18 months
(Bynote, 2008). This difference is likely due, at least in part, to the large proportion of B
cells in CD19Cre/+; ERαfl/- mice that retain ERα expression. Additionally, ERα signaling in
other cell types may also contribute to lupus in (NZB x NZW)F1 mice.
Male mice with B cell specific ERα deletion also experience significantly delayed
mortality. Male CD19Cre/+; ERαfl/+ control mice had a median lifespan of 257 days, which
is significantly shorter that of CD19Cre/+; ERαfl/- males which had a median lifespan of 329
days (Figure 4.3d). Only 3% of male CD19Cre/+; ERαfl/+ mice survived until the end of the
study, and 12.5% of CD19Cre/+; ERαfl/- mice survived for one year. The 72 day difference
in the median survival of male mice in this study is only slightly less than the 85-113 day
difference in median survival observed between ERα+/+ or ERα+/- and ERα-/- male (NZB x
NZW)F1 mice (Bynote, 2008).
Mice from All Groups Develop Glomerulonephritis
(NZB x NZW)F1 mice typically develop and succumb to severe glomerulonephritis.
Kidneys were collected from mice when they showed signs of advanced illness or
reached one year of age, and were removed from the survival study. Periodic Acid Schiff
stained sections were analyzed to determine the extent of glomerular damage. (NZB x
NZW)F1 mice with the CD19-Cre knockin allele developed glomerulonephritis that was
histologically indistinguishable from CD19+/+ mice (data not shown). Almost all female
and male CD19Cre/+; ERαfl/+ and CD19Cre/+; ERαfl/- mice had ≥ 50% abnormal glomeruli,
which indicates severe glomerulonephritis (Figure 4.4a). The B cell ERα genotype had
no impact on the extent of glomerulonephritis. Representative PAS stained images show
a similar extent of damage in both CD19Cre/+; ERαfl/+ and CD19Cre/+; ERαfl/- mice (Figure
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4.4b). Additionally, no difference was found in the amount of immune complex deposition
in the glomeruli (Figure 4.4c). Therefore, although mice with B cell specific deletion of
ERα survive significantly longer than control mice, both groups of mice develop severe
glomerulonephritis. This also indicates that the CD19-Cre knockin allele does not cause
mortality that is not related to glomerulonephritis.
Mice with B cell Specific ERα Deletion Produce Fewer Pathogenic Autoantibodies
The production of high levels of dsDNA-reactive antibodies is characteristic of lupus. In
lupus patients and (NZB x NZW)F1 mice, serum levels of dsDNA IgG antibodies
correlate with disease severity. The development of autoreactive B cells and production
of pathogenic autoantibodies are promoted by ERα signaling (Hill, 2011). To determine
the effect of ERα expression in B cells on autoantibody production, serum anti-dsDNA
IgG levels were measured by ELISA. Serum levels of anti-dsDNA IgG were significantly
higher in control CD19Cre/+; ERαfl/+ mice at 5 months of age compared to female
CD19Cre/+; ERαfl/- mice (Figure 4.5a). Similarly, male CD19Cre/+; ERαfl/+ control mice had
significantly higher levels of anti-dsDNA IgG antibodies compared to CD19Cre/+; ERαfl/males (Figure 4.5b). Lower levels of pathogenic autoantibodies in mice with B cell
specific ERα deletion indicate amelioration of lupus, and are consistent with the
attenuated mortality observed in these mice.
Different isotypes of anti-dsDNA IgG antibodies have different pathogenic potentials;
autoreactive IgG2a and IgG2b antibodies are especially pathogenic because they
activate both complement and Fcγ receptors (Azeredo da Silveira, 2002). To determine
if these antibodies were affected by ERα in B cells, serum levels of anti-dsDNA IgG2a
and anti-dsDNA IgG2b were measured by ELISA at 4 months of age in females and 7
months of age in males. Compared to CD19Cre/+; ERαfl/+ controls, levels of anti-dsDNA

117

Figure 4.4 B cell ERα deletion does not prevent the development of
glomerulonephritis
118

Figure 4.4 B cell ERα deletion does not prevent the development of
glomerulonephritis
(a) The majority of mice of both sexes developed severe glomerulonephritis by the end
of the survival study. (b) Representative histological sections show abnormalities
characteristic of glomerulonephritis. (c) Semi-quantitative analysis of immune complex
staining showed immune complex deposition occurred in equally in CD19Cre/+; ERαfl/- and
CD19Cre/+; ERαfl/+ mice of both sexes.
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Figure 4.5 part 1 B cell specific ERα deletion causes reduced production of
pathogenic autoantibodies but does not affect total antibody production
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Figure 4.5 part 2 B cell specific ERα deletion causes reduced production of
pathogenic autoantibodies but does not affect total antibody production
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Figure 4.5 B cell specific ERα deletion causes reduced production of pathogenic
autoantibodies but does not affect total antibody production
(a) Female and (b) male CD19Cre/+; ERαfl/- mice produce less α-dsDNA IgG than
CD19Cre/+; ERαfl/+ controls (a. p=0.03; b. p=0.02). (c) Less α-dsDNA IgG2a is produced
by both female and male CD19Cre/+; ERαfl/- mice (p=0.04 females and p=0.02 males). (d)
Male CD19Cre/+; ERαfl/- mice produce less α-dsDNA IgG2b (p=0.002). There is no
difference in total IgM, total IgG, or IgG1, IgG2a, or IgG2b in (e) female and (f) male
mice. Female CD19Cre/+; ERαfl/- mice produce less total IgG3 than CD19Cre/+; ERαfl/+
controls (p=0.005).
The data for 4.5e-f was produced by Kimberly Bynote and analyzed by Dana Tabor.
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IgG2a were significantly lower in both female and male CD19Cre/+; ERαfl/- mice (Figure
4.5c). Additionally, compared to CD19Cre/+; ERαfl/+ controls, male CD19Cre/+; ERαfl/- mice
had lower serum levels of anti-dsDNA IgG2b antibodies, but no difference was observed
in anti-dsDNA IgG2b levels in female mice (Figure 4.5d).
To evaluate the effect of B cell specific ERα deletion on total antibody production, and to
determine if the significant reduction in anti-dsDNA IgG autoantibodies is due to global
changes in antibody production, we measured serum IgM, IgG1, IgG2a, IgG2b, and
IgG3 levels by ELISA. Total IgG was calculated by totaling the antibodies of the various
IgG isotypes. In female mice, the only difference detected was that CD19Cre/+; ERαfl/+
mice produce significantly more IgG3 than CD19Cre/+; ERαfl/- females (Figure 4.5e). In
male mice, there were no differences in the production of IgM or any IgG isotype (Figure
4.5f). Therefore, the reduction in dsDNA IgG is not due to a global decrease in antibody
production, but is specific to dsDNA antibodies. Thus, it is likely that the dramatic
reduction in anti-dsDNA IgG antibodies is primarily responsible for the attenuation of
lupus in mice with B cell specific deletion of ERα.
B cell ERα Deletion Leads to Decreased B cell Activation
ERα affects the development of B cells in the bone marrow. Specifically, E2 causes a
decrease in developing bone marrow B cells on a mixed C57BL/6/129 genetic
background (Thurmond, 2000; Erlandsson, 2003). Reports vary on the effect of ERα
knockout on B cell populations in the bone marrow; however there is consensus that the
effects of E2 on B cell populations are mainly mediated by signaling through ERα
(Thurmond, 2000; Erlandsson, 2003). It is not known if these effects are B cell intrinsic.
To evaluate the effects of B cell intrinsic ERα on B cell populations in the bone marrow,
cells from 3 month old pre-autoimmune (NZB x NZW)F1 mice were analyzed by flow
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cytometry. In females, but not males, we observed a decrease in the percentage of preB cells and increase in the percentage of immature B cells, which was due to the CD19Cre knockin allele (Table 4.2). The deletion of ERα from B cells did not cause changes in
the bone marrow or spleen populations in either female or male mice.
The effect of global ERα knockout on B cell populations in the spleen has not previously
been reported. In order to have a comparison for our mice with B cell specific ERα
deletion, we evaluated follicular and marginal zone B cell populations in 3 month old
ERα-/- and ERα+/+ (NZB x NZW)F1s. The population of follicular B cells was not affected
by ERα genotype (Table 4.3). However, the population of marginal zone B cells was
significantly increased in ERα-/- female mice. This was somewhat unexpected because
the marginal zone B cell population is enriched for autoreactive B cells compared to
follicular B cells, and ERα-/- female mice produce less autoantibodies than ERα+/+ mice
(Grimaldi, 2001; Bynote, 2008). However, the marginal zone B cell population also
increases significantly in high-estrogen conditions or upon treatment with an ERα
specific agonist (Grimaldi, 2006; Hill, 2011). Female ERα-/- mice have significantly
elevated serum E2 (Couse, 1995), which may be the reason for the increase in marginal
zone B cells in these mice.
The same analysis of spleen populations was done on 3 month old (NZB x NZW)F1
CD19-Cre mice. The percentage of follicular and marginal zone B cells is similar
between ERα+/+ and CD19+/+; ERαfl/+ mice. ERα deletion in B cells did not have a
significant impact on follicular or marginal zone B cell populations, but the CD19-Cre
knockin allele significantly impacted these populations (Tale 4.4). The CD19-Cre knockin
allele causes an increase in the proportion of follicular B cells and a decrease in the
proportion of marginal zone B cells. Several other lymphocyte populations were
examined in the spleen, and no significant differences were caused by B cell ERα
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Table 4.2 Bone marrow B cell populations in (NZB x NZW)F1 mice
CD19Cre/+; ERαfl/-

CD19Cre/+; ERαfl/+

CD19+/+; ERαfl/+

40.6 ± 1.9 *

42.6 ± 2.8 *

53.0 ± 1.5

27.7 ± 1.4 *

31.9 ± 1.6 *

18.4 ± 1.6

29.3 ± 1.2 †

23.2 ± 1.8

26.6 ± 1.2

50.1 ± 5.7

48.9 ± 3.1

50.9 ± 5.3

24.5 ± 3.0

24.4 ± 1.8

25.3 ± 2.9

24.0 ± 4.3

24.9 ± 2.5

21.8 ± 3.2

Females
Pre-B cells
(IgM- IgD-)
Immature B cells
(IgM+ IgD-)
Recirculating B cells
(IgM+/- IgD+)
Males
Pre-B cells
(IgM- IgD-)
Immature B cells
(IgM+ IgD-)
Recirculating B cells
(IgM+/- IgD+)
% of live B220+ cells

* Indicates p ≤ 0.05 compared to CD19+/+; ERαfl/+
† indicates p ≤ 0.05 compared to CD19Cre/+; ERαfl/+
3 month old mice were used for this experiment.
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Table 4.3 Spleen B cell populations in (NZB x NZW)F1 mice
ERα+/+

ERα-/-

Follicular B cells
(CD21+ CD23+)

55.4 ± 1.4

54.5 ± 0.9

Marginal zone B cells
(CD21+ CD23-)

26.6 ± 1.1

36.4 ± 0.9 *

Follicular B cells
(CD21+ CD23+)

57.2 ± 2.0

53.9 ± 5.3

Marginal zone B cells
(CD21+ CD23-)

28.6 ± 2.1

31.5 ± 2.2

Females

Males

% of live B220+ CD5- cells
* indicates p ≤ 0.05 compared to ERα+/+
3 month old mice were used for this experiment.
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deletion or CD19-Cre in transitional B cell, or T follicular helper cell populations (Table
4.4). These results suggest that CD19-Cre reduces the relative abundance of marginal
zone B cells in the spleen, but that deletion of ERα in B cells does not affect the relative
abundance of splenic B cell populations. Thus, the attenuated development of lupus in
CD19Cre/+; ERαfl/- mice is not the result of a shift in the relative abundance of splenic B
cell subsets
Previous studies from our lab suggest that ERα may promote lupus by enhancing
immune cell activation (Yoachim, 2015). Therefore, the percentage of activated B and T
cells in the spleen was examined in these young mice. Female CD19Cre/+; ERαfl/- mice
had significantly fewer activated B cells than CD19Cre/+; ERαfl/+ mice (Table 4.5). This was
not observed in males at this age. There was no change in proportion of activated T cells
in mice of either sex. This suggests that ERα promotes B cell activation in female lupusprone mice in a B cell intrinsic manner, and further suggests that the ability of ERα to
promote B cell activation may underlie the ability of ERα to promote lupus.
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Table 4.4 Spleen lymphocyte populations in (NZB x NZW)F1 mice
CD19Cre/+; ERαfl/-

CD19Cre/+; ERαfl/+

CD19+/+; ERαfl/+

Follicular B cells
(CD21+ CD23+)

66.0 ± 1.0 *

68.1 ± 1.6 *

59.8 ± 1.2

Marginal zone B cells
(CD21+ CD23-)

18.9 ± 1.6 ^

18.0 ± 1.1 *

25.2 ± 2.0

Transitional B cells
(AA4.1+)

5.6 ± 0.6

6.0 ± 0.5

5.6 ± 0.5

T follicular helper cells
(% of live CD4+
CXCR5+ PD1+)

51.9 ± 3.9

49.3 ±2.4

46.0 ± 1.4

Follicular B cells
(CD21+ CD23+)

67.7 ± 1.6 *

65.0 ± 1.3 ^

60.4 ± 1.9

Marginal zone B cells
(CD21+ CD23-)

20.8 ± 0.3 *

19.2 ± 0.4 *

25.0 ± 1.4

Transitional B cells
(AA4.1+)

4.2 ± 0.3

5.3 ± 0.5

4.8 ± 0.3

T follicular helper cells
(% of live CD4+
CXCR5+ PD1+)

45.8 ± 2.8

46.9 ± 1.5

42.5 ± 1.3

Females

Males

B cells- % of live B220+ CD5- cells
* indicates p ≤ 0.05 compared to CD19+/+; ERαfl/+
^ indicates p ≤ 0.1 compared to CD19+/+; ERαfl/+
3 month old mice were used for this experiment.

128

Table 4.5 B and T cell activation in (NZB x NZW)F1 mice
CD19Cre/+; ERαfl/-

CD19Cre/+; ERαfl/+

CD19+/+; ERαfl/+

Activated B cells
(% live of B220+
CD86+)

1.9 ± 0.3 †

5.7 ± 0.8 *

3.0 ± 0.6

Activated T cells
(% live of CD4+
CD69+)

5.5 ± 0.9

9.2 ± 2.3

6.2 ± 0.8

Activated B cells
(% live of B220+
CD86+)

2.3 ± 0.4 ^

2.7 ± 0.4

3.5 ± 0.5

Activated T cells
(% live of CD4+
CD69+)

4.7 ± 0.6

5.2 ± 0.9

5.4 ± 0.8

Females

Males

* Indicates p ≤ 0.05 compared to CD19+/+; ERαfl/+
^ indicates p ≤ 0.1 compared to CD19+/+; ERαfl/+
† indicates p ≤ 0.05 compared to CD19Cre/+; ERαfl/+
3 month old mice were used for this experiment.
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Discussion
To study the impact of ERα in B cells on lupus, we created (NZB x NZW)F1 mice with
ERα deletion in B cells. This was accomplished using the CD19-Cre knockin allele which
causes the expression of cre recombinase in B cells, and an allele of ERα flanked by
loxP sites (floxed ERα). The cre-loxP system is widely used in mammalian systems to
cause targeted deletion of DNA segments from the genome. Although this system is
potentially very useful, models created with the cre-loxP system are often undercharacterized. In our studies, we found that the CD19-Cre knockin allele by itself caused
significant effects in (NZB x NZW)F1 mice. Cre recombinase can cleave pseudo-loxP
sites throughout the mammalian genome, causing severe DNA damage (Thyagarajan,
2000). Indeed, we observed a small increase in apoptotic CD19+ splenocytes in CD19Cre mice.
The CD19-Cre knockin allele not only causes cre recombinase expression in B cells, but
because it is a knockin allele, it interrupts the coding region of CD19, resulting in a null
allele. To our knowledge, the effect of CD19 heterozygosity on B cell populations has not
been reported. However, it is known that total CD19 knockout in (NZB x NZW)F1 mice
accelerates the development of lupus (Watanabe, 2010). In our (NZB x NZW)F1 CD19Cre mice we were unable to determine whether the effects of the CD19-Cre allele were
due to the decreased expression of CD19 or the expression of cre recombinase, both of
which could contribute to the changes we observed.
Survival studies showed that female and male CD19Cre/+; ERαfl/+ mice (which carry the
CD19-Cre knockin allele but do not have B cell ERα deletion) have a significantly
reduced median survival compared to CD19+/+; ERαfl/+ mice. In females, the CD19-Cre
knockin allele also caused changes in B cell populations in the bone marrow, and
differences in B cell populations were observed in both sexes in the spleen. Therefore, in
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the studies presented here, CD19Cre/+; ERαfl/+ mice are the appropriate controls for
CD19Cre/+; ERαfl/- mice with B cell specific ERα deletion. A recent study from our lab
showed that the Lck-Cre allele significantly accelerates lupus in (NZB x NZW)F1 mice by
causing increased apoptosis and an increase in the proportion of activated T cells
(Nelson, 2016). Although we did find that the CD19-Cre knockin allele caused increased
apoptosis of CD19+ splenocytes, it did not lead to an increase in B or T cell activation.
Although the effects of cre were not identical, these studies show that cre-loxP systems
can have significant, unintended effects in some models.
In addition to examining the effects of the CD19-Cre knockin allele on survival and B cell
populations, the efficiency of ERα deletion in CD19+ B cells from CD19Cre/+; ERαfl/- and
CD19Cre/+; ERαfl/+ mice was analyzed. On the 129 genetic background, CD19-Cre causes
75-80% deletion in bone marrow B cells and 90-95% deletion in spleen B cells (Rickert,
1997). The deletion efficiency was much lower in (NZB x NZW)F1 CD19-Cre mice. Only
~20% of CD19+ bone marrow cells had ERα deletion while ~50% of CD19+ B cells had
ERα deletion. These results indicate that the B cells in CD19Cre/+; ERαfl/- mice are a
mixed population of ERα+/- and ERα-/- cells. Therefore, the effects that we have observed
in these studies are the result of loss of ERα signaling in only a portion of the B cell
population.
Loss of ERα signaling in a portion of B cells in (NZB x NZW)F1 mice significantly
attenuated lupus. Female and male CD19Cre/+; ERαfl/- mice survived significantly longer
than CD19Cre/+; ERαfl/+ mice. The increase in survival time observed in mice with B cell
ERα deletion is not as dramatic as the increase in survival that occurred when ERα was
knocked out globally in (NZB x NZW)F1 mice. However, we speculate that the increase
in survival time between CD19Cre/+; ERαfl/- and CD19Cre/+; ERαfl/+ mice would be even
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greater if there was more complete deletion of ERα in B cells. It is also possible that ERα
signaling in other cell types contributes to lupus.
Glomerulonephritis is a highly penetrant manifestation of lupus in (NZB x NZW)F1 mice
and is the main cause of death. At the end of the survival study, kidneys were collected
and analyzed for glomerulonephritis and immune complex deposition. Almost all mice
from each group had severe glomerulonephritis. There were no significant differences in
the proportion of mice with severe glomerulonephritis or in the amount of immune
complex deposition between CD19Cre/+; ERαfl/+ and CD19Cre/+; ERαfl/- mice. Therefore,
although ERα deletion in B cells prolonged survival, these mice still developed fatal
glomerulonephritis.
Higher levels of dsDNA IgG autoantibodies are associated with increased disease
severity in lupus-prone mice. (NZB x NZW)F1 mice of both sexes with B cell ERα
deletion have significantly lower levels of pathogenic anti-dsDNA IgG antibodies than
mice with intact B cell ERα. Some isotypes of dsDNA antibodies are particularly
pathogenic, especially the IgG2a and IgG2b isotypes which cause immune activation
through multiple pathways (Azeredo da Silveira, 2002). CD19Cre/+; ERαfl/+ mice of both
sexes have higher levels of anti-dsDNA IgG2a than CD19Cre/+; ERαfl/- mice, and males
have more anti-dsDNA IgG2b. Therefore, B cell specific loss of ERα causes a significant
decrease in the levels of pathogenic dsDNA autoantibodies.
To determine if the decreased levels of autoantibodies in CD19Cre/+; ERαfl/- mice were
unique to dsDNA specific antibodies or were the result of general suppression of the
immune response, we measured the amount of total serum IgM and IgG. The levels of
total IgM and IgG are not different in CD19Cre/+; ERαfl/+ and CD19Cre/+; ERαfl/- mice. This
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indicates that the reduced levels of autoantibodies in CD19Cre/+; ERαfl/- mice are not due
to general immunosuppression, but are the result of the loss of ERα signaling.
It has been shown that global ERα knockout does not affect the proportion of each B cell
population in the bone marrow (Thurmond, 2000). Therefore, we examined the
populations of developing B cells in the bone marrow to see if this was also the case in
mice with ERα deletion in B cells. B cells first express CD19 at the pro-B cell stage, so
the populations we examined have all undergone at least some cre-mediated deletion of
ERα. The only differences that we observed in B cell development in the bone marrow
were due to the CD19-Cre knockin allele. In female mice, CD19-Cre caused an increase
in the pre-B cell population and a decrease in immature B cells, but these populations
were not affected in males. In mb1-Cre mice, which contain a different B cell specific
driver of cre which is expressed in very early pro-B cells, there were no changes
observed in bone marrow B cell populations on the BALB/c genetic background,
although the sex of mice was not reported (Hobeika, 2006). These results suggest that
CD19 heterozygosity affects B cell development in females.
Additionally we sought to determine if B cell ERα impacted the follicular and marginal
zone B cell populations in the spleen. In (NZB x NZW)F1 mice, the marginal zone B cell
population was enriched for autoreactive B cells (Enghard, 2011). Studies with a
different model have shown that an increased marginal zone population corresponds to
an increase in the number of autoreactive B cells (Grimaldi, 2001). To the best of our
knowledge, the effect of global ERα knockout on follicular and marginal zone B cell
populations has not been previously reported. In female ERα-/- (NZB x NZW)F1 mice, the
marginal zone population was significantly increased. This was somewhat surprising
because ERα-/- (NZB x NZW)F1 females have significant attenuation of lupus (Bynote,
2008). There were no changes in these populations in ERα-/- male mice.
133

The follicular and marginal zone B cell populations in the spleens of CD19Cre/+; ERαfl/+
and CD19Cre/+; ERαfl/+ mice were examined to determine if ERα deletion in B cells
affected these populations. CD19-Cre increased the proportion of follicular B cells and
decreased the proportion of marginal zone B cells in both sexes of mice, but B cell
specific deletion of ERα did not impact these populations. These results from global ERα
knockout and B cell ERα deletion mice contradict the currently accepted dogma that an
increase in the marginal zone B cell population corresponds with an increased
population of activated autoreactive B cells and increased disease activity. One possible
explanation is that the marginal zone B cells in ERα knockout females may be composed
of cells which are resistant to activation or anergic. It has been shown that ERα knockout
prevents B cell activation (Yoachim, 2015), but resistance to activation has not been
tested in these mice. In mb1-Cre mice, no changes in the splenic B cell populations were
found (Hobeika, 2006). This suggests that the alterations in these populations in CD19Cre mice may be due to CD19 heterozygosity. Unfortunately, the effect of CD19
heterozygosity on splenocytes has not been reported in the literature.
The expression of ERα in B cells did not affect T cell activation in the spleen, but it did
cause a significant decrease in activated splenic B cells in female mice. This effect was
not observed in young male mice, but a difference in activation may develop at a later
stage in males. Our data suggests that the significant decrease in activated B cells in
female mice is the cause of attenuated autoantibody production, delayed development of
glomerulonephritis, and attenuated mortality.
B cell specific deletion of ERα prolongs median survival by 68 days in females and 72
days in males. In mice with global ERα knockout, the median survival of females was
increased by more than 219 days, and the median survival of males was increased by
85-113 days (Bynote, 2008). Compared to female mice, male mice with B cell ERα
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deletion come closer to recapitulating the complete attenuation of lupus observed in ERα
knockout mice. In female ERα knockout mice, serum levels of E2 are elevated by 10fold, which likely causes increased ERβ signaling (Couse, 1995). Previous studies with
(NZB x NZW)F1 mice have suggested that ERβ may slightly attenuate lupus (Li, 2007).
In the high-E2 environment of ERα knockout female mice, this modest effect may be
exaggerated, and be responsible for part of the attenuation of lupus seen in these mice.
In any case, it is clear that deletion of ERα in B cells significantly ameliorates lupus in
both female and male (NZB x NZW)F1 mice.
In conclusion, these studies showed that loss of ERα in a moderate proportion of B cells
significantly attenuated lupus in (NZB x NZW)F1 mice. ERα deletion in B cells
significantly decreased the production of autoantibodies and prolonged survival in both
female and male mice. A decrease in B cell activation was found in young female mice
with B cell specific ERα deletion. We propose that an even more dramatic attenuation of
lupus would likely be observed if there was greater efficiency of ERα deletion in B cells.
Although the low efficiency of B cell specific ERα deletion in this model was unintended,
the significant reduction in lupus observed in these mice suggests that disruption of ERα
signaling in B cells may be a reasonable target for the treatment of lupus.
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General Discussion and Conclusion
Lupus is an autoimmune disease characterized by the production of autoreactive
antibodies against nuclear antigens, and aberrant immune activation. Estrogens, through
activation of ERα, exacerbate lupus, but it is not known which cell type or types mediate
this effect. Additionally, estrogens affect hematopoietic cells in ways that autoimmunity,
but it is not known if these effects are hematopoietic cell intrinsic.
In the studies presented here, we sought to discover the cell type or types in which ERα
signaling promotes lupus. We hypothesized that ERα promotes lupus in B cells, and
more generally, in hematopoietic cells. To test this hypothesis, we created two different
mouse models on the (NZB x NZW)F1 lupus-prone genetic background that allowed us
to assess the effect of ERα knockout in all hematopoietic cells, and the effect of B cell
specific ERα deletion.
In chapter 3, we presented data from our studies that sought to determine the impact of
ERα in hematopoietic cells on lupus. To address this, we created chimeric mice with
ERα-/- or ERα+/+ hematopoietic cells in ERα+/+ lupus-prone (NZB x NZW)F1 mice. When
characterizing this model, we observed that ERα in hematopoietic cells has a significant
impact on the ability of hematopoietic cells to successfully reconstitute the bone marrow
in female mice. A smaller proportion of ERα-/-→ERαfl/+ transplanted female mice had
successful engraftment compared to ERα+/+→ERαfl/+ transplanted females. These grafts
were stable, without a significant increase in the proportion of host ERαfl/+ hematopoietic
cells, until at least 6 months after transplant. Both ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+
male chimeras had high rates of successful engraftment. These results indicate that
ERα-/- hematopoietic cells from female mice are not able to reconstitute the
hematopoietic compartment as efficiently as ERα+/+ cells. Estrogen signaling through
ERα plays an important role in the proliferative capacity of hematopoietic stem cells.
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ERα-/- bone marrow cells do not repopulate the bone marrow as rapidly as ERα+/+ cells
after transplantation due to the reduced population size and proliferative capacity of
ERα-/- HSCs in female mice (Sanchez-Aguilera, 2014; Nakada, 2014). Therefore, the
lower proliferative capacity of HSCs from ERα-/- female mice could be the cause of the
decreased engraftment efficiency that we observed.
In addition to proliferative capacity, to achieve successful engraftment, HSCs must be
able to localize to the stem cell niche in the bone marrow. A defect in HSC homing could
be responsible for the decreased engraftment efficiency in ERα-/-→ERαfl/+ female mice.
To investigate this, we examined the expression of CXCR4, CXCR7, and CXCL12 in
bone marrow from ERα+/+ and ERα-/- mice. CXCR4 is a G-protein coupled chemokine
receptor expressed on the surface of hematopoietic stem and progenitor cells. HSCs are
guided to the niche stem cell niche by the CXCR4 ligand, CXCL12 (also called stromalderived factor 1), which is secreted by bone marrow stromal cells. The concentration of
CXCL12 is higher in the bone marrow than in the peripheral blood, and CXCR4expressing HSCs locate the stem cell niche based on this gradient. CXCL12 can also
bind CXCR7, a scavenger receptor which targets CXCL12 for degradation, and thus
prevents CXCL12 from binding CXCR4 (Naumann, 2010). The balance between CXCR4
and CXCR7 expression regulates HSCs’ ability to hone to the bone marrow stroma.
Estrogen increases the expression of CXCL12 and CXCR4, and decreases the
expression of CXCR7 (Boudot, 2011; Li, 2013). The CXCR4-CXCL12 interaction is not
the only factor involved in HSC homing, but it plays a significant role in the engraftment
potential of transplanted hematopoietic cells (Adamiak, 2015). Our analysis of the mRNA
levels of these chemokine receptors and ligand did not find a difference in the
expression of these molecules between ERα+/+ and ERα-/- mice of either sex. These
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results do not preclude the possibility that other factors that affect HSC homing could be
affected by the loss of ERα in females.
Despite a lower than expected rate of success in producing ERα-/-→ERαfl/+ female mice
with high levels of engraftment, we were able to produce enough successfully
transplanted mice to study the effects of ERα in hematopoietic cells on lupus. The
survival of ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ chimeric mice was monitored for up to one
year. There was no difference in the median lifespan of ERα-/-→ERαfl/+ and
ERα+/+→ERαfl/+ female mice. Additionally, there was no difference in median survival
between ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ males. This suggests that ERα in
hematopoietic cells does not affect the rate of lupus-related mortality in either female or
male mice.
In addition to its effects on survival, we examined the effects of ERα in hematopoietic
cells on the production of autoantibodies. Autoantibody production was measured in
ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ chimeric mice. We found that female ERα-/-→ERαfl/+
mice produced less anti-chromatin IgG and anti-dsDNA IgG at 6 months of age. By 7
months of age, there was no difference in the amount of these autoantibodies produced
by ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+ mice. This suggests that mice with ERα-/hematopoietic cells have attenuated autoantibody production at a young age, but that
loss of ERα does not protect against autoantibody production as the mice age. The rate
of engraftment in these mice remained high for at least 6 months after the transplant
(about 8 months old), which suggests that progressive graft failure is not the cause of
increased autoantibody production in ERα-/-→ERαfl/+ female mice. We hypothesized that
there may be some pathogenic element of the host immune system that remained in
ERα-/-→ERαfl/+ mice which was able to overcome the protective effects of ERα-/hematopoietic cells and cause increased immune activation in these mice.
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Short-lived plasmablasts and long-lived plasma cells in (NZB x NZW)F1 mice are
resistant to depletion by cyclophosphamide (Hoyer, 2004), which suggests that these
cells may be able to survive irradiation. When we examined the DNA of plasma cells
isolated from mice at the end of the survival study, many months after irradiation, we
were able to detect host plasma cell DNA in many mice. Additionally, we isolated
dsDNA-reactive long-lived and short-lived plasma cells from 10 week old mice that had
been irradiated and not given replacement bone marrow. 0.27-0.41% of the plasma cells
isolated from these mice were dsDNA-reactive, which is a large percent of cells of a
single reactivity. These results show that a significant population of pathogenic dsDNA
reactive plasma cells are present in pre-autoimmune (NZB x NZW)F1 mice and that
these cells survive irradiation. Therefore, chimeric ERα-/-→ERαfl/+ and ERα+/+→ERαfl/+
mice are likely to have a significant population of autoreactive plasma cells from the
host. These host-derived autoreactive plasma cells may be sufficient to drive the
progression of lupus in ERα-/-→ERαfl/+ mice. The ERα+/+→ERαfl/+ chimeric mice had
ERα+/+ plasma cells from both the host and the donor hematopoietic cells, and produced
more autoantibodies initially. The delayed antibody production in ERα-/-→ERαfl/+ female
mice could be from activation of autoreactive host-derived ERαfl/+ plasma cells, and not
ERα-/- cells. This would suggest that ERα-/- hematopoietic cells do attenuate lupus in
(NZB x NZW)F1 mice, but in this chimeric model, these effects are masked by the
activity of residual dsDNA-reactive ERαfl/+ plasma cells.
Although we had hypothesized that ERα in hematopoietic cells impacts lupus, ERα is
widely expressed by cells throughout the body, and the expression of ERα in other cell
types could impact lupus. For instance, ERα could impact lupus through bone marrow
stromal cells (BMSCs). BMSCs support hematopoietic cells both through direct contact
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and through the secretion of growth factors. BMSCs express ERα, and estrogen
regulates the ability of BMSCs to support hematopoietic cells (Smithson, 1995).
In addition to the chimeras created to study the role of ERα in hematopoietic cells on
lupus, we also created chimeric mice designed to address the role of ERα in nonhematopoietic cells on lupus. To do this, we transplanted (NZB x NZW)F1 ERα+/+
hematopoietic cells into ERα-/- or ERα+/- (NZB x NZW)F1 recipients. Studies with these
mice revealed that loss of ERα in non-hematopoietic cells has a significant, negative
effect on engraftment in female mice. The transplant efficiency in female ERα+/+→ERα-/mice was dramatically lower than in female ERα+/+→ERα+/- mice. The proportion of
ERα-/- hematopoietic cells in ERα+/+→ERα-/- females increased significantly over time,
indicating progressive failure of the donor cells. Male ERα+/+→ERα-/- and ERα+/+→ERα+/chimeras had successful transplants that were stable over time. Again, we observed that
ERα impacted the success of hematopoietic engraftment in female mice and not males.
In this case, the hormonal environment in ERα-/- females likely leads to exhaustion of the
transplanted HSCs, and failure of ERα+/+ HSC grafts in ERα-/- recipient females.
Elevated levels of estrogen significantly affect the proliferation of HSCs. A moderate
increase in serum E2, like the approximately 2-fold increase that occurs during
pregnancy, causes HSCs to divide more frequently, and causes an increase in the
number of HSCs (Nakada, 2014). However, in conditions of high serum E2, the HSC
population decreases, likely as the result of exhaustion due to rapid division (Thurmond,
2000). After chronic exposure to estrogen, HSCs are unable to effectively repopulate
some hematopoietic populations (Illing, 2012). Female ERα knockout mice have serum
E2 levels about 10x higher than ERα+/+ females (Eddy, 1996). Therefore, in female
ERα+/+→ERα-/- mice, the donor ERα+/+ HSCs are likely exhausted after rapid estrogeninduced proliferation, which causes the proportion of ERα+/+ cells in the hematopoietic
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population to progressively decrease. Male ERα knockout mice do not have elevated
levels of E2, so ERα+/+ hematopoietic cells would not undergo rapid proliferation in ERα-/males.
Examining the rate of hematopoietic engraftment in chimeric mice revealed that the ERα
genotype of both donor and host play a significant role in the success of hematopoietic
reconstitution in females, but not males. Female ERα-/-→ERαfl/+ chimeras have a lower
rate of successful reconstitution than ERα+/+→ERαfl/+ females. Female ERα+/+→ERα-/chimeras have a dramatically lower rate of engraftment than ERα+/+→ERα+/- chimeras
which progressively decreases over time due to exhaustion of the HSC population.
Transplantation of hematopoietic cells has been investigated as a treatment for many
diseases, particularly cancers. The use of high dose chemotherapy followed by
autologous stem cell transplant (HDCT/ASCT) has been investigated as a treatment for
breast cancer with mixed results. The amount of estrogen in breast cancer patients
could impact the engraftment of the transplanted hematopoietic cells, and the ability of
immune cells to fight cancer cells. Breast cancer patients can be either pre- or postmenopausal and some receive fulvestrant treatment, which makes it difficult to
determine the estrogen level in patients and how this affects the success of the
HDCT/ASCT treatment. Phase I/II trials of HDCT/ASCT were done in young,
premenopausal women and showed promise for treating breast cancer, but later trials
that included both premenopausal and postmenopausal women had mixed results. One
study showed that postmenopausal women given HDCT/ASCR were more likely to die
of tumor-related death than premenopausal women (Wild, 2004). Although far from
conclusive, these results may indicate that low levels of estrogen negatively affect the
effectiveness of this transplantation therapy. If this is true, it is likely related to the effects
of estrogen on hematopoietic cell division.
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In our experiments, because of the unsuccessful engraftment of ERα+/+→ERα-/- female
mice, we were unable to use these female mice to draw conclusions about the role of
ERα in non-hematopoietic cells in lupus. The median survival times of male
ERα+/+→ERα-/- and ERα+/+→ERα+/- mice are not different. Therefore, the ERα genotype
of non-hematopoietic cells does not have an impact on survival in males.
The development of fatal glomerulonephritis is characteristic of lupus in (NZB x NZW)F1
mice. Therefore, when chimeric mice died or were sacrificed at the end of the one year
survival study, kidneys were collected and evaluated for nephritis. All chimeric mice from
each group had moderate to severe glomerulonephritis. This is similar to what was
observed in ERα+/+ (NZB x NZW)F1 mice, where all female and male mice developed
severe glomerulonephritis by the end of an 18 month survival study (Bynote, 2008).
Although glomerulonephritis and autoantibody production are characteristic of lupus in
(NZB x NZW)F1 mice, they can also be symptoms of graft versus host disease (GVHD),
a condition that can develop after transplantation of hematopoietic cells. GVHD occurs
when there is a mismatch in histocompatibility loci between the donor and recipient,
which causes the donor hematopoietic cells to launch an immune response against host
cells. Acute GVHD (aGVHD) manifests immediately after transplantation and causes
severe skin rash and diarrhea. Murine models of aGVHD result in continual weight loss
and death by one month after transplant (Lin, 2014). Chronic graft vs host disease
(cGVHD) develops later, and can cause autoantibody production and glomerulonephritis
(Fraile, 2013). In our chimeric mouse model, both the donor and recipient mice are (NZB
x NZW)F1s and should not have any mismatches at histocompatibility loci. Although the
chimeric mice produced for these studies initially lost weight after the transplant, they
gained back almost all of this weight within 2 weeks. Additionally, no diarrhea or skin
manifestations were observed in these mice over the course of the study. In these
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chimeric (NZB x NZW)F1 mice, significant sex-specific survival differences were
observed, which is characteristic of lupus, and not GVHD. Therefore, we are confident
that these mice did not develop GVHD, and the autoantibody production and
glomerulonephritis that occurred in these mice were due to lupus.
In conclusion, although we were not able to show that ERα in hematopoietic cells
significantly affected lupus, the persistence of host-derived long-lived plasma cells,
combined with the partial attenuation of autoantibody production in ERα-/-→ERαfl/+
females suggests that a small population of ERα+/+ dsDNA-reactive plasma cells may be
sufficient to cause lupus in (NZB x NZW)F1 mice. These studies also demonstrated that
estrogen signaling, through ERα, in hematopoietic and non-hematopoietic cells is
important for successful engraftment after transplantation in females.
In addition to investigating the impact of ERα in hematopoietic cells on lupus, we were
also interested in examining the effects of ERα in B cells on lupus. High levels of
estrogen promote the development of high-affinity autoreactive B cells through ERα.
Activated autoreactive B cells become plasma cells that produce pathogenic
autoantibodies. These pathogenic autoantibodies form immune complexes, which cause
inflammation and tissue damage in lupus patients.
In chapter 4, we presented data from our studies on lupus-prone (NZB x NZW)F1 mice
with B cell specific deletion of ERα. To achieve B cell specific deletion of ERα, a cre-loxP
system was used in which the CD19-Cre knockin allele, which is expressed in B cells,
caused the deletion of a floxed allele of ERα. The efficiency of ERα deletion by CD19Cre was much lower than has been previously reported, with only ~50% deletion of ERα
in CD19+ splenocytes. Another study from our lab which used Lck-Cre to cause ERα
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deletion in T cells also found that the deletion efficiency was lower on the (NZB x
NZW)F1 genetic background than had been previously reported (Nelson, 2016).
Mammalian cells contain cryptic or pseudo loxP sites, which can deviate significantly
from the consensus loxP sequence and be cleaved by cre recombinase (Thyagarajan,
2000). Defects in double strand break repair are associated with lupus, and unrepaired
dsDNA breaks can lead to apoptosis. (NZB x NZW)F1 mice with the CD19-Cre knockin
allele have a small but significant increase in apoptotic CD19+ splenocytes compared to
mice without cre. (NZB x NZW)F1 mice with Lck-Cre also have a significant increase in
apoptotic T cells (Nelson, 2016). Cells that have high enough cre expression to cause
deletion of ERα may also have DNA damage at pseudo loxP sites caused by cre.
Unrepaired DNA damage leads to apoptosis, and could contribute to the moderate
deletion efficiency we observed in (NZB x NZW)F1 mice.
Another possible reason for the moderate deletion efficiency of ERα observed in these
mice would be if B cells that lacked ERα expression were at a survival disadvantage. We
found that the rate of deletion of the floxed ERα allele was the same in B cells that had
total loss of ERα in B cells, and those that retained one functional copy of ERα after
recombination. Therefore, ERα knockout B cells were not at a survival disadvantage,
and the reduced proportion of CD19+ cells that underwent cre-mediated deletion was
likely an effect of the (NZB x NZW)F1 genetic background.
Despite the moderate rate of ERα deletion, our studies showed that loss of ERα in a
moderate proportion of B cells caused a significant improvement in lupus. Young female
mice with B cell ERα deletion had a lower percentage of activated B cells compared to
CD19-Cre controls. Therefore, deletion of ERα in B cells prevented B cell activation in
pre-autoimmune mice. Although we did not observe a difference in B cell activation in
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young male mice, we predict that there would be a difference in slightly older male mice,
since males have a longer latency to disease than females.
In addition to decreased activation of B cells, mice of both sexes with B cell ERα deletion
had significantly lower levels of pathogenic anti-dsDNA IgG autoantibodies than CD19Cre only controls. There was no difference in the production of total IgM or IgG, which
indicates that the reduction in anti-dsDNA IgG is particular to this antibody specificity and
is not due to general immunosuppression from loss of ERα in B cells.
Lower levels of pathogenic autoantibodies in mice with B cell ERα deletion caused a
delay in the development of fatal glomerulonephritis. Both female and male mice with B
cell ERα deletion had longer median survival than CD19-Cre only controls. The
differences in median survival between female and male (NZB x NZW)F1 mice with B
cell specific ERα deletion and CD19-Cre controls are 68 days and 72 days, respectively.
Therefore, partial deletion of ERα in B cells attenuated lupus-related mortality by a
similar amount of time in females and males.
Female (NZB x NZW)F1 mice with whole-body ERα knockout had a far longer
attenuation of lupus than the 68 days in females with B cell specific deletion of ERα
(Bynote, 2008). However, this study was complicated by the hormonal changes
associated with ERα knockout in females. Female ERα knockout mice have about 10x
more serum E2 than ERα+/+ mice, while there is no change in serum E2 in ERα knockout
males (Eddy, 1996). The increased level of serum E2 in (NZB x NZW)F1 females would
have caused increased ERβ activation. It has been suggested that ERβ activation has a
moderate protective effect in (NZB x NZW)F1 mice (Li, 2007), and this could contribute
significantly to the attenuation of lupus in (NZB x NZW)F1 ERα knockout females. The
attenuation of lupus in male ERα knockout mice is 85-113 days, which is similar to the
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attenuation of 72 days in males with B cell specific ERα deletion (Bynote, 2008). So,
even though we did not observe a sex-specific difference in the attenuation of lupus in
mice with partial ERα deletion in B cells, this is not necessarily inconsistent with past
studies, because female mice with partial ERα deletion in B cells should not have
hormonal abnormalities like global ERα knockout females.
There are several studies that we would like to perform to further characterize this
model. To determine if the development of glomerulonephritis is indeed attenuated in
mice with B cell specific ERα deletion, we will collect kidneys from female and male mice
at a pre-defined age, after initiation of disease, but before mice begin to succumb to
disease. These kidneys will be evaluated for glomerulonephritis and immune complex
deposition. At this time, we will also analyze B cell activation in male mice to see if males
with B cell ERα deletion have a lower proportion of activated B cells. It has been
reported that estrogen, through activation of ERα, causes an increase in the frequency
of Ig-producing B cells (Erlandsson, 2003). To see if ERα deletion in B cells causes a
change in the total number of autoantibody producing B cells, an ELISpot assay will be
performed.
The studies presented here suggest that ERα in B cells may be an attractive target for
lupus therapy. Although unintended, the modest efficiency of ERα deletion in this model
suggests that disruption of ERα signaling in only a portion of B cells is sufficient to cause
significant attenuation of lupus. Therefore, after the studies to further characterize this
model have been completed, the next step is to begin designing a targeted method to
deliver an ERα blocking molecule to B cells. It has been shown that liposomes loaded
with doxorubicin can be targeted to B cells with anti-CD19 antibodies. A similar design
could be used to encapsulate an anti-estrogen, such as fulvestrant, for delivery to B
cells.
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In addition to the effects of B cell specific deletion of ERα on lupus, we also observed
many changes in our experimental mice that can be attributed to the CD19-Cre knockin
allele. In both female and male mice, the survival of CD19-Cre only control mice was
significantly shorter than CD19+/+ mice. We were not able to determine if this was an
effect of CD19 heterozygosity, cre recombinase expression, or a combination of both.
CD19 promotes BCR signaling (Depoil, 2008), and CD19-Cre mice have about half the
CD19 expression as CD19+/+ mice, which could lead to less effective BCR signaling, and
increased survival of autoreactive B cells. Alternatively, a cre-induced increase in
apoptosis could cause the release of nuclear antigens and increased activation of
autoreactive B cells. In support of this, an increase in apoptosis was observed in CD19+
splenocytes from mice with the CD19-Cre knockin allele. Whatever the cause, the
CD19-Cre knockin allele had significant effects on mortality in these studies. This
emphasizes the need for appropriate cre-only controls in experiments using the cre-loxP
system. Without comparing the survival of these two groups, we would have incorrectly
concluded that B cell specific deletion of ERα did not affect the survival of lupus-prone
mice.
The results of the two studies presented here appear contradictory. The study presented
in chapter 3 failed to show that ERα in hematopoietic cells promotes lupus, while the
study presented in chapter 4 showed that deletion of ERα in a moderate proportion of B
cells significantly attenuates lupus. There are a few possible explanations for this
disconnect.
The hematopoietic compartment is made up of many types of cells, which play different
roles in immunity. ERα is widely expressed in hematopoietic cells from HSCs to fully
differentiated cells, and activation of ERα causes varied effects in different cell types.
Consequently, the loss of ERα in various immune cell types will have different effects.
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Our studies have shown loss of ERα in even a portion of B cells leads to a lower level of
immune activation. However, the loss of ERα in a different cell type, like Tregs, which
negatively regulate the immune response, could lead to unchecked immune activation.
E2 causes an increase in the Treg population, and also increases the suppressor
capacity of Tregs via multiple mechanisms (Polanczyk, 2004; Prieto, 2006; Polanczyk,
2007). Some of these effects are mediated by ERα. Therefore, it is possible that loss of
ERα from the entire hematopoietic compartment affects some cells in a lupus-promoting
and others in others in a lupus-attenuating manner, and that in the environment of an
ERα+/+ mouse, changes in the number or function of different types of immune cells
results in no net change in the development of lupus. Thus, proper ERα signaling in
Tregs may provide crucial protection from unattenuated lupus.
Another explanation for these results is that while ERα in hematopoietic cells promotes
lupus, the chimeric (NZB x NZW)F1 mice produced for our studies did not have a pure
enough population of hematopoietic cells to show an effect on survival. We have shown
that ERα+/+ host-derived dsDNA-reactive plasma cells survive irradiation in (NZB x
NZW)F1 mice and can be detected months after the transplant. A large percentage of
these surviving plasma cells were dsDNA-reactive. In an environment where most other
hematopoietic cells are ERα-/-, ERα+/+ plasma cells could be free from the inhibitory
signals that normally prevent high levels of activation. Activated dsDNA reactive plasma
cells could then produce large amounts of autoantibodies, thus promoting lupus.
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Conclusion
We created chimeric (NZB x NZW)F1 mice with different ERα genotypes in
hematopoietic and non-hematopoietic cells to study the impact of ERα in these cells on
lupus. Although we were not able to show that ERα in hematopoietic cells promotes
lupus, our studies with these chimeric mice did show that ERα plays an important role in
the successful engraftment of hematopoietic cells in female mice. Loss of ERα in
hematopoietic cells led to decreased engraftment efficiency.
Additionally, to study the role of ERα in B cells in lupus, we created a (NZB x NZW)F1
model with ERα deletion specifically in B cells. Loss of ERα in a moderate proportion of
B cells significantly reduced B cell activation and attenuated autoantibody production
and mortality in (NZB x NZW)F1 mice. As a result of these studies, we have identified
ERα in B cells as a potential new target for lupus therapy. Additionally, we have shown
that the CD19-Cre knockin allele alone has significant effects in lupus-prone mice,
emphasizing that cre-only controls are essential in experiments that utilize cre-loxP
systems.
Although the results of these studies appear contradictory, there are a few possible
explanations for these results. One possibility is that the hematopoietic compartment of
the chimeric mice produced to study the role of ERα in hematopoietic cells was not
composed of a pure population of cells from the donor mouse, and that residual hostderived cells were sufficient to cause lupus in chimeric mice. Another possibility is that
by knocking out ERα from the entire hematopoietic compartment, both cells that promote
and attenuate lupus were affected, leading to no net change in the development of
lupus.
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Abstract
Objective

To evaluate the potentially improved therapeutic efficacy and safety of nephrotropic
macromolecular prodrugs of glucocorticoids (GC) in the treatment of lupus nephritis.

Methods

Monthly injection of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-based
dexamethasone prodrug (P-Dex) and daily injection of dexamethasone phosphate
sodium (Dex, overall dose equivalent to P-Dex) were given to lupus-prone
(NZB×NZW)F1 female mice for two months. The animals were monitored for
albuminuria, mean arterial pressure and serum autoantibody levels during the treatment.
Nephritis, renal immune complexes and macrophage infiltration were evaluated
histologically. The bone quality was analyzed with pDEXA and μ-CT. Optical imaging,
immunohistochemistry (IHC) and fluorescence-activated cell sorting (FACS) were used
to understand the in vivo distribution of P-Dex. The anti-inflammatory effect of P-Dex
was validated using LPS-activated human proximal tubule epithelial cells (HK-2).

Results

Monthly P-Dex injection completely abolished albuminuria in the (NZB×NZW)F1 mice,
which is significantly (P < 0.001) more efficacious than daily Dex treatment. P-Dex did
not reduce serum levels of anti-dsDNA antibodies or renal immune complexes, but did
reduce macrophage infiltration, a marker of chronic inflammation. IHC and FACS
analyses revealed that P-Dex was primarily sequestered by proximal tubule epithelial
cells and it could attenuate the inflammatory response in HK-2 cell culture. Different from
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Dex treatment, P-Dex did not lead to any significant bone quality deterioration or total
serum IgG reduction.

Conclusion

Macromolecularization of GCs renders them nephrotropic. The protracted retention,
subcellular processing and activation of GC prodrugs by kidney cells would potentiate
nephritis resolution with reduced risk of systemic toxicities.

Introduction

Lupus is an autoimmune disease in which autoantibodies are produced against nuclear
antigens, including double stranded DNA (dsDNA). Renal deposition of anti-dsDNA IgG
containing immune complexes leads to nephritis, a major cause of morbidity and
mortality in lupus patients. Renal immune complexes induce inflammation and immune
cell infiltration, which if unresolved, lead to renal injury, dysfunction, and failure. Nephritis
is treated with glucocorticoids (GCs), which are suboptimal because they frequently
cause off-target toxicity. Because lupus patients often take GCs continuously for many
years, they are at high risk for developing GC-associated adverse side effects, including
osteoporosis and immunosuppression.

The therapeutic efficacy of a drug depends on its specificity for its molecular target and
its concentration at the site of interaction with the target. Advances in understanding
lupus have stimulated progress in the identification of drugs that interact with molecular
targets and pathways associated with disease [1]. These efforts, nevertheless, have not
addressed the problems created by our inability to control the in vivo drug concentration
at either the intended site(s) of action or off target sites, where drug action results in
adverse side effects.
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To address this challenge, we have developed a macromolecular prodrug of
dexamethasone (P-Dex), which passively targets inflamed tissues and provides superior
and sustained resolution of inflammation in several animal models [2–4]. Here, we
demonstrate that P-Dex prevents nephritis in lupus-prone (NZB×NZW)F1 mice. P-Dex
demonstrated reduced systemic toxicity compared to the equivalent dose of
dexamethasone. Mechanistic studies indicate that the nephrotropism, cell-mediated local
sequestration, subcellular processing and activation of P-Dex likely contribute to its
superior therapeutic efficacy and reduced systemic toxicities.

Materials and Methods
Synthesis of macromolecular prodrugs

P-Dex (Figure 1A) was synthesized by reversible addition-fragmentation chain transfer
(RAFT) copolymerization as described previously [3]. Briefly, N-(2hydroxypropyl)methacrylamide (HPMA), N-methacryloylglycylglycylhydrazyl
dexamethasone (MA-Dex) [3] and other comonomers {N-methacryloylaminopropyl
fluorescein thiourea [5] and N-(3-aminopropyl)methacrylamide hydrochloride (APMA,
Polysciences, Inc. Warrington, PA)} were copolymerized at 40°C under Argon for 48
hours (h) with 2,2′-azobisisobutyronitrile as the initiator and S,S′-bis(α, α ′-dimethyl-α″acetic acid) trithiocarbonate as the RAFT agent [6]. The resulting polymers were purified
by LH-20 column (GE HealthCare, Waukesha, WI) and lyophilized. IRDye 800CW and
Alexa Fluor® 488 labeled P-Dex (P-Dex-IRDye and P-Dex-Alexa) were obtained via
polymer analogous reactions between poly(HPMA-co-MA-Dex-co-APMA) and NHS
esters of these dyes [2].

Experimental animals and drug treatment
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Figure 1. Dexamethasone prodrug (P-Dex) prevents albuminuria and reduces
glomerular damage in female (NZB x NZW)F1 mice. A, Chemical structure of P-Dex.
B, Albuminuria readings for mice in the saline (n =10), N-(2hydroxypropyl)methacrylamide homopolymer (PHPMA) (n = 10), dexamethasone 21phosphate disodium (Dex) (n = 15), and P-Dex (n = 15) treatment groups at the
pretreatment (PT) and 8-week time points. The percentages shown are the incidence of
albuminuria at the 8-week time point. Each data point represents an individual mouse. C,
Quantification of the incidence of abnormal glomeruli in each treatment group. Values
are the mean ± SEM. * = P < 1 x 10-3; ** = P < 5 x 10-4. D, Representative periodic acid–
Schiff–stained histologic sections from each treatment group. Bars = 50 μm.
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(NZB×NZW)F1 and NZW females (Jackson Laboratories, Bar Harbor, ME) were housed
under controlled humidity, temperature and lighting conditions in facilities accredited by
the American Association for Accreditation of Laboratory Animal Care, operating in
accordance with standards set by the Guide for the Care and Use of Laboratory Animals
(The National Academies Press, 1996). Mice were given Harlan irradiated rodent diet
7904 (Harlan Teklad, Madison, WI) and allowed to feed ad libitum. All procedures
involving live animals were approved by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee.

At 16 weeks of age, mice were treated via i.v. injection with saline, N-(2hydroxypropyl)methacrylamide homopolymer (PHPMA), or P–Dex (250 mg/kg) every 4
weeks. A fourth group of mice were given daily i.p. injections of dexamethasone 21phosphate disodium (Dex, 1.32 mg/kg, containing 1.00 mg/kg of dexamthasone,
Hawkins, Inc., Minneapolis, MN). Dosages of Dex and P-Dex were calculated and
prepared as such that mice received the same dose of dexamethasone over the 8-week
treatment period.

Mice were monitored weekly for albuminuria using Albustix (Siemens Corp., Washington
DC). Albuminuria was defined as two consecutive 2+ readings (100 mg/dL). Every 4
weeks, serum was isolated from peripheral blood, and mean arterial pressure (MAP)
was recorded via tail-cuff method using the CODA blood pressure measuring system
and software (Kent Scientific, Torrington, CT). One week after cessation of treatment,
mice were euthanized and tissues harvested.

Analysis of nephritis, renal immune complexes and macrophage infiltration
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Kidneys were fixed, paraffin-embedded, sectioned and stained with Periodic Acid-Schiff
(PAS) (Sigma-Aldrich, St. Louis, MO) and analyzed by light microscopy. One hundred
glomeruli per mouse were evaluated as described previously [7].

Renal immune complexes were visualized by immunohistochemistry. After
deparaffinization and rehydration, slides were incubated in H2O2, washed and incubated
in citrate buffer (Vector Laboratories, Burlingame, CA). Slides were blocked with normal
horse serum (Vector Labs), and incubated with anti-mouse IgG (Vector Labs). Antibody
binding was visualized using Vectastain Elite reagents (Vector Labs). Staining intensity
(represented as arbitrary gray units or AGU) of fifty glomeruli per mouse was quantified
using Axiovision software (v4.6.3.0; Carl Zeiss, Thornwood, NY). A second set of slides
stained for immune complexes was counterstained with hematoxylin; these slides were
for illustration purposes only.

Renal macrophage infiltration was assessed via immunofluorescence with the
macrophage marker Iba-1 (Biocare Medical, Concord, CA) as described previously [8],
with an added blocking step in Sudan Black B. Staining was visualized and quantitated
using confocal microscopy and Zen 2010 software (v6; Carl Zeiss).

Serological analysis of serum immunoglobulin levels

Serum immunoglobulin concentrations were determined by ELISA (Southern Biotech,
Birmingham, AL). The IgG1, IgG2a, IgG2b, and IgG3 levels were added together to obtain
total serum IgG levels. Serum Anti-dsDNA IgG levels were determined by ELISA (Alpha
Diagnostics International, San Antonio, TX) as described previously [7].

Analysis of bone quality
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Femoral bone mineral density (BMD) and micro-architectural parameters were
measured as described previously [9], using pDEXA® Sabre™ X-ray bone densitometer
(Norland Medical System, Inc, Fort Atkinson, WI) and Skyscan 1172 micro-CT system
(Skyscan, Kontich, Belgium), respectively. pDEXA analysis was performed with a 20
mm/sec scanning speed and a 0.2 × 0.2 mm resolution. Areal BMD was calculated using
SABRE RESEARCH software (v3.9.4). Micro-CT scanning parameters were: voltage, 55
kV; current, 189 μA; exposure time, 230 ms; resolution, 6.2 μm; and aluminum filter (0.5
mm). Three-dimensional reconstructions were performed with NRecon and Dataviewer
software (Skyscan). Trabecular bone was selected for analysis by a polygonal region of
interest within the center of the femur, starting at 20 slices (0.25 mm) proximal from the
growth plate and extending proximally 80 slices (0.99 mm) further. Trabecular bone
volume fraction, number and thickness were quantified with CTAn software (Skyscan).

Near infrared imaging analysis

Mice received P-Dex-IRDye (148 nmol IRDye per kg body wt.) by i.v. injection. Mice
were euthanized 2 or 7 days (d) later and tissues were harvested and imaged using an
XENOGEN IVIS® 200 Series Imaging System (Caliper Life Sciences, Hopkinton, MA).

Immunohistochemical analyses of P-Dex distribution within kidney

Mice were given P-Dex-Alexa (300 nmol Alexa Fluor® 488 per kg body wt.) via i.v.
injection. Seven days later, mice were perfused and euthanized. Kidneys were fixed,
paraffin-embedded and sectioned. For direct staining, APC-labeled anti-mouse B220
and CD8a, and PE-labeled anti-mouse CD31 and CD4 (BD Pharmingen, San Diego,
CA) antibodies were used. For indirect staining, sections were incubated with antimouse CD11c (eBioscience, San Diego, CA), E-cadherin (R&D Systems, Minneapolis,
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MN), F4/80 and Ly-6G (eBioscience) antibodies, followed with PE-labeled secondary
antibody (eBioscience; R&D Systems; and Invitrogen, Carlsbad, CA). Stained sections
were examined under a Nikon Swept Field confocal microscope (Nikon Instruments Inc,
Melville, NY).

Flow cytometry

Mice received an i.v. injection of P-Dex-Alexa. At necropsy (7 d post injection), white
blood cells (WBCs) were isolated from peripheral blood. Mice were perfused, and
tissues were isolated, macerated and passed through a 70-μm strainer to obtain single
cell suspensions. Cells were analyzed with Becton Dickinson FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA). The following antibodies were used: APClabeled anti-mouse B220, CD19, CD5 and CD8a; PE-labeled anti-mouse F4/80
(eBioscience), Ly6B.2 (AbD Serotec, Raleigh, NC), CD4, CD138, CD31 and IgD (BD
Pharmingen); PECy7-labeled anti-mouse IgM (BD Pharmingen); anti-mouse CD11c, αsmooth muscle actin and E-cadherin followed with PE-labeled secondary antibody.

Cell culture

Human proximal tubule epithelial cells (HK-2) were grown in RPMI 1640 with 10% fetal
bovine serum (FBS), penicillin (100 units/mL) and streptomycin (0.1 mg/mL). To
investigate the internalization of fluorescein isothiocyanate (FITC) labeled P-Dex (P-DexFITC), HK-2 cells were stimulated overnight with LPS (10 μg/mL). P-Dex-FITC (final
concentration 200 μg/mL) was added to LPS-stimulated and untreated HK-2 cells. After
specified intervals, cells were rinsed and analyzed by FACS.

For subcellular localization studies, HK-2 cells were cultured overnight with LPS and
then incubated with P-Dex-FITC (200 μg/mL) for 24 h. Cells were rinsed and incubated
158

with 75 nM Lysotracker DND-99 (Invitrogen) for 3 h. After rinsing, cells were stained with
DAPI, fixed, mounted and observed by confocal microscopy.

To analyze the anti-inflammatory effect of P-Dex, HK-2 cells were treated with LPS plus
Dex (2 μM) or P-Dex (2 μM dexamethasone equivalent) for 24 h. Supernatants were
collected and stored at −80°C. Cells were rinsed and incubated with fresh medium
containing LPS for an additional 48 h. Supernatants were collected and assayed for IL-6
level by ELISA (R&D Systems).

Statistical methods

Comparisons were performed using Fishers exact test, Wilcoxon signed-ranks test,
Mann-Whitney U test, independent or paired samples t-test, or one-way ANOVA with
Tukey’s post hoc test where appropriate. Statistical analyses were performed using
SPSS software (version 19.0). A two-sided P ≤ 0.05 was considered significant. Twosided p-values are provided. Mean ± standard error of the mean is presented.

Results
P-Dex prevents albuminuria and reduces glomerular damage

Albuminuria was measured in (NZB×NZW)F1 mice to assess nephritis-associated loss
of renal function. Prior to treatment, none of the mice displayed albuminuria. However,
after 8 weeks, 100% of saline treated mice and 70% of PHPMA treated mice exhibited
albuminuria (Figure 1B). The incidence of albuminuria in these groups did not differ
significantly (P = 0.2). After eight weeks, 47% of Dex treated mice displayed albuminuria
(Figure 1B), which was significantly different from the saline (P < 0.01), but not the
PHPMA group (P = 0.4). Strikingly, after eight weeks, 0% of P-Dex treated mice
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exhibited albuminuria (Figure 1B), which is significantly different from the saline (P <
5×10−7), PHPMA (P < 5×10−4) and Dex (P < 5×10−2) groups. Thus, P-Dex was more
effective than Dex in preventing albuminuria.

To further assess renal function, PAS-stained kidney sections were analyzed for
glomerular abnormalities induced by nephritis. Abnormal glomeruli were found at a
frequency of 16% in the saline group and 14.9% in the PHPMA group (Figure 1C, 1D).
There was no significant difference between these two groups (P = 0.9). The frequency
of abnormal glomeruli in Dex and P-Dex treated mice was 11.3% and 9.9%, respectively
(Figure 1C, 1D). There was no significant difference between the Dex and P-Dex groups
(P = 0.7), but the frequency in both groups was significantly lower than that in the saline
group (P < 0.01). Although the frequency of abnormal glomeruli in the Dex and P-Dex
groups was lower than that in the PHPMA group, the difference achieved significance for
the P-Dex (P < 5×10−3) but not the Dex (P = 0.07) group. Thus, both Dex and P-Dex
preserve the structural integrity of glomeruli, suggesting that these treatments attenuate
nephritis.

P-Dex does not reduce anti-dsDNA IgG levels or renal immune complexes
Nephritis in (NZB×NZW)F1 mice correlates with serum levels of pathogenic anti-dsDNA
IgG [10]. Therefore, serum anti-dsDNA IgG levels were assessed. Over the 8-week time
course, serum anti-dsDNA IgG levels increased in the saline (P = 0.07) and PHPMA (P
< 0.01) groups, although this increase fell short of statistical significance in the saline
group (Figure 2A). Over this time period, serum anti-dsDNA IgG levels rose significantly
in the Dex and P-Dex groups (Figure 2A; P ≤ 0.01), indicating that neither treatment
prevented this pathognomonic increase in anti-dsDNA IgG. Nonetheless, at the 8-week
time point, serum anti-dsDNA IgG levels in the Dex group were significantly lower than
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Figure 2. Effect of different treatments on serum anti–double-stranded DNA (anti
dsDNA) IgG and renal immune complex levels. A, Anti-dsDNA IgG levels at the
pretreatment, 4-week, and 8-week time points, as determined by enzyme-linked
immunosorbent assay. B, Representative kidney sections from each treatment group,
immunohistochemically stained for renal deposition of anti-dsDNA IgG. Bars = 50 μm. C,
Quantification of immune complex staining. Values in A and C are the mean ± SEM. * =
P < 0.02; ** = P < 0.001; *** = P < 1 x 10-12. See Figure 1 for other definitions.
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those in the PHPMA and P-Dex groups (P < 0.05). Thus, Dex blunts the increase in antidsDNA IgG, which correlated with reduced incidence of albuminuria and nephritis in this
group. By contrast, in the P-Dex group, reduced glomerular damage did not correlate
with serum anti-dsDNA IgG, suggesting that P-Dex prevents nephritis through a
mechanism that is independent of production of pathogenic autoantibodies.

Because nephritis in (NZB×NZW)F1 mice is associated with renal deposition of antidsDNA IgG-containing immune complexes [11], renal immune complex deposition was
evaluated (Figure 2B). Quantification of staining indicated that immune complex
deposition in the PHPMA treated group did not differ from that in the saline group (Figure
2C; P ≥ 0.2). Renal immune complex staining in the Dex treated group was significantly
less than that in the other groups (Figure 2C; P < 1 ×10−12). Immune complex staining in
the P-Dex group was not reduced compared to saline or PHPMA groups (Figure 2C; P ≥
0.7). Thus, in contrast to Dex, P-Dex does not prevent nephritis by diminishing renal
immune complex deposition.

P-Dex reduces renal macrophage infiltration

To test the hypothesis that P-Dex reduced renal inflammation, we examined renal
macrophage infiltration, a marker of chronic inflammation. Staining with the macrophage
marker Iba-1 was detected in all groups. Quantification of Iba-1 staining indicated that
macrophage infiltration in the saline and PHPMA groups did not differ (Figure 3; P = 0.4).
Macrophage infiltration was not significantly reduced in the Dex group compared to
either the saline (P = 0.2) or PHPMA (P = 0.7) group (Figure 3). By contrast, renal
macrophage infiltration was significantly lower in the P-Dex group than in the saline and
PHPMA groups (Figure 3; P < 0.04). Although macrophage infiltration was less abundant
in the P-Dex group than the Dex group, this difference fell just short of statistical
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Figure 3. Impact of treatment on renal macrophage infiltration in (NZB x NZW)F1
mice. A, Representative confocal microscopic images of immunohistochemical staining
of kidney sections from mice in each treatment group. Sections were stained with an
anti-Iba1 antibody (red) and DAPI (blue). Negative control (no Iba1 antibody) and
merged images are shown. Bars = 25 μm. B, Quantification of Iba1 staining. Values are
the mean ± SEM. * = P < 0.05. See Figure 1 for definitions.
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significance (Figure 3; P = 0.06). These results suggest that P-Dex may maintain renal
function by attenuating renal inflammation.

P-Dex reduces mean arterial pressure
Because GC therapy can lead to hypertension, we assessed the impact of each
treatment on blood pressure. In mice treated with either saline or PHPMA, MAP was not
significantly altered after 8 weeks (Figure 4A; P ≥ 0.4). In the Dex group, MAP was
reduced after 8 weeks of treatment (Figure 4A), although this decrease fell short of
statistical significance (P = 0.08). By contrast, P-Dex significantly reduced MAP after 8
weeks of treatment (Figure 4A; P < 1×10−4).

P-Dex treatment does not affect bone quality

Long-term GC use is associated with osteoporosis. To understand the impact of P-Dex
on the skeleton, the femoral BMD and micro-architecture were evaluated. No significant
difference in femoral BMD was observed between the saline and PHPMA groups (Figure
4B). Dex treatment, however, was associated with a significantly lower BMD (Figure 4B;
P < 5×10−7). By contrast, BMD in the P-Dex group did not differ from that in the saline
and PHPMA groups (P > 0.05). No significant differences in trabecular bone volume
fraction or number were found between groups. However, in the Dex group, trabecular
thickness was significantly lower than that in the other groups (Figure 4C; P < 0.05).
Thus, in contrast to free Dex, P-Dex did not negatively affect BMD or microarchitecture
of the bone.

P-Dex treatment does not reduce serum IgG levels

GC therapy causes immunosuppression and reduces serum IgG [12, 13]. We therefore
analyzed the impact of treatment on serum immunoglobulin levels. None of the
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Figure 4. Analysis of side effects associated with treatment in (NZB x NZW)F1
mice. A, Mean arterial pressure (MAP) at the pretreatment, 4-week, and 8-week time
points, as measured using the tail-cuff method. The horizontal line represents the MAP
(mean _ SEM 109 _ 2 mm Hg) in a group of nonautoimmune female NZW mice (n _ 12)
ages 4–6 months. B and C, Bone mineral density (BMD) (B) and trabecular thickness
(C) after 8 weeks of treatment. D, Total serum IgG levels at the pretreatment and 8-week
time points, as determined by enzyme-linked immunosorbent assay. Values are the
mean ± SEM. * = P < 0.05; ** = P < 0.001; *** = P < 0.0005. See Figure 1 for other
definitions.
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treatments affected serum IgA or IgM levels (data not shown). Prior to treatment, no
significant differences in serum IgG levels were observed between groups (Figure 4D; P
> 0.4). In the saline and PHPMA groups, serum IgG concentrations increased
significantly after 8 weeks (Figure 4D; P = 0.01). In the Dex group, serum IgG level
decreased significantly after 8 weeks (Figure 4D; P < 5×10−3). By contrast, serum IgG
concentration increased after 8 weeks in the P-Dex group (Figure 4D; P < 5×10−3). At
the 8-week time point, Dex treated mice had significantly lower serum IgG levels than
mice in the saline, PHPMA, and P-Dex groups (P < 5×10−3). Thus, in contrast to free
Dex, P-Dex did not reduce serum IgG.

P-Dex exhibits nephrotropism in (NZB×NZW)F1 mice

To elucidate the mechanism underlying the enhanced efficacy and decreased toxicity of
P-Dex in (NZB×NZW)F1 mice, optical imaging was performed to evaluate the in vivo
distribution of P-Dex. (NZB×NZW)F1 and NZW (healthy control) mice received i.v.
injections of P-Dex-IRDye and P-Dex-Alexa and imaging was performed at 2 and 7 d
post injection. P-Dex-IRDye preferentially accumulates (2 d) and is retained (7 d) in
inflamed kidneys of (NZB×NZW)F1 mice, but not healthy kidneys of NZW controls
(Figure 5A). FACS revealed that ~61% of kidney cells from (NZB×NZW)F1 mice were PDex-Alexa+ whereas less than 20% of kidney cells from NZW mice were P-Dex-Alexa+
(Figure 5B). Furthermore, the mean fluorescence intensity of P-Dex-Alexa+ kidney cells
of (NZB×NZW)F1 mice was substantially greater (~ 4.5 fold) than that of P-Dex-Alexa+
kidney cells in NZW mice. This observation suggests that on a per cell basis, larger
quantities of P-Dex are taken up and retained in the kidneys of (NZB×NZW)F1 mice than
NZW mice. Persistent near-infrared fluorescence signals were also observed in the
spleen and liver of (NZB×NZW)F1 mice (Figure 5A). FACS analysis showed that ~81%
of spleen cells and ~10% of liver cells were P-Dex-Alexa+ (Figure 5B). In peripheral
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Figure 5. Nephrotropism and renal cell retention of the dexamethasone prodrug (PDex) in (NZB x NZW)F1 mice. A, Representative optical images of organs isolated from
(NZB x NZW)F1 mice and NZW mice. Images were obtained 2 days and 7 days after
intravenous injection of IRDye 800CW–labeled P-Dex (P-Dex–IRDye). B,
Representative results of fluorescence-activated cell sorting analysis of cells isolated
from the organs of (NZB x NZW)F1 or NZW mice without (white) or with Alexa Fluor
488–labeled P-Dex (P-Dex–Alexa) treatment (blue), 7 days after injection. C,
Representative fluorescence microscopic images of kidney sections from (NZB x
NZW)F1 mice without or with P-Dex–Alexa treatment, 7 days after injection. Bars = 150
μm. D, Representative confocal microscopic images of immunohistochemical staining of
kidney sections from (NZB x NZW)F1 mice without or with P-Dex–Alexa treatment, 7
days after injection. Sections were stained with an anti-mouse E-cadherin antibody and
DAPI. Antibody signal (red), P-Dex–Alexa signal (green), DAPI signal (blue), and a
merged image are shown. Bars = 15 μm. Ht = heart; Lv = liver; Kd = kidney; Sp =
spleen; Lu = lung.
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blood, ~69.7% of WBCs were P-Dex-Alexa+, but virtually no signal was seen in red blood
cells (data not shown).

Renal distribution of P-Dex-Alexa

To identify the mechanism responsible for renal retention of P-Dex, mice were injected
with P-Dex-Alexa, and 7 days later, kidneys were isolated and analyzed by fluorescence
microscopy and FACS. P-Dex-Alexa+ cells were most abundant in proximal tubules of
the renal cortex (Figure 5C). Immunohistochemical staining indicated that a large
proportion of retained prodrug was localized within cortical epithelial cells, which were
identified based upon histology and E-cadherin positivity (Figure 5D). Flow cytometry
indicated that 21.3% of the P-Dex-Alexa+ kidney cells were E-cadherin+ (data not
shown). The identity of the remaining P-Dex-Alexa+ cells could not be determined
definitively by flow cytometry, despite the use of an extensive panel of antibodies
designed to identify various cells in the inflamed kidney. Less than 0.1% of the P-DexAlexa+ cells in kidney were F4/80+ macrophages, CD11c+ dendritic cells, CD4+ helper T
cells or CD8a+ cytotoxic T cells (data not shown).

Internalization, intracellular localization and activation of P-Dex

Proximal tubule epithelial cells contribute to nephritis by secreting chemokines and
inflammatory cytokines in response to albumin and immune complexes [14–17].
Because these cells represent the largest defined population of P-Dex-Alexa+ cells, the
internalization kinetics of P-Dex-FITC was examined in HK-2 renal proximal tubule cells
in vitro. HK-2 cells rapidly internalized P-Dex-FITC (Figure 5A). To test the hypothesis
that renal inflammation enhances uptake of P-Dex, we examined prodrug uptake in HK-2
cells treated with LPS, which causes renal inflammation in vivo and induces the release
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Figure 6. In vitro internalization, intracellular localization, and activation of
fluorescein isothiocyanate (FITC)–labeled dexamethasone prodrug
(P-Dex) in human proximal tubule epithelial (HK-2) cells. A, Quantification of
internalized P-Dex–FITC in untreated and lipopolysaccharide (LPS)–stimulated (10
μg/ml) HK-2 cells over a 72-hour time course. B, Representative confocal microscopic
images showing internalization and intracellular localization of P-Dex–FITC in LPSstimulated (10 μg/ml) HK-2 cells. LysoTracker DND-99 signal (red), P-Dex–FITC signal
(green), DAPI signal (blue), and a merged image are shown. Bars = 15 μm. C, Impact of
dexamethasone 21-phosphate disodium (Dex) and P-Dex on LPS-induced interleukin-6
(IL-6) secretion in HK-2 cells. Values in A and C show the mean ± SEM (n = 3 individual
experiments). * = P < 5 x 10-7; ** = P < 1 x 10-12. All treatments (LPS, LPS + Dex, LPS +
P-Dex) resulted in a significant increase in IL-6 secretion versus untreated (P <1 x 10-4).
However, asterisks for these comparisons are not shown.

169

of proinflammatory cytokines and mediators from renal cells in vitro [18, 19]. LPS did not
alter prodrug internalization kinetics (Figure 6A).

To examine the fate of internalized P-Dex-FITC, we used immunohistochemistry and
confocal microscopy. Internalized P-Dex-FITC co-localized with the LysoTracker®
lysosome marker in HK-2 cells (Figure 6B), suggesting that P-Dex-FITC is internalized
and processed by an endocytic pathway, that results in sequestration in a lysosomal
compartment, where P-Dex would gradually undergo processing in the acidic
environment, leading to the release of active drug [2–4].

To examine the impact of P-Dex on LPS-induced cytokine release in HK-2 cells, ELISA
was used to evaluate secretion of the proinflammatory cytokine IL-6 into the
supernatant. Although untreated HK-2 cells secrete low levels of IL-6, secretion can be
stimulated 60-fold by LPS (Figure 6C; P < 1×10−5). Dex and P-Dex significantly
attenuated the LPS-induced increase in IL-6 secretion (Figure 6C; P < 5×10−3),
indicating that both treatments can inhibit secretion of inflammatory cytokines by
activated proximal tubule epithelial cells.

Discussion

Recent lupus drug development strategies have focused on targeting specific molecules
and pathways that impact immunologic and proinflammatory processes. Although
progress has been made, off-target toxicity due to the inability to manage in vivo drug
distribution still poses a significant clinical challenge. Targeting inflammation with
macromolecular prodrugs is a new nanomedicine-based therapeutic strategy. This
approach is based on a mechanism involving extravasation of macromolecules through
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leaky vasculature and inflammatory cell-mediated sequestration (ELVIS) and has been
validated in several inflammatory disease models [2, 4, 20].

Based upon these studies, we hypothesized that a dexamethasone prodrug could
selectively target lupus-associated renal inflammation and become activated locally to
ameliorate nephritis. Furthermore, we postulated that this prodrug would avoid the offtarget toxicity associated with traditional GC therapy. To test this hypothesis, we treated
(NZB×NZW)F1 mice with saline, PHPMA, Dex, or P-Dex beginning at 4 months of age,
prior to the onset of albuminuria. Over the next 8 weeks, the majority of mice treated with
saline or PHPMA developed albuminuria. As expected, Dex decreased the incidence of
albuminuria by ~50%, and reduced both serum anti-dsDNA IgG levels and renal immune
complexes [21]. Strikingly, P-Dex was more effective than Dex and completely
prevented albuminuria. P-Dex did not affect serum anti-dsDNA IgG levels or renal
immune complexes, but did reduce renal macrophage infiltration. These observations
suggest that P-Dex may attenuate nephritis by reducing renal inflammation and act via
different mechanisms than free Dex. Importantly, our results also demonstrate that PDex does not cause osteoporosis, a major systemic side effect associated with GC
treatment.

Based upon the above data and the ELVIS mechanism, we hypothesized that P-Dex
would extravasate and be retained at sites of renal inflammation. Optical imaging,
immunohistochemistry and FACS analysis confirmed preferential accumulation and
retention of P-Dex in inflamed kidneys of lupus-prone but not healthy control mice.
Furthermore, these in vivo data validate that cell sequestration is the major mechanism
for retention of P-Dex in the inflamed kidney, with proximal tubule epithelial cells being
the primary cellular reservoir of sequestered P-Dex.
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Our data, together with previously published work, support a model in which reduced
glomerular capillary macromolecular permselectivity associated with renal inflammation
enhances passage of P-Dex into the ultrafiltrate. This in turn leads to uptake and
sequestration of significant quantities of the prodrug by the activated proximal tubule
epithelium. The glomerulus is responsible for forming a nearly protein-free plasma
ultrafiltrate. The essential components of the glomerular filtration barrier, the barrier
between the blood and urinary space, are the fenestrated capillary endothelium, the
surrounding basement membrane, and the filtration slit (spanned by the slit diaphragm)
between adjacent foot processes of podocytes. In the normal kidney, small solutes
readily pass through the filtration barrier, with passage increasingly restricted as
molecular weights exceed 15 kDa; solutes of >50–60 kDa have very limited passage into
the ultrafiltrate. Macromolecules having a net negative charge are further impeded from
crossing the filtration barrier. Given that P-Dex is a neutral molecule of ~36 kDa, some
P-Dex filtration is likely under normal conditions. Loss of integrity of the filtration barrier
results in enhanced permeability (reduced permselectivity) of large molecules such as
albumin, leading to albuminuria. Nephritis in (NZB×NZW)F1 mice is associated with
vascular damage, alterations in the glomerular basement membrane and distortion of slit
diaphragms [22–24], and this likely accounts for the enhanced filtration of P-Dex in these
mice. The higher proportion of plasma P-Dex likely passing into the ultrafiltrate in
(NZB×NZW)F1 mice compared to controls, results in increased P-Dex delivery to the
apical aspect of the renal tubular epithelium. Proximal tubule epithelial cells reabsorb
multiple substances from the tubular fluid, and previous reports indicate that polymer
carriers can achieve renal targeting through uptake by these cells [25–29]. Enhanced
prodrug delivery to and uptake by proximal tubule epithelial cells likely contributes to the
efficacy of P-Dex.
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Albumin and immune complexes activate proximal tubule epithelial cells and induce
secretion of chemokines and cytokines such as IL-6 that promote renal inflammation and
immune cell infiltration [14–17]. Our in vitro data indicate that P-Dex, similar to free Dex,
inhibits LPS-induced IL-6 release from proximal tubule epithelial cells, suggesting that PDex may reduce renal inflammation by attenuating the pro-inflammatory response of
proximal tubule epithelial cells. We postulated that inflammation would enhance
endocytosis and P-Dex uptake in proximal tubule epithelial cells. Though not supported
by our cell culture studies, this hypothesis was consistent with results from our in vivo
studies, which indicate that kidney cells in the (NZB×NZW)F1 mice take up and retain
larger quantities of P-Dex than those in NZW mice.

Although proximal tubule epithelial cells were identified as a major population of P-DexAlexa+ cells in kidney, the identity of a substantial percentage of P-Dex-Alexa+ cells in
kidney remains to be determined. Furthermore, P-Dex was also found in liver, spleen
and peripheral WBCs of (NZB×NZW)F1 mice, which is consistent with our findings in
other disease models [2, 4, 30]. A clear understanding of how P-Dex uptake or retention
in these cells or tissues impacts the ability of P-Dex to prevent nephritis and reduce offtarget toxicities needs further investigation.

In summary, monthly administration of P-Dex provided superior prevention of lupus
nephritis and reduced toxicity in (NZB×NZW)F1 mice, as compared to dose equivalent,
daily administered Dex. We speculate that the nephrotropism and retention of P-Dex in
(NZB×NZW)F1 mice is, at least partially, attributed to reduced glomerular capillary
permselectivity and enhanced uptake by activated kidney cells including proximal tubule
epithelial cells. The intracellular processing of P-Dex into free dexamethasone and
sustained release of active drug at the site of inflammation provides a rational
explanation for the superior, sustained anti-inflammatory effect of P-Dex in the local
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environment. These data provide a rationale for the future development of this
macromolecular prodrug system as a potential preventive and/or therapeutic agent for
lupus patients. Further clarification of the mechanisms underlying P-Dex action will be
essential for its structural optimization and clinical translation.
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Abstract

We evaluated the ability of a macromolecular prodrug of dexamethasone (P-Dex) to
treat lupus nephritis in (NZB × NZW)F1 mice. We also explored the mechanism
underlying the anti-inflammatory effects of this prodrug. P-Dex eliminated albuminuria in
most (NZB × NZW)F1 mice. Furthermore, P-Dex reduced the incidence of severe
nephritis and extended lifespan in these mice. P-Dex treatment also prevented the
development of lupus-associated hypertension and vasculitis. Although P-Dex did not
reduce serum levels of anti-dsDNA antibodies or glomerular immune complexes, P-Dex
reduced macrophage recruitment to the kidney and attenuated tubulointerstitial injury. In
contrast to what was observed with free dexamethasone, P-Dex did not induce any
deterioration of bone quality. However, P-Dex did lead to reduced peripheral white blood
cell counts and adrenal gland atrophy. These results suggest that P-Dex is more
effective and less toxic than free dexamethasone for the treatment of lupus nephritis in
(NZB × NZW)F1 mice. Furthermore, the data suggest that P-Dex may treat nephritis by
attenuating the renal inflammatory response to immune complexes, leading to
decreased immune cell infiltration and diminished renal inflammation and injury.

Introduction

Lupus nephritis is a leading cause of morbidity and mortality among lupus patients [1].
Lupus nephritis is associated with inflammation caused by renal deposition of immune
complexes containing autoantibodies, particularly IgG autoantibodies recognizing double
stranded DNA (anti-dsDNA IgG). If not resolved, renal inflammation can lead to renal
injury, dysfunction, and failure.

179

Lupus nephritis can be effectively treated with glucocorticoids (GCs). However, because
long-term GC therapy is required, this treatment frequently is associated with numerous
side effects involving the endocrine, cardiovascular, hematopoietic and musculoskeletal
systems [2]. These adverse side effects, especially secondary osteoporosis, contribute
significantly to morbidity in lupus patients. Nevertheless, because of the lack of
alternative therapeutic options, GCs continue to be the mainstay of clinical management
of lupus nephritis [3].

In an attempt to reduce GC-associated side effects, we previously employed a
nanomedicine-based strategy to modify the pharmacokinetic/biodistribution profile of
GCs to enhance drug delivery to the site of inflammation while reducing systemic
exposure to the drug. Specifically, we developed a macromolecular prodrug of
dexamethasone (P-Dex); P-Dex is taken up preferentially by the proximal tubule
epithelial cells in the inflamed kidneys of (NZB × NZW)F1 females, but the prodrug is
also found to a much lesser extent in splenocytes and circulating blood cells [4]. We
observed that P-Dex prevents the development of nephritis in young lupus-prone (NZB ×
NZW)F1 female mice without causing osteoporosis, a side effect associated with the
equivalent dose of free Dex [4]. Our previous studies also suggest that P-Dex prevents
nephritis by attenuating the response of the kidney to immune complex deposition and
decreasing the recruitment of infiltrating immune cells to the kidney.

Here, we sought to further explore the therapeutic potential of P-Dex for the treatment of
lupus nephritis using a preclinical mouse model. The primary objective of the present
study was to determine if P-Dex could effectively treat established nephritis in (NZB ×
NZW)F1 mice. Additionally, we sought to assess the safety of longer term P-Dex
administration and to further explore the potential underlying mechanism of action of this
prodrug.
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Results
P-Dex reverses established albuminuria, extends survival and reduces incidence of
severe nephritis and tubulointerstitial disease in (NZB × NZW)F1 mice
To determine if P-Dex could ameliorate established nephritis, P-Dex was administered
monthly to (NZB × NZW)F1 females beginning at ~22 weeks of age, after they had
developed nephritis, as evidenced by sustained albuminuria. Treatment was continued
for 12 weeks. Two control groups, one receiving dose equivalent daily Dex and the other
receiving a monthly dose of saline, were also treated for 12 weeks. Mice were monitored
for an additional two weeks after cessation of treatment. Over the entire experimental
time course, albuminuria not only persisted in 100% of the mice in the saline treated
group, but also increased in severity in most of these mice (93%) (Figure 1A). In the Dex
group, albuminuria likewise continued in 100% of the mice. However, albuminuria
intensified in just 23% of the Dex treated mice, indicating that Dex treatment could
prevent progression of renal dysfunction. By contrast, albuminuria resolved in 78% of the
mice in the P-Dex group (Figure 1A). Albuminuria persisted but did not increase in the
remaining 22% of mice in this group. The fraction of mice in the P-Dex group that
showed resolution of albuminuria was significantly greater than that in the Dex treated
group, indicating that P-Dex is more effective than dose equivalent Dex in resolving
albuminuria associated with lupus nephritis (P ≤ 1x10-6).

Prior to the end of the experiment, ~55% of mice in the saline group were euthanized
due to severe nephritis (Figure 1B). In the saline treated group, median survival was ~13
weeks after initiation of treatment, which corresponded to ~35 weeks of age. The median
survival in this group is similar to what we and others have reported previously for (NZB
× NZW)F1 females [5-7]. All mice in the Dex and P-Dex groups survived the entire
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Figure 1. P-Dex ameliorates albuminuria, extends lifespan and attenuates
development of severe nephritis and tubulointerstitial disease in (NZB × NZW)F1
females.
(A), Albuminuria data for mice in saline (n=13), Dex (n=13), and P-Dex (n=9) treatment
groups is illustrated at the pretreatment (PT) and 14-week time points. The incidence of
albuminuria at the 14-week time point for each group is shown (in %) in upper right
corner of each sub-section. For mice in the saline group that did not survive to the 14week time point (n=7), the albuminuria reading shown is the last recorded value. (B), A
Kaplan-Meier survival curve for each treatment group is shown. (C), The fraction of mice
in each treatment group with mild, moderate and severe renal disease is shown. (D), A
PAS stained histological section illustrating representative glomeruli from each treatment
group are provided. Scale bars: 20 μm. (E), A representative PAS stained histological
section illustrating the tubulointerstitium from each treatment group is provided. Scale
bars: 40 μm. The asterisk (*) indicates a statistically significant difference (P < 0.05) from
the saline control group.
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treatment period, indicating that both therapies significantly increased the fraction of
mice surviving until the end of the treatment period (P = 0.001). These data indicate that
Dex and P-Dex can extend the lifespan of (NZB × NZW)F1 mice.

The kidneys from 86% of mice in the saline group showed histological evidence of
severe glomerulonephritis, characterized by diffuse glomerular hypercellularity, matrix
deposition and crescent formation (Figure 1 C, D). By contrast, in the Dex treated group,
the incidence of severe glomerulonephritis was 46%, which was significantly less than
that in saline controls (Figure 1C, D; P = 0.04). In the P-Dex treated group, none (0%) of
the kidneys showed histological evidence of severe glomerulonephritis; incidence of
severe nephritis in this group was different than that in the saline and Dex groups (P <1
x10-3).

Furthermore, 100% of the kidneys from mice in the saline group showed evidence of
marked tubulointerstitial disease, which was typified by tubular dilation, tubular casts,
and immune cell infiltration into the interstitium. The immune cell infiltrates were found in
both the cortex and medulla, and were distributed throughout the interstitium as well as
in prominent perivascular lymphoid aggregates (Figure 1E). By contrast, in both the Dex
and P-Dex groups, there was little indication of tubulointerstitial disease; kidneys
displayed mild tubular dilation, sparse tubular casts and scant evidence of interstitial
immune cell infiltration (Figure 1E).

P-Dex does not reduce serum anti-dsDNA IgG or glomerular immune complexes
In (NZB × NZW)F1 mice, severity of nephritis typically correlates with serum levels of
pathogenic autoantibodies, particularly anti-dsDNA IgG [8]. Therefore, serum antidsDNA IgG levels were assessed. In the saline group, serum anti-dsDNA IgG levels
increased significantly over the experimental time course (Figure 2A; P = 0.02). By
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contrast, in the Dex group, serum anti-dsDNA IgG did not change significantly over the
experimental time course (Figure 2A; P > 0.05). Consequently, at the end of the
experimental time course, serum anti-dsDNA IgG levels in the Dex group were
significantly lower than those in the saline group (P = 0.02). Serum anti-dsDNA IgG
levels increased in the P-Dex group over the experimental time course (Figure 2A; P =
0.03). There were no significant differences in serum anti-dsDNA IgG levels between the
P-Dex and saline groups (P > 0.05). However, serum anti-dsDNA IgG levels in the PDex group were significantly greater than those in the Dex group at the end of the
experimental time course (P < 0.008). These results demonstrate that P-Dex attenuates
nephritis through a mechanism independent of the production of pathogenic
autoantibodies.

Although our results indicate that P-Dex did not impact the total levels of serum antidsDNA IgG, this observation does not preclude the possibility that P-Dex alters the
relative abundance of different subclasses of anti-dsDNA IgG autoantibodies. Such an
effect could be important given the fact that anti-dsDNA IgG autoantibodies of different
subclasses are not equally pathogenic [8-10]. Therefore, we examined the impact of
treatment on the levels of anti-dsDNA IgG of each subclass individually. In the Dex
treated group, serum levels of anti-dsDNA IgG1, IgG2a, IgG3 and were significantly lower
than in the saline control group (Figure 2B; P < 0.05). By contrast, the levels of serum
anti-dsDNA IgG1 and IgG2a autoantibodies did not differ between the P-Dex and saline
groups (Figure 2B; P > 0.05). However, the P-Dex treated group did display lower serum
levels of anti-dsDNA IgG3 autoantibodies compared to the saline group (Figure 2B; P =
0.03). There were no differences in serum levels of anti-dsDNA IgG2b autoantibodies
between any of the groups (data not shown). These results indicate that P-Dex does not
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Figure 2. The effect of treatment on serum anti-dsDNA IgG and renal immune
complexes.
(A), Anti-dsDNA IgG levels for mice in saline (n=13), Dex (n=13), and P-Dex (n=9)
treatment groups were determined via ELISA at pretreatment, 4-week, 8-week, and 12
week time points. For the saline group, serum was available for analysis only from the
subset of mice surviving at each time point: 12 mice at 4-week time point; 11 mice at 8week time point; 9 mice at 12-week time point (B), Levels of anti-dsDNA IgG of each
subclass were determined via ELISA at the 12-week time point. For the saline group,
serum was available for this analysis only from the 9 mice that survived to the 12-week
time point (C), Representative sections of kidney from each treatment group are shown.
Sections were stained for renal deposition of anti-dsDNA IgG via immunohistochemistry.
(D), Quantification of immune complex staining is illustrated. Scale bars: 25 μm; The
asterisk (*) indicates a statistically significant difference (P < 0.05) from the saline control
group. The dagger (†) indicates a statistically significant difference (P < 0.05) from the
pretreatment time point of the same treatment group.
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cause a dramatic shift in the relative abundance of different subclasses of anti-dsDNA
IgG. Importantly, these results also clearly illustrate that P-Dex does not decrease the
abundance of anti-dsDNA IgG2a autoantibodies, which are considered to be the most
pathogenic autoantibodies in (NZB x NZW)F1 mice [8-10].

Because glomerular deposition of anti-dsDNA IgG-containing immune complexes
contributes to the development and progression of nephritis [11], we evaluated the
impact of treatment on glomerular immune complex deposition. In the kidneys of mice in
the saline group, prominent glomerular immune complex deposition was observed
(Figure 2C, D). In the kidneys of the Dex group, glomerular immune complex deposition
was significantly less than that in the saline group (Figure 2C, D; P = 0.04). Glomerular
immune complex staining in the P-Dex group was similar to that in the saline group
(Figure 2C, D; P > 0.05), but was significantly different than that in the Dex group (P ≤
0.025). Thus, P-Dex treated mice do not develop nephritis despite the presence of
abundant glomerular immune complexes.

P-Dex reduces renal macrophage infiltration and tubulointerstitial injury
In (NZB × NZW)F1 mice, the presence of glomerular immune complexes is not sufficient
for the development of nephritis. Rather, the development of nephritis requires the
recruitment of FcR-expressing myeloid cells, including macrophages, to the kidney and
the subsequent activation of these cells by glomerular immune complexes [12,13].
These activated macrophages are thought to contribute to the chronic renal inflammation
and tissue damage associated with nephritis. Therefore, the impact of P-Dex treatment
on macrophage recruitment in the kidney was evaluated. Quantification of staining with
the macrophage marker Iba1 revealed abundant macrophage infiltration into the
tubulointerstitium and periglomerular area in the saline group (Figure 3A,B). By contrast,
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macrophage infiltration in both the Dex and P-Dex groups was significantly less than that
the saline control group (Figure 3A, B; P < 0.04). The modest recruitment of
macrophages to kidneys from the P-Dex treated mice, despite the presence of abundant
glomerular immune complexes, suggests that P-Dex attenuates nephritis by impairing
the macrophage infiltration that occurs in response to renal immune complex deposition.

The recruitment of macrophages to the kidney in lupus-prone mice leads to
tubulointerstitial inflammation and injury [14,15]. To determine whether the reduced
macrophage recruitment in the P-Dex group was also associated with decreased
tubulointerstitial injury, the expression of Toll-like receptor 9 (TLR9) and Lipocalin 2
(LCN2), markers for renal tubule damage and tubulointerstitial injury, were assessed
[16-20]. Consistent with the observation that the kidneys of the mice in the saline group
contained numerous macrophages and showed pronounced tubulointerstitial disease,
abundant tubular TLR9 staining was observed in this group (Figure 4A, B). By contrast,
in both the Dex and P-Dex groups, there was significantly less tubular TLR9 staining
than in the saline group (Figure 4A,B; P < 0.05). To assess the impact of Dex and P-Dex
on TLR9 expression in a more quantitative fashion, quantitative RT-PCR was performed
to determine the level of expression of the Tlr9 transcript. This analysis confirmed that
the levels of Tlr9 transcript were significantly less in the Dex and P-Dex groups
compared to that in the saline control group (Figure 4C; P ≤ 0.01). Likewise, there was
robust expression of LCN2 in the kidneys of the saline group, and significantly less
LCN2 in the kidneys of both the Dex and P-Dex groups (Figure 4D; P ≤ 0.05).

P-Dex prevents the development of lupus-associated hypertension, splenomegaly and
vasculopathy
Since systemic inflammation and renal dysfunction promote hypertension in lupus
patients and (NZB × NZW)F1 mice [21,22], we assessed the impact of treatment on
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Figure 3. Impact of treatment on renal macrophage infiltration in (NZB × NZW)F1
mice.
(A), Representative confocal images of immunohistochemical staining of kidney sections
from mice in the saline (n=13), Dex (n=13), and P-Dex (n=9) treatment groups are
shown. Sections were stained with an anti-Iba1 antibody (red) and DAPI (blue). Negative
control (no Iba1 antibody) and merged images are shown. (B), Quantification of Iba1
staining is illustrated. Scale bars: 50 μm; the asterisk (*) indicates a statistically
significant difference (P < 0.05) from the saline control group.

188

Figure 4. Impact of treatment on tubulointerstitial inflammation and injury in (NZB
× NZW)F1 mice.
(A), Representative images of immunohistochemical staining of kidney sections from
mice in the saline (n=13), Dex (n=13), and P-Dex (n=9) treatment groups are shown.
Sections were stained with an anti-TLR9 antibody (brown) and counterstained with
hematoxylin (blue). (B), Quantification of TLR9 staining is illustrated. (C), TLR9 transcript
levels in the kidney were measured by quantitative RT-PCR. For the saline group, frozen
kidneys were available for RNA extraction only from the 6 mice that survived until the 14week time point. (D), Levels of LCN2 were measured in kidney lysates by ELISA. For the
saline group, frozen kidneys were available for preparation of protein lysates only from
the 6 mice that survived until the 14-week time point. Scale bars: 25 μm; the asterisk (*)
indicates a statistically significant difference (P < 0.05) from the saline control group.
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mean arterial pressure (MAP). Prior to treatment, mice in the saline group were
normotensive (Figure 4A). However, over the experimental time course, MAP rose
significantly and virtually all of the mice in this group became hypertensive (Figure 5A; P
≤ 0.01). By contrast, there was no significant change in MAP in either the Dex or P-Dex
groups over this time course (Figure 5A; P > 0.05).

Splenomegaly occurs only in a subset of human lupus patients. By contrast,
splenomegaly is observed in virtually all lupus prone mouse strains, including the (NZB ×
NZW)F1 hybrid. Therefore, spleen mass of the animals was investigated at necropsy.
Splenomegaly was pronounced in the saline group (Figure 5B). By contrast, there was
little evidence of splenomegaly in either the Dex or P-Dex treated groups; mean spleen
mass in the Dex and P-Dex groups was significantly different than that in the saline
group (P < 0.001). The spleen mass in the P-Dex group was significantly different than
that in the Dex group (P = 0.03), although the biological significance of this difference is
unclear. All differences persisted when spleen mass was normalized to total body mass
(data not shown). Thus, both Dex and P-Dex can attenuate splenomegaly in (NZB ×
NZW)F1 mice.

Lupus patients are also at high risk for vasculitis. Vasculitis, evidenced by fibrinoid
necrosis in the walls of the splenic blood vessels, was found in 54% of mice from the
saline group. Fibrin deposits were also noted within the lumen of splenic vessels in 39%
of the mice in the saline group (Figure 5C). No fibrin deposition or fibrinoid necrosis was
observed in mice from the Dex and P-Dex groups, indicating that both treatments
attenuated vascular disease in lupus prone mice.
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Figure 5. Impact of treatment on hypertension, splenomegaly and vasculitis in
(NZB × NZW)F1 mice.
(A), Mean arterial pressure was measured at pretreatment, 4-week, 8-week, 12 week
time points via tail-cuff method. For the saline group, measurements were obtained only
for the subset of mice surviving at each time point: 12 mice at 4-week time point; 11
mice at 8-week time point; 9 mice at 12-week time point (B), Spleen mass was
determined at the time of sacrifice in each mouse. (C), A representative hematoxylin and
eosin stained histological section illustrating a splenic vessel from each treatment group
is provided. The arrow indicates perivascular fibrin deposits indicative of vasculitis. Scale
bars: 50 μm; the asterisk (*) indicates a statistically significant difference (P < 0.05) from
the saline control group. The double asterisk (**) indicates a statistically significant
difference (P < 0.05) from the Dex group. The dagger (†) indicates a statistically
significant difference (P < 0.05) from the pretreatment time point of the same treatment
group. For saline and Dex treatments, n=13; for P-Dex treatment, n=9.
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P-Dex treatment does not affect bone quality
Osteoporosis is a major adverse side effect of long-term use of GCs [23]. To investigate
the impact of P-Dex on the skeleton, the femoral BMD and micro-architecture were
evaluated. As expected, the mean bone mineral density (BMD) and trabecular bone
volume/tissue volume (BV/TV) in the femurs of Dex treated mice were significantly lower
than that observed in the saline group (Figure 6A, B; P < 0.05). Trabecular number did
not differ significantly between the Dex and saline groups (Figure 6C; P > 0.05). In the PDex group, mean femoral BMD, BV/TV and trabecular number did not differ significantly
from the means in the saline group (Figure 6A, B, C; P > 0.05). By contrast, compared to
the Dex group, the P-Dex group exhibited significantly greater BMD (Figure 6A; P =
0.004), BV/TV (Figure 6B; P = 0.007) and trabecular number (Figure 6C; P = 0.01).
Thus, unlike Dex, P-Dex did not negatively affect BMD or microarchitecture of the bone.

P-Dex treatment reduces peripheral white blood cells but does not reduce serum IgG
levels
GC therapy is associated with immunosuppression [24,25]. Therefore, we monitored
peripheral white blood cell (WBC) counts and serum IgG levels during the experimental
time course. Prior to treatment, no significant differences in peripheral WBC counts were
observed between groups (Figure 6D; P > 0.05). In the saline group, peripheral WBC
counts initially remained constant, but were significantly reduced at the 12 week time
point (Figure 6D; P = 0.049). By contrast, peripheral WBC counts were significantly
reduced by the 4-week time point in the Dex (Figure 6D; P = 0.0004) and P-Dex (Figure
6D; P = 0.0007) groups; WBC counts remained low in both of these treatment groups for
the duration of the study. No significant changes in serum IgG levels were observed in
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Figure 6. Evaluation of treatment-induced side effects.
At sacrifice, femurs were collected for endpoint analysis of bone quality. (A), bone
mineral density (B), bone volume/tissue volume and (C), trabecular number
measurements in each treatment group are shown. (D), white blood cell counts and (E),
total serum IgG levels were determined at pretreatment 4-week, 8-week and 12-week
time points. For the saline group, measurements were obtained only for the subset of
mice surviving at each time point: 12 mice at 4-week time point; 11 mice at 8-week time
point; 9 mice at 12-week time point (F), Adrenal mass was determined at the time of
sacrifice in each mouse. The asterisk (*) indicates a statistically significant difference (P
< 0.05) from the saline control group. The double asterisk (**) indicates a statistically
significant difference (P < 0.05) from the Dex group. The dagger (†) indicates a
statistically significant difference (P < 0.05) from the pretreatment time point of the same
treatment group. For saline and Dex treatments, n=13; for P-Dex treatment, n=9.
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any group (Figure 6E; P > 0.05). Thus, treatment with either Dex or P-Dex reduced
peripheral WBC counts, but did not reduce serum IgG levels.

P-Dex treatment induces adrenal gland atrophy
GC therapy causes suppression of hypothalamic-pituitary-adrenal (HPA) axis and
atrophy of the adrenal glands. Therefore, at necropsy, we determined the mass of the
adrenal glands in each mouse. The mean adrenal mass in the Dex group was
significantly different than the saline group (Figure 6F; P = 0.01). Although the mean
adrenal mass in the P-Dex group was less than that in the saline group, this difference
fell short of statistical significance (Figure 6F; P = 0.07). There was no significant
difference in adrenal gland mass between the P-Dex and Dex groups (Figure 6F; P
>0.05). These data suggest that treatment with either Dex or P-Dex induced adrenal
gland atrophy.

Discussion
Nanomedicine-based approaches that permit the modulation of the in vivo
pharmacokinetic/biodistribution profile of drugs represent a promising strategy for the
development of novel therapeutics to treat lupus nephritis. This approach is particularly
helpful for existing drugs, such as glucocorticoids, for which high potency is
accompanied by severe side effects due to ubiquitous distribution within the body.

Previously, we demonstrated that P-Dex can be passively targeted to the kidneys of
lupus-prone mice, likely due to the leaky vasculature in this inflamed tissue. In the
kidneys of lupus-prone mice, P-Dex is internalized and activated by proximal tubule
epithelial cells. In our previous study, we found that P-Dex is more effective than free
Dex at preventing nephritis in young (NZB × NZW)F1 mice, but it does not cause typical
Dex-associated side effects, such as osteopenia [4].
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In the present study, we evaluated the potential of P-Dex to treat established nephritis in
(NZB × NZW)F1 mice. Over the experimental time course, albuminuria intensified in the
mice in the saline control group, and almost all of these mice developed severe
nephritis. Furthermore, 55% of the saline treated mice succumbed to severe nephritis.
By contrast, all the animals treated with either Dex or P-Dex survived the entire 14-week
experimental time course. Although albuminuria worsened in only a fraction of the mice
in the Dex group, albuminuria persisted in all of the mice in this group. Strikingly,
albuminuria was eliminated in almost 80% of the mice in the P-Dex group. These data
indicate the P-Dex improved renal function whereas the equivalent dose of free Dex only
maintained the extant level of renal function.

Consistent with our previous observations, we found that P-Dex did not attenuate
nephritis by reducing serum anti-dsDNA IgG or glomerular immune complex deposition.
We also determined that P-Dex did not attenuate nephritis by causing a shift toward less
pathogenic subclasses of anti-dsDNA IgG. However, P-Dex did reduce the infiltration of
macrophages into the kidney. The modest recruitment of macrophages to the kidney in
the P-Dex group, despite the presence of abundant glomerular immune complexes,
suggests that P-Dex may impair the renal pro-inflammatory response to immune
complex deposition. It has been suggested that stimulation of the TLR and FcR signaling
pathways may act synergistically to initiate the chronic inflammation that leads to
nephritis [26]. Both of these pathways are activated by the presence of immune
complexes containing dsDNA. Our observation that P-Dex inhibits both tubulointerstitial
TLR9 expression as well as the recruitment of FcR-bearing macrophages to the
tubulointerstitium, despite the presence of such immune complexes, suggests that the
ability to inhibit both of these pathways may contribute to the enhanced therapeutic
benefit of P-Dex.
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P-Dex also attenuated tubulointerstitial injury and disease. In lupus patients,
tubulointerstitial inflammation and injury correlate with impaired renal function more
strongly than glomerular damage [27]. Furthermore, tubulointerstitial inflammation is the
best predictor of risk of progression to renal failure in lupus nephritis patients [27,28].
Altogether, these data suggest that P-Dex may restore renal function and extend
lifespan in (NZB × NZW)F1 females by reducing inflammatory cell infiltration in the
kidney, thereby minimizing tubulointerstitial inflammation and protecting the
tubulointerstitium from injury. By contrast, Dex inhibits nephritis and extends lifespan in
lupus prone mice by reducing serum levels of pathogenic anti-dsDNA IgG
autoantibodies.

In our previous study, we found that P-Dex was taken up not only by cells in the kidney,
but also by spleen cells in (NZB × NZW)F1 mice [4]. Therefore, in the present study, we
evaluated the impact of treatment on the spleen. Neither Dex nor P-Dex induced
histopathological abnormalities in spleen. Rather, both treatments attenuated the
splenomegaly that develops in (NZB × NZW)F1 mice. Dex and P-Dex also prevented the
development of vasculitis affecting the splenic blood vessels.

Due to the passive-targeting of P-Dex to the inflamed kidney, one would expect P-Dex to
exhibit a superior safety profile compared to free Dex. To assess the side effects of PDex, we measured femoral bone quality, serum IgG levels, peripheral WBC counts and
adrenal gland mass. All of these parameters are usually reflective of GC-associated
toxicities (e.g. osteoporosis, adrenal gland atrophy and immunosuppression). As
expected, Dex treatment significantly reduced femoral BMD and other micro-architecture
parameters. By contrast, femoral BMD, trabecular BV/TV and trabecular number in the
P-Dex group was not different than that in the saline group. Mice in the Dex and P-Dex
groups displayed similar reductions in peripheral WBC counts and adrenal gland
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atrophy. This residual toxicity in the P-Dex group is likely due to the fact that P-Dex is
taken up to some degree by splenocytes and circulating blood cells [4]. Additionally,
these side effects could be due to the free dexamethasone that is released as a result of
the cleavage of P-Dex. Collectively, these data suggest that P-Dex treatment partially
eliminates the side effects associated with free Dex treatment. Further study is needed
to understand why the skeleton was shielded from GC-associated toxicity following PDex treatment whereas other tissues and organs remained vulnerable. Acquisition of
such knowledge may provide insight that would facilitate the further optimization of the
design of this prodrug to improve its safety profile.

Materials and Methods
Ethics statement
Mice were housed under controlled humidity, temperature and lighting conditions in
facilities accredited by the American Association for Accreditation of Laboratory Animal
Care, operating in accordance with standards set by the Guide for the Care and Use of
Laboratory Animals (The National Academies Press, 1996). Mice were given Harlan
irradiated rodent diet 7904 (Harlan Teklad, Madison, WI) and allowed to feed ad libitum.
All procedures involving live animals were approved by the University of Nebraska
Medical Center Institutional Animal Care and Use Committee under protocol 03-008.

Experimental animals and drug treatment
Beginning at 20 weeks of age, (NZB × NZW)F1 female mice (Jackson Laboratories, Bar
Harbor, ME) groups of mice were randomized into saline, Dex and P-Dex groups and
monitored weekly for albuminuria using Albustix (Siemens Corp., Washington DC).
Albustix readings between 1 and 2 (30-99mg/dl) are considered “normal”, whereas
readings of ≥2+ (≥100mg/dl) indicate the presence of albuminuria. Only the mice in each
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group with established nephritis, evidenced by sustained albuminuria (≥100 mg/dl) over
an initial monitoring period of 3 weeks, were officially enrolled in the study and are
described here. The P-Dex (250 mg/kg, containing 30 mg/kg of dexamethasone) and
saline groups were administered monthly i.v. injections. The third group was given daily
i.p. injections of dexamethasone 21-phosphate disodium (Dex, 1.32 mg/kg, containing
1.00 mg/kg of dexamethasone, Hawkins, Inc., Minneapolis, MN). Over the three-month
(12 weeks) treatment period, the overall dose of dexamethasone in the P-Dex and Dex
groups was the same. P-Dex was synthesized as described previously [4,29].

Every month, serum was isolated from peripheral blood, mean arterial pressure was
recorded via tail-cuff method using the CODA blood pressure measuring system and
software (Kent Scientific, Torrington, CT), and peripheral white blood cells were isolated
from whole blood and counted by hemocytometer. Mice were weighed and monitored for
albuminuria on a weekly basis. Visual inspection of mice showing evidence of increasing
albuminuria and/or weight loss was performed daily. Mice that developed severe
albuminuria (≥ 2000 mg/dl) or showed signs of distress (i.e. reduced mobility, weight loss
>20%, edema, unkempt appearance) were sacrificed immediately. The remaining mice
were sacrificed two weeks after cessation of treatment (14 weeks after initiation of
treatment). All mice were sacrificed by CO2 asphyxiation, and tissues were harvested
after sacrifice. No anesthesia or analgesia was used.

Analysis of nephritis, renal immune complexes and renal macrophage infiltration
Kidneys were fixed, paraffin-embedded, sectioned and stained with Periodic Acid-Schiff
(PAS) (Sigma-Aldrich, St. Louis, MO) and analyzed by light microscopy. Nephritis was
assessed using a semi-quantitative 0 to 4 scale as described previously [5].
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Renal immune complexes were visualized by immunohistochemistry as described
previously [4]. Staining intensity (represented as arbitrary gray units or AGU) of fifty
glomeruli per mouse was quantified using region of interest analysis in Axiovision
software (v4.6.3.0; Carl Zeiss, Thornwood, NY).

Renal macrophage infiltration was assessed via immunofluorescence with the
macrophage marker Iba1 (Biocare Medical, Concord, CA) as described previously
[4,30]. Staining was visualized and quantified using confocal microscopy and Zen 2010
software (v6; Carl Zeiss).

Analysis of serum immunoglobulin and autoantibody levels
Serum immunoglobulin concentrations were determined by ELISA (Southern Biotech,
Birmingham, AL) as described previously [4,5]. The IgG1, IgG2a, IgG2b, and IgG3 levels
were added together to obtain total serum IgG levels. Serum anti-dsDNA IgG levels
were determined by ELISA (Alpha Diagnostics International, San Antonio, TX) as
described previously [4,5].

Analysis of markers of tubulointerstitial activation and injury
Renal expression of LCN2 protein was assessed in diluted kidney cell lysates by ELISA
(BioPortoDiagnostics, Gentofte, Denmark) according to the manufacturers’ instructions.
The protein in the supernatant was quantified using the Bradford method. LCN2
expression levels were normalized to total protein input levels.

TLR9 protein expression was assessed via immunohistochemical staining with an
antibody specific for this receptor (Santa Cruz Biotechnology, Santa Cruz, CA) as
described previously [4,19]. Staining intensity (in AGU) of fifty glomeruli per mouse was
quantified using Axiovision software. Tlr9 transcript level was assayed by quantitative
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RT-PCR. For this analysis, total RNA was isolated from kidney using the Absolutely RNA
Miniprep Kit (Agilent Technologies, La Jolla, CA) and cDNA using SS VILO Master Mix
(Life Technologies, Carlsbad, CA). PCR was performed using Tlr9–specific primers [19],
SYBR Green PCR Master Mix (Life Technologies) and the Applied Biosystems 7500
Real-Time PCR System.

Histological analysis of vasculitis
Spleens were fixed, paraffin-embedded, sectioned and stained with hematoxylin and
eosin stain (H&E) (Sigma-Aldrich, St. Louis, MO) and analyzed by light microscopy using
sections from age-matched NZW female mice as a healthy control.

Analysis of bone quality
Femoral BMD and micro-architectural parameters were measured using Skyscan 1172
micro-CT system (Skyscan, Kontich, Belgium) as described previously [4,31]. Micro-CT
scanning parameters were identical to those described previously [4]. Femoral BMD,
BV/TV and trabecular number and thickness were quantified with CTAn software
(Skyscan).

Statistical methods
Comparisons were performed using Fishers exact test, Wilcoxon signed-rank test,
Mann-Whitney U test, independent or paired samples t-test, or one-way ANOVA with
Tukey’s post hoc test where appropriate. Kaplan-Meier survival analysis and log-rank
test were used to assess the impact of treatment on lifespan. Statistical analyses were
performed using SPSS software (v. 21.0). A two-sided P ≤ 0.05 was considered
significant. Two-sided P-values are provided. Mean ± standard error of the mean is
presented.
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